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Th1-polarizing cytokine IL-12 exhibits potent anti-tumor activity in multiple cancer models; 
however, therapeutic use of this cytokine is limited due to severe IFN-γ-mediated toxicity.  To 
reduce the amount of IL-12 needed to elicit a therapeutic response, and thereby decrease 
associated toxicity, it is necessary to characterize novel cytokines to use in conjunction with IL-
12.  Newly described IL-12 family member IL-23 shares the IL-12 p40 subunit and promotes 
Th1 immunity by inducing IFN-γ expression and specifically stimulating proliferation of 
memory CD4+ T-cells.  I have demonstrated that injection of an adenovirus expressing IL-23 
(Ad.IL-23) into the tumor microenvironment results in significantly enhanced survival and tumor 
rejection in 40 percent of animals, with concomitant induction of protective anti-tumor 
immunity.  Furthermore, the anti-tumor activity of IL-23 is dependent on IL-12, IFN-γ and 
CD4+ and CD8+ T-cells, indicating generation of a Th1 response.  Delivery of adenovirus 
expressing IL-12 (Ad.IL-12) into the tumor microenvironment also results in enhanced survival 
and tumor rejection in up to 90 percent of animals.  In contrast to Ad.IL-23, Ad.IL-12 anti-tumor 
activity requires only IFN-γ and induces protective immunity only 50 percent of the time, 
suggesting activation primarily of innate immunity.  Due to the similar, yet divergent, effector 
mechanisms used in Ad.IL-12 and Ad.IL-23 anti-tumor effects, I hypothesized that use of these 
two viruses together would result in synergistic enhancement of tumor eradication.  Surprisingly, 
Ad.IL-12 and Ad.IL-23 do not synergistically enhance anti-tumor effects over use of either 
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 v 
cytokine alone, possibly due to IL-23 p19 sequestration of p40.  To circumvent this possibility, 
adenovirus expressing single chain IL-23 (Ad.scIL-23) was constructed and characterized.  
Ad.scIL-23 expresses greater levels of cytokine than Ad.IL-23 and treatment of tumor bearing 
mice results in tumor rejection in 90 percent of animals.  However, Ad.scIL-23 does not 
synergize with Ad.IL-12.  Overall, I have shown that IL-23 does possess therapeutic anti-tumor 
effects, but does not synergize with IL-12 to enhance tumor eradication.  Future studies could 
include characterizing CD4+ T-cell infiltrate of tumors treated with both Ad.IL-12 and Ad.IL-23 
to elucidate the mechanism behind the lack of synergy between these two cytokines.   
 
 
 vi 
TABLE OF CONTENTS 
PREFACE ................................................................................................................................. XVI 
1.0 INTRODUCTION ........................................................................................................ 1 
1.1 CANCER .............................................................................................................. 1 
1.1.1.1 Current Therapies................................................................................. 2 
1.1.2 MCA205 mouse fibrosarcoma model ............................................................ 3 
1.1.3 The immune system and cancer ..................................................................... 4 
1.1.3.1 CD4+ T-cells .......................................................................................... 5 
1.1.3.2 Role of the immune system in carcinogenesis ..................................... 8 
1.2 INTERLEUKIN 12 ............................................................................................ 10 
1.2.1 Discovery ........................................................................................................ 10 
1.2.2 Expression ...................................................................................................... 11 
1.2.3 IL-12 Receptor ............................................................................................... 11 
1.2.4 IL-12 Regulation ............................................................................................ 12 
1.2.5 Biological Activity .......................................................................................... 13 
1.2.6 IL-12 therapy in preclinical cancer models ................................................. 14 
1.2.6.1 Mechanism of IL-12-mediated anti-tumor effects ........................... 16 
1.2.7 IL-12 in Clinical Trials .................................................................................. 17 
1.2.7.1 Recombinant IL-12 ............................................................................. 17 
 vii 
1.2.7.2 IL-12 gene therapy .............................................................................. 18 
1.2.8 Augmentation of IL-12 anti-tumor effects .................................................. 18 
1.3 INTERLEUKIN 23 ............................................................................................ 20 
1.3.1 Discovery ........................................................................................................ 20 
1.3.2 Expression ...................................................................................................... 21 
1.3.3 Receptor .......................................................................................................... 21 
1.3.4 Biological activity ........................................................................................... 22 
1.3.5 Regulation....................................................................................................... 24 
1.3.6 IL-23 and cancer ............................................................................................ 25 
1.3.6.1 Anti-tumor activity ............................................................................. 25 
1.3.6.2 Pro-tumor effects ................................................................................. 28 
1.3.7 Th17 cells and cancer .................................................................................... 29 
1.4 ADENOVIRUS .................................................................................................. 31 
1.4.1 Structure ......................................................................................................... 31 
1.4.2 Replication ...................................................................................................... 32 
1.4.3 Immune response ........................................................................................... 33 
1.4.4 Gene Therapy ................................................................................................. 33 
1.5 SUMMARY ........................................................................................................ 35 
2.0 THERAPEUTIC, ANTITUMOR ACTIVITY OF ADENOVIRALLY 
DELIVERED IL-23 .................................................................................................................... 37 
2.1 INTRODUCTION ............................................................................................. 37 
2.2 METHODS ......................................................................................................... 40 
2.2.1 Adenoviruses .................................................................................................. 40 
 viii 
2.2.2 Animals ........................................................................................................... 40 
2.2.3 Cell Lines ........................................................................................................ 41 
2.2.4 Cytotoxic T-Lymphocyte Assay ................................................................... 41 
2.2.5 In Vivo Tumor Studies .................................................................................. 42 
2.2.6 Statistics .......................................................................................................... 42 
2.3 RESULTS ........................................................................................................... 43 
2.3.1 Confirmation of IL-12 and IL-23 expression from adenovirally 
transduced MCA205 tumor cells .............................................................................. 43 
2.3.2 Adenoviral delivery of IL-12 or IL-23 into the tumor microenvironment 
result in eradication of subcutaneous MCA205 tumors ......................................... 44 
2.3.2.1 Three injections of Ad.IL-12 or Ad.IL-23 result in enhanced 
survival and tumor rejection ............................................................................ 44 
2.3.2.2 Ad.IL-12 and Ad.IL-23 mediated generation of protective immunity 
and tumor-specific cytotoxic T-lymphocytes ................................................... 45 
2.3.2.3 Determining the minimal effective dose of Ad.IL-12 and Ad.IL-2346 
2.3.2.4 Systemic Anti-tumor effects of Ad.IL-12 and Ad.IL-23 .................. 48 
2.3.3 Ad.IL-23 anti-tumor activity is not model-specific ..................................... 49 
2.3.4 IL-12 and IL-23 anti-tumor activity is independent of endogenous IL-17 
production ................................................................................................................... 50 
2.3.5 IL-12 and IL-23 anti-tumor activity is independent of perforin ............... 52 
2.3.6 IL-12 and IL-23 anti-tumor activity is independent of Fas ligand............ 53 
2.3.7 Interferon gamma is necessary for IL-12 and IL-23 anti-tumor activity . 54 
 ix 
2.3.8 Anti-tumor activity of IL-23, but not IL-12, is dependent on CD4+ T-cells
 55 
2.3.9 IL-23, but not IL-12, utilizes CD8+ T-cells to exert its anti-tumor effects 56 
2.4 DISCUSSION ..................................................................................................... 57 
2.4.1 The case for IL-23-mediated gene therapy of cancer ................................. 57 
2.4.2 In vitro expression of IL-12 and IL-23 ......................................................... 58 
2.4.3 Anti-tumor activity of IL-23 ......................................................................... 59 
2.4.4 Anti-tumor activity of IL-12 ......................................................................... 61 
2.4.5 Comparison of Ad.IL-12 and Ad.IL-23 anti-tumor activities ................... 62 
2.4.6 Evaluation of the mechanisms of IL-12 and IL-23-mediated anti-tumor 
activities ....................................................................................................................... 63 
2.4.6.1 Role of CD4+ T cells ........................................................................... 63 
2.4.6.2 Role of CD8+ T cells ........................................................................... 64 
2.4.6.3 Role of IL-17 ........................................................................................ 65 
2.4.6.4 Role of perforin ................................................................................... 66 
2.4.6.5 Role of Fas ligand ................................................................................ 66 
2.4.6.6 Role of IFN-γ ....................................................................................... 67 
2.4.7 Mechanism of anti-tumor activities of IL-12 and IL-23 ............................ 68 
2.4.8 Summary ........................................................................................................ 69 
3.0 INVESTIGATION INTO ANTI-TUMOR SYNERGY BETWEEN 
ADENOVIRALLY DELIVERED IL-12, IL-23 AND IL-17 .................................................. 70 
3.1 INTRODUCTION ............................................................................................. 70 
3.2 METHODS ......................................................................................................... 73 
 x 
3.2.1 Adenoviruses .................................................................................................. 73 
3.2.1.1 Cytokine production and biological activity of adenoviruses ......... 73 
3.2.2 Animals ........................................................................................................... 74 
3.2.3 Cell Lines ........................................................................................................ 74 
3.2.4 In Vivo Tumor Studies .................................................................................. 75 
3.2.5 Immunohistochemistry ................................................................................. 76 
3.2.5.1 CD4 and CD8 ....................................................................................... 76 
3.2.5.2 Dendritic cells ...................................................................................... 77 
3.2.5.3 Foxp3 .................................................................................................... 77 
3.2.5.4 Angiogenesis ........................................................................................ 78 
3.2.6 Statistics .......................................................................................................... 78 
3.3 RESULTS ........................................................................................................... 79 
3.3.1 Anti-tumor activity of Ad.IL-23 requires endogenous IL-12, while Ad.IL-
12 does not ................................................................................................................... 79 
3.3.2 Anti-tumor activities of neither Ad.IL-12 nor Ad.IL-23 require 
endogenous IL-23 expression .................................................................................... 80 
3.3.3 Ad.IL-12 and Ad.IL-23 co-infection of MCA205 cells in vitro results in 
enhanced IL-12 and IL-23 expression ...................................................................... 81 
3.3.4 Investigation of synergism between Ad.IL-12 and Ad.IL-23..................... 83 
3.3.4.1 Treatment with Ad.IL-12 and Ad.IL-23 at separate time points does 
not lead to enhanced anti-tumor benefit .......................................................... 83 
3.3.4.2 Co-treatment with Ad.IL-12 and Ad.IL-23 does not enhance anti-
tumor benefit ...................................................................................................... 85 
 xi 
3.3.5 Determining the mechanism of lack of synergism between Ad.IL-12 and 
Ad.IL-23 ...................................................................................................................... 90 
3.3.5.1 Ad.IL-12 and Ad.IL-23 co-treatment does not alter CD4+ T-cell 
infiltrate .............................................................................................................. 90 
3.3.5.2 Ad.IL-12 and Ad.IL-23 co-treatment significantly reduces tumor-
infiltrating CD8+ T-cells ................................................................................... 90 
3.3.5.3 Ad.IL-12 and Ad.IL-23 treatment does not affect dendritic cell 
infiltrate in tumors ............................................................................................. 92 
3.3.5.4 Co-treatment with Ad.IL-12 and Ad.IL-23 does not alter Foxp3 
infiltrate .............................................................................................................. 92 
3.3.5.5 Ad.IL-12 and Ad.IL-23 co-treatment significantly enhances 
angiogenesis ........................................................................................................ 94 
3.3.6 Generation and characterization of adenoviruses expressing single chain 
IL-12 and IL-23 .......................................................................................................... 95 
3.3.6.1 Adenovirus expressing single-chain IL-12 possesses potent anti-
tumor effects, but is characterized by severe toxicity .................................... 96 
3.3.6.2 Adenovirus expressing single-chain IL-23 possesses potent anti-
tumor activity ..................................................................................................... 96 
3.3.7 Co-treatment with Ad.scIL-23 and Ad.IL-12 does not result in enhanced 
anti-tumor activity ..................................................................................................... 99 
3.3.8 Determining the mechanism behind the lack of synergy between Ad.IL-12 
and Ad.scIL-23 ......................................................................................................... 101 
 xii 
3.3.8.1 Ad.IL-12 and Ad.scIL-23 co-treatment does not alter CD4+ T-cell 
infiltrate ............................................................................................................ 101 
3.3.8.2 Co-treatment with Ad.IL-12 and Ad.scIL-23 does not alter CD8+ T-
cell infiltrate versus controls ........................................................................... 102 
3.3.8.3 Co-treatment with Ad.IL-12 and Ad.scIL-23 does not alter Foxp3 
positive cell infiltrate ....................................................................................... 102 
3.3.8.4 DC infiltrate ....................................................................................... 102 
3.3.8.5 Angiogenesis ...................................................................................... 103 
3.3.9 Investigation into synergism between Ad.IL-17 and Ad.IL-23 ............... 103 
3.3.9.1 Ad.IL-17 co-treatment inhibits Ad.IL-23 anti-tumor effects ........ 103 
3.3.9.2 Inhibition of IL-17 signaling does not enhance IL-23 anti-tumor 
activity 105 
3.4 DISCUSSION ................................................................................................... 106 
3.4.1 Rationale for IL-12 and IL-23 anti-tumor synergism .............................. 106 
3.4.2 Ad.IL-12 and Ad.scIL-23 co-treatment does not synergistically enhance 
anti-tumor effects ..................................................................................................... 109 
3.4.3 Determining the mechanism behind the lack of synergism between Ad.IL-
12 and Ad.IL-23 ........................................................................................................ 111 
3.4.3.1 CD4 T-cell infiltrate .......................................................................... 112 
3.4.3.2 CD8+ T-cell infiltrate ........................................................................ 113 
3.4.3.3 Dendritic cell infiltrate...................................................................... 115 
3.4.3.4 Regulatory T-cell infiltrate ............................................................... 116 
3.4.3.5 Angiogenesis ...................................................................................... 117 
 xiii 
3.4.4 Summary of investigation into anti-tumor synergy between Ad.IL-12 and 
Ad.IL-23 .................................................................................................................... 117 
3.4.5 Investigation of synergism between Ad.IL-12 and Ad.scIL-23 ............... 118 
3.4.5.1 Investigating the lack of synergy between Ad.IL-12 and Ad.scIL-23
 120 
3.4.6 Explaining the lack of anti-tumor synergism between IL-12 and IL-23 121 
3.4.7 Neither IL-17, nor inhibition of IL-17 signaling, enhances Ad.IL-23 anti-
tumor activity ........................................................................................................... 122 
3.4.8 A step closer to explaining the lack of synergy between IL-12 and IL-23
 123 
4.0 DISCUSSION ........................................................................................................... 125 
BIBLIOGRAPHY ..................................................................................................................... 129 
 xiv 
 LIST OF FIGURES 
Figure 1: CD4+ T-cell subsets   ........................................................................................................ 7
Figure 2: Biological effects of IL-12   ............................................................................................ 14
Figure 3:  Ad.IL-12 and Ad.IL-23 express detectable levels of cytokine   ..................................... 43
Figure 4: Three treatments with Ad.IL-12 or Ad.IL-23 result in potent anti-tumor effects   ......... 45
Figure 5: Ad.IL-23, but not Ad.IL-12, treatment results in generation of tumor-specific CTLs   . 46
Figure 6: Two treatments with Ad.IL-12 or Ad.IL-23 mount an anti-tumor response   ................. 47
Figure 7: 1 treatment with Ad.IL-12 or Ad.IL-23 mounts an anti-tumor response   ...................... 48
Figure 8: Ad.IL-12 or Ad.IL-23 treatment induces systemic anti-tumor immunity   ..................... 49
Figure 9: Ad.IL-23 exhibits anti-tumor activity against B16 melanoma   ...................................... 50
Figure 10: Ad.IL-12 and Ad.IL-23 anti-tumor activity in IL-17R-deficient mice   ....................... 51
Figure 11: Ad.IL-12 and Ad.IL-23 anti-tumor activity in perforin-deficient mice   ...................... 53
Figure 12: Ad.IL-12 and Ad.IL-23 anti-tumor activity in Fas ligand-deficient mice   ................... 54
Figure 13: Ad.IL-12 and Ad.IL-23 anti-tumor activity in IFN-γ-deficient mice   .......................... 55
Figure 14: Ad.IL-12 and Ad.IL-23 anti-tumor activity in CD4-deficient mice   ............................ 56
Figure 15: Ad.IL-12 and Ad.IL-23 anti-tumor activity in CD8-deficient mice   ............................ 57
Figure 16: Ad.IL-12 and Ad.IL-23 anti-tumor activity in p40-deficient mice   ............................. 80
Figure 17: Ad.IL-12 and Ad.IL-23 anti-tumor activity in p19-deficient mice   ............................. 81
Figure 18: Ad.IL-12 and Ad.IL-23 co-infection results in enhanced cytokine expression   .......... 82
 xv 
Figure 19: Ad.IL-12 and Ad.IL-23 do not synergize when delivered at separate time points   ..... 84
Figure 20: Ad.IL-12 and Ad.IL-23 do not synergistically enhance systemic anti-tumor activity   85
Figure 21: Co-treatment with Ad.IL-12 (1x109 particles) and Ad.IL-23 (5x1010 particles) does 
not synergistically enhance tumor eradication   .............................................................................. 86
Figure 22: Co-treatment with Ad.IL-12 (5x108 particles) and Ad.IL-23 (2.5x1010 particles) does 
not synergistically enhance anti-tumor effects   ............................................................................. 87
Figure 23: Co-treatment with Ad.IL-12 (1x108 particles) and Ad.IL-23 (1x1010 particles) does 
not synergistically enhance anti-tumor activity   ............................................................................ 88
Figure 24: Ad.IL-12 and Ad.IL-23 co-treatment does not result in synergistic systemic anti-
tumor effects   ................................................................................................................................. 89
Figure 25:  Effects of Ad.IL-12 and Ad.IL-23 co-treatment on CD4+ and CD8+ T-cell infiltrate
 ....................................................................................................................................................... 91
Figure 26:  Effects of Ad.IL-12 and Ad.IL-23 co-treatment on dendritic cell and regulatory T-cell 
infiltrate   ......................................................................................................................................... 93
Figure 27:  Effects of Ad.IL-12 and Ad.IL-23 co-treatment on angiogenesis   .............................. 95
Figure 28: Characterization of adenovirus expressing single-chain IL-12   ................................... 98
Figure 29: Characterization of adenovirus expressing single-chain IL-23   ................................. 100
Figure 30: Co-treatment with Ad.scIL-23 and Ad.IL-12 do not synergistically enhance anti-
tumor effects   ............................................................................................................................... 101
Figure 31:  Effects of Ad.scIL-23 and Ad.IL-12 co-treatment on immune cell infiltrate and 
angiogenesis   ................................................................................................................................ 104
Figure 32: Effects of co-treatment with Ad.IL-17 and Ad.IL-23   ............................................... 105
Figure 33: Effects of co-treatment with Ad.IL-23 and Ad.IL-17RFc  ......................................... 106
 xvi 
PREFACE 
This work is dedicated to my mother, Maureen, who taught me strength and grace in the face of 
adversity and who endowed me with the resolve  necessary to get to this point in my life  and 
especially to my amazing husband, Dan and wonderful son, Lennon, whose love and support 
carried me through the adventure of graduate school and gave me the strength to persevere to the 
end.  I love you all much more than you will ever know. 
 
 
 
Portions of the work in this dissertation were published originally as “Adenoviral-mediated, 
intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response” in Cancer 
Gene Therapy, in October 2009. 
 
 1 
1.0  INTRODUCTION 
1.1 CANCER 
In spite of the declaration of the “War on Cancer” by Richard Nixon in 1971 and subsequent 
billions of federal dollars funneled into research, cancer remains a top public health concern in 
the United States and abroad.  According to the Centers for Disease Control and Prevention, 
cancer is second only to cardiovascular disease as the leading cause of death amongst men and 
women in the United States.1  In fact, 1 in every 2 men and women born in the United States 
today will be diagnosed with some form of cancer in their lifetimes.2  Currently, 11,384,892 men 
and women alive have a history of cancer, with a median age of diagnosis at 66 years of age.2  In 
2009, approximately 1,479,350 individuals were diagnosed with cancer in the United States, with 
562,340 succumbing to the disease.  Currently, the leading causes of death from cancer amongst 
men include lung, prostate and colorectal.  For women, the leading causes of cancer deaths are 
lung, breast and colorectal cancer.3  Overall, cancer incidence is higher for men than women.3  
At most, only 10 percent of cancers arise as a result of germ line mutations; thus the remaining 
90 percent are a result of lifestyle or environmental factors.  Diet is the highest contributing 
factor to cancer development at 35%.  Exposure to tobacco smoke is the second leading cause 
(30%), followed by obesity (20%), infections (18%) and radiation and pollutants (7%).4   
Although cancer remains a leading cause of death in the United States, some progress has 
been made towards its eradication.   1998 marked the first year since 1930 that a sustained 
decline in cancer deaths was reported.5  This trend continued from 1999 to 2006, during which 
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time diagnoses of new cancers and deaths due to cancer significantly declined amongst all racial 
and ethnic groups in the United States.3  This was due largely to declines both in rates of new 
cancers and deaths from three of the most common cancers in men (lung, prostate and colorectal) 
and two of the three most common cancers in women (breast and colorectal).3  Overall, diagnosis 
of new cancer cases in the United States has declined almost 1 percent per year from 1999 to 
2006, while deaths due to cancer have declined 1.6 percent per year from 2001 to 2006.3 
However, while cancer rates overall have declined, incidence of various cancers in both 
men and women continue to rise.  In men, rates of renal, esophageal and liver cancers, as well as 
melanoma, myeloma and leukemia, continue to climb.  Likewise, in women, incidence of lung, 
bladder, thyroid and pancreatic cancers continue to mount, in addition to non-Hodgkin 
lymphoma, melanoma and leukemia.3  Thus, while some progress is being made to conquer 
cancer, the development of more effective therapies is still needed. 
1.1.1.1 Current Therapies 
Traditional treatments for cancers are broadly divided into categories that include radiation, 
chemotherapy, surgery or biological therapies.  Chemotherapy specifically targets rapidly 
dividing cells, while radiation therapy destroys all cells within the targeted area.  Surgery simply 
involves removal of the tumor mass itself.  Due to the ability of the immune system to recognize 
and eradicate tumor cells, biological therapies that aim to activate the host immune response to 
tumors have gained much interest and many are currently on the market.  Approved biological 
therapies for cancer include monoclonal antibodies, immune adjuvants and cytokines.  Nine 
monoclonal antibodies against six cancer-specific proteins are currently in use and function by 
rapidly activating both innate and adaptive immune responses to tumors.6  In a similar vein, 
immune adjuvants activate the immune response to tumor antigens and agents such as TLR7 
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agonist imiquimod and bacilli Calmette-Guérin (BCG) have been used to effectively treat 
epithelial tumors and bladder cancer, respectively.6  Cytokines clinically utilized in cancer 
therapy include IFN-α, IL-2 and TNF-α.  IFN-α has been approved for the treatment of renal cell 
carcinoma and melanoma.7-8  IL-2 has been used to effectively treat metastatic melanoma, as 
well as renal cell carcinoma.9-10  TNF-α has been efficacious in treatment of soft tissue 
sarcomas.11  However, administration of recombinant cytokines is often associated with severe 
toxicity.9  Thus, activation of the host immune response to various tumor antigens using 
cytokines has proven an effective therapeutic strategy in cancer therapy.  However, much work is 
still needed to identify cytokines possessing both immune stimulating and anti-tumor efficacy 
with minimal off-target toxicities.   
1.1.2 MCA205 mouse fibrosarcoma model 
Preclinical animal models of cancer are an efficient means by which to test and characterize a 
variety of anti-cancer therapies.  MCA205 is a mouse model of fibrosarcoma derived by 
intramuscular injection of carcinogen 3-methylcholanthrene in C57BL/6 mice, is H-2b restricted 
and considered weakly immunogenic.12  A variety of immunotherapies have proven highly 
effective in activating the host immune response to MCA205 tumors.  Stable expression of IFN-
α, either alone or in combination with CD80, led to regression of MCA205 tumors and was 
associated with accumulation of CD4+ and CD8+ T-cells, as well as dendritic cells.13  Dendritic 
cells pulsed with tumor peptides significantly inhibited established MCA205 tumor growth.14  
Additionally, dendritic cells expressing IL-12 resulted in regression of established MCA205 
tumors by induction of a Th1-type anti-tumor response.15   Treatment of established MCA205 
tumors with IL-18, either alone or in combination with IL-2, resulted in suppressed tumor 
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growth.16-17  Adenoviral-mediated expression of IL-12, IL-18 and IL-1H4 resulted in significant 
anti-tumor effects in established MCA205 tumors.18-20  Treatment of established tumors with IL-
21 cDNA also resulted in suppression of tumor growth by enhancing cytotoxic activity of NK 
cells.21  Overall, a variety of biological therapies have been proven to effectively activate both 
innate and adaptive immune responses against the weakly immunogenic MCA205 tumors.  Thus, 
these agents could possibly be broadly applied clinically to combat other weakly immunogenic 
cancers. 
1.1.3 The immune system and cancer 
The role the immune system is maintenance of tissue homeostasis, defense against foreign 
pathogens and destruction of damaged cells.  Conceptually, immunity is divided into two arms, 
innate and adaptive, which differ with respect to timing of activation and recognition of antigen.  
While cells of innate immune system are rapidly activated, their repertoire for recognizing 
antigens is limited by germline encoded receptors.  Cells involved in innate immunity include 
monocytes, macrophages, granulocytes (neutrophils, eosinophils, basophils), mast cells, dendritic 
cells (DCs) and natural killer (NK) cells.  NK cells destroy virus infected normal cells and cancer 
cells.  Macrophages and DCs act as sentinels by continuously monitoring tissues for infection or 
“danger signals.”  Upon encountering antigen, macrophages present antigens on their cell surface 
and produce various cytokines, while DCs migrate to the lymph nodes to present antigens to 
adaptive immune cells and initiate an adaptive immune response.  Adaptive immune cells, in 
contrast, are activated over days and recognize antigen via diverse antigen receptors that are 
specific for each antigen encountered.  Adaptive immune cells include B-cells, CD4+ T-helper 
cells and CD8+ cytotoxic T-lymphocytes.  CD4+ T-cells drive various types of adaptive immune 
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responses, B-cells are responsible for antibody production, while CTLs are responsible for 
mediating the lysis of virus-infected or tumor cells.22-23 
1.1.3.1 CD4+ T-cells 
CD4+ T-cells are also referred to T-helper cells, due to their ability to activate B-cells, CTLs and 
macrophages, as well as to direct different types of adaptive immune responses via production of 
distinct patterns of cytokines and chemokines.24  Th1 cells recognize antigens within the context 
of major histocompatibility complex class II (MHC II) molecules, which are expressed on the 
cell surface of antigen presenting cells (APCs) such as DCs.25  Two types of CD4+ T-cells 
emerge from the thymus fully differentiated: natural killer T (NKT) cells and natural T 
regulatory cells.24  Other CD4+ T-cells leave the thymus in a “naive” state, with subsequent 
activation and functional polarization occurring in the periphery.  T-cell exposure to antigen in 
the context of the T-cell receptor via APCs (Signal 1), followed by co-stimulation of the CD28 
co-receptor with APC-expressed CD80/86 (Signal 2) leads to activation of the CD4+ T-cell, 
which is followed by proliferation and differentiation into effector and memory subsets.25  The 
type of T-helper cell generated depends upon cytokines present within the extracellular milieu 
during activation (Signal 3).25  To date, four different subsets of CD4+ T-cells have been 
identified, each of which appears responsible for driving a distinct type of adaptive immune 
response.  These include Th1, Th2, Th17 and induced T-regulatory cells (Tregs) (Figure 1).  In 
1986, Tim Mossman and Bob Coffman identified the seminal Th1 and Th2 T-helper cell subsets 
and showed they could be distinguished based on their cytokine secretion profiles.26  Th1 T-cells 
were ultimately found to drive cell mediated immune responses capable of eradicating 
intracellular pathogens by activation of cytotoxic T-lymphocytes (CTLs).  In addition, Th1 cells 
have also been implicated in a variety of autoimmune diseases such as experimental autoimmune 
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encephalitis (EAE) and multiple sclerosis (MS), although the recent discoveries of IL-23 and 
Th17 T-cells has called their dominance in this role into question.27  Th1 cells generate an 
effective immune response to tumors by generating and enhancing tumor-specific CTL 
responses.25  Th1 cells are characterized by production of IFN-γ, IL-2 and lymphotoxin alpha 
and by expression of transcription factor T-bet.26,28  Th1 cell differentiation is driven by 
production of IL-12 by APCs, which stimulates NK cells to produce IFN-γ, which in turn 
enhances T-bet expression in CD4+ T-cells via activation of STAT1.24  T-bet drives IFN-γ 
production, which upregulates IL-12Rβ2 expression (IL-12Rβ1 is constitutively expressed on 
naïve CD4+ T-cells) and sensitizes CD4+ T-cells to IL-12, which results in additional production 
of IFN-γ and commitment to the Th1 phenotype.24 
Th2 cells support humoral or antibody-mediated adaptive immune responses that are 
effective in eradicating extracellular pathogens, but have also been implicated in asthma.  Th2 
cells are characterized by production of IL-4, IL-5, IL-10 and IL-13 and by expression of 
transcription factor GATA-3.    IL-2 and IL-4 are necessary for driving a humoral immunity; IL-
4 activates STAT6, which upregulates GATA-3 expression.24  While overall Th2 cells are 
regarded as pro-tumorigenic due their ability to induce angiogenesis and inhibit cell-mediated 
immune responses to tumors, there have also been reports that Th2 cells may promote anti-tumor 
immunity under certain circumstances.29 
Th17 cells provide immunity to extracellular bacteria and fungi, but are also implicated in 
a variety of autoimmune diseases.  Th17 cells are characterized by expression of IL-17A and IL-
17F, as well as IL-6 and TNF.30  Th17 cells are generated under priming conditions containing 
TGF-β and IL-6, which induces T-cell expression of the transcription factor RORγt.31-33  IL-23 is 
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necessary for maintenance of the Th17 lineage.34  Th17 cells have been shown to possess both 
pro- and anti-tumor effects.35 
Regulatory T-cells are responsible for curtailing immune responses, as well as for 
maintaining self tolerance.  Tregs are characterized by secretion of immunosuppressive cytokines 
such as IL-10 and TGF-β and by expression of transcription factor Foxp3.  IL-2 and TGF-β are 
necessary for polarization of responder T-cells towards a Treg phenotype, due to STAT5 and 
Smad3-mediated induction of Foxp3 expression, respectively.24  Treg-mediated suppression of 
anti-tumor immune cells have been implicated in immune tolerance to tumors.36      
 
 
    Figure 1: CD4+ T-cell subsets 
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1.1.3.2 Role of the immune system in carcinogenesis 
It has been well established that a link exists between the host immune response and cancer 
development; however, the precise role of the immune system in cancer pathogenesis remains 
unclear.  In general, there are three possible scenarios for the role of the host immune response to 
tumors (1) the host immune system recognizes the tumor as foreign and subsequently limits 
tumor growth or mediates its regression (2) chronic inflammation creates an environment that is 
conducive to tumor growth, neoangiogenesis and immune suppression or (3) the host immune 
system is rendered tolerant or ignorant of the cancer, leading to unchecked regression. 
 Indeed several lines of evidence implicate host immunity and inflammation in the early 
pathogenesis of cancer.  Various types of chronic inflammation are associated with cancer 
development, such as infections (including H. pylori and hepatitis B and C viruses) and presence 
of inflammatory bowel disease.37  Likewise, proven risk factors for cancer, such as tobacco 
smoke and obesity, are also linked to inflammation.37  Activation of innate immune cells 
contributes to carcinogenesis using such means as induction of DNA damage by free radicals, 
promotion of angiogenesis and tissue remodeling by various cytokines, chemokines and matrix 
metalloproteinases and suppression of anti-tumor immune responses.23  However, adaptive 
immune cells can also support tumor progression.  Regulatory T-cells (Treg) suppress effector T-
cell responses against tumors and generation of humoral immune responses within the tumor 
increases chronic inflammation.23   
However, there are reports that the host immune system plays only a minor role in the 
development and progression of some types of cancers.  Some tumors do not exhibit any immune 
cell infiltrates, which may be a result of physical separation from secondary lymphoid organs, 
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and thus, T-cells.  In this scenario, the tumor remains completely unrecognized by T-cells, but 
does not actively suppress the host immune response, either.38   
In the final scenario, the tumor itself is antigenic due to expression of altered or 
overexpressed “self” antigens, which is recognized and destroyed by the host immune system 
utilizing both innate and adaptive components.  Indeed, the importance of the host immune 
response in attenuating cancer pathogenesis has been well established in a variety of clinical 
cancer studies.  In advanced ovarian carcinoma, presence of T-cells within the tumor 
microenvironment correlated with significantly enhanced 5-year survival compared to patients 
with tumors lacking T-cell infiltrate (38 versus 4.5 percent survival) and was associated with 
increased IFN-γ.39  Likewise, enhanced 5-year survival rates were also associated with enhanced 
lymphocyte infiltration in rectal cancer patients.40  Infiltration of tumors by CD8+ T-cells was 
associated with better overall survival in colorectal patients.41  The association of immune cell 
infiltrate of tumors with a favorable prognosis suggests that at least some attempt is made by the 
host immune system to eliminate tumors.  Other lines of evidence in a variety of mouse models 
of cancer highlight the role of the immune system in preventing tumor growth.  Mice deficient in 
B, T and NKT cells are more susceptible to chemical induced carcinogenesis,42-43 as are mice 
deficient in various cytokines associated with a cytotoxic lymphocyte response, such as IFN-γ  
and IL-12/23 p40.42,44-45   
Overall, it is apparent that the immune system can indeed control tumor growth; 
however, it appears that the timing and type of immunity activated dictates whether the immune 
system will play friend or foe in carcinogenesis.  Generation of a full anti-tumor adaptive 
immune response should result in eradication of malignancies, while chronic activation of innate 
cells in premalignant tissues may promote tumorigenesis.23  My project is based upon the 
 10 
hypothesis that the immune system can recognize and eradicate tumors, but that cancer develops 
and progresses as a result of tumor-induced suppression of an otherwise effective anti-tumor 
immune response.  Specifically, I believe that initially the majority of CD4+ T-helper cells 
within the tumor are Th1-polarized and can effectively generate an anti-tumor immune response.  
However, over time, T-cell polarization progresses to a Th2 and eventually a Treg phenotype 
characterized by immunosuppression and inhibition of an effective anti-tumor response.  I 
propose that local, adenoviral-mediated expression of Th1 polarizing cytokines, such as IL-12 
and IL-23, would repolarize the T-helper immune response to tumors from a Treg to a Th1 and 
mount an anti-tumor immune response capable of eradicating tumors.   
1.2 INTERLEUKIN 12 
1.2.1 Discovery 
Interleukin 12 (IL-12) was first described in the late 1980’s as a cytotoxic T-lymphocyte (CTL) 
maturation factor upon discovery that supernatants from human leukocytes, PBMCs and B-
lymphoblast cells could stimulate CTLs in synergy with IL-2.46-48  Simultaneously, T-cell 
stimulating factor, a secreted product possessing the ability to reactive resting T-cells, was 
described.49  Yet another factor, termed natural killer cell (NK) stimulatory factor, was purified 
from B-lymphoblast cells and, like its name suggests, was found to induce production of IFN-γ 
from and enhance mitogen-induced proliferation of PBMCs, as well as stimulate NK 
cytotoxicity.50  Cloning of the IL-12 p35 and p40 genes from B-lymphoblasts led to the 
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realization that CTL maturation factor, T-cell simulating factor and natural killer cell stimulatory 
factor were indeed identical and this cytokine was subsequently renamed interleukin 12.51  
1.2.2 Expression 
IL-12 is heterodimeric cytokine comprised of disulfide-bonded p35 and p40 subunits.48,50  The 
p40 subunit is similar to cytokine receptors, while p35 is related to IL-6 and GCSF.52  Both the 
p40 and p35 subunits must be co-expressed within the same cell to be secreted as biologically 
active IL-12.51  While p35 is constitutively expressed in many cell types, p40 expression is 
limited primarily to phagocytic cells.  Interestingly, however, within p40-expressing cells, p35 
expression appears to be the limiting factor in IL-12 production.53  
IL-12 is expressed by a variety of cells, including monocytes, macrophages, dendritic 
cells, neutrophils and some B-cells.54  IL-12 expression can be induced by a variety of 
pathogens, including bacteria, fungi, parasites and viruses.  Additionally, CD40-CD40 ligand 
engagement between antigen presenting cells (APCs) and T-helper cells induces IL-12 
production.55  IL-12 elicits IFN-γ expression from resting and activated NK and T-cells.50,56-57  
T-cell-derived IFN-γ, in turn, primes monocytes for LPS-induced production of IL-12 by 
upregulating p40 and p35 transcription, thus generating a positive feedback loop for IL-12 
production.58  
1.2.3 IL-12 Receptor  
The IL-12 receptor is likewise comprised of two subunits, IL-12Rβ1 and IL-12β2.  Both IL-
12Rβ1 and IL-12Rβ2 are Type 1 transmembrane proteins most closely related to the cytokine 
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receptor gp130.59-60  Both subunits must be present to form a high affinity, functional IL-12 
receptor.60  IL-12 binds to its receptor primarily via interaction of the p40 subunit with IL-
12Rβ1.61  IL-12Rβ2 binds both the p35 subunit, which is required for signaling, and the IL-
12p70 heterodimer.61  The cytoplasmic portion of the IL-12Rβ2 subunit contains numerous 
tyrosine residues and is responsible for signal transduction.60  Binding of IL-12 to its receptor 
activates JAK2 and TYK2, leading to the phosporylation of multiple STAT transcription factors, 
including STAT1,3, 4, and 5.62-64  STAT4 appears to be the most prominent STAT activated, as 
IL-12 induced activation of NK and T-cells, as well as generation of an effective Th1 immune 
response, is effectively abrogated in STAT4-deficient mice.65-66   
The IL-12 receptor is expressed by activated, but not resting, NK and CD4 and CD8-
positive T-cells, as well as some B-cells.67  IL-12 receptor is also expressed on DCs; however, in 
these cells, signaling is mediated via NF-κB activation.68  Activation of T-cells via the T-cell 
receptor upregulates expression of both chains of the IL-12 receptor.69  Furthermore, IFN-γ 
induces transcription factor T-bet expression in T-cells, which in turn upregulates IL-12Rβ2 
expression, thereby driving and maintaining a Th1 response.70-71 
1.2.4 IL-12 Regulation 
IL-12 expression in APCs can be inhibited by a number of cytokines.  IL-10 inhibits IL-12 
expression by inhibition of p40 transcription, thereby leading to less IL-12 production.72  TGF-β 
inhibits production of IL-12 and interferes with IL-12 receptor-mediated signaling, including 
inhibition of STAT4.73-74  Finally, p40 homodimers inhibit IL-12 mediated proliferation and 
production of IFN-γ from mouse splenocytes and activation of NK cells by binding to the IL-12 
receptor.61  
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1.2.5 Biological Activity 
IL-12 induces activation and proliferation of, as well as IFN-γ production from, NK and T-
cells.50,75  IL-12-mediated induction of IFN-γ requires the presence of TNF-α and IL-1β.72  
Additionally, IL-12-mediated proliferation of and IFN-γ production from T-cells is 
synergistically enhanced by IL-2 and B7/CD28 costimulation.57,76  IL-12 also synergizes with 
IL-18 to enhance IFN-γ production from T77 and NK cells,78 possibly by inducing IL-18 
expression and/or upregulating the IL-18Rβ chain.79  Furthermore, in response to microbial 
infection, IL-12 is produced by activated macrophages, which in turns drives generation of a 
Th1-type adaptive immune response; therefore, IL-12 acts as a bridge between both innate and 
adaptive arms of the immune system (Figure 2).80  IL-12 plays a key role in the generation and 
activation of cytotoxic T-lymphocytes (CTLs) and its absence or presence decides between 
tolerance or generation of cytotoxic function.81-82  Finally, in the context of cancer, IL-12 may 
repolarize dysfunctional T-helper cells to a Th1 phenotype.83  
IL-12 is known mainly for its role in driving Th1, or cell-mediated, immune responses.  
Early studies suggested that IL-12 was required for commitment to the Th1 lineage: IL-12 was 
shown to induce IFN-γ expression and drive CD4 positive T-cells towards a Th1 phenotype, 
while blocking expression of IL-4 and a generation of a Th2 response.84  However, further 
studies have indicated that expression of transcription factor T-bet actually determines lineage 
fate by upregulating IL-12Rβ2 expression and allowing for expression of IFN-γ independent of 
IL-12, suggesting that IL-12 is required mainly for proliferation and maintenance, and hence 
survival, of the Th1 lineage.85  Regardless of the sequence of events, IL-12 is obviously 
intimately involved with the development of Th1 T-helper cells.   
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Additionally, the importance of IL-12 in inhibition of carcinogenesis has been well 
documented.  Mice deficient in p40 are more susceptible to UV86-87 and methylcholanthrene42 
induced tumors.  Additionally, IL-12 neutralization decreases rejection of transplantable 
tumors.88 
 
 
Figure 2: Biological effects of IL-12 
1.2.6 IL-12 therapy in preclinical cancer models 
Due to the ability of IL-12 to enhance NK and CTL cytotoxic activity, induce IFN-γ expression 
and drive a Th1 response, while blocking Th2 immunity, IL-12 was expected to be an effective 
anti-cancer agent.  Indeed, not long after its discovery, studies highlighting the ability of IL-12 to 
enhance cytotoxicity of NK cells against a variety of cancer cell lines in vitro were published.89-
91  Not long thereafter, recombinant mouse IL-12, when injected either systemically or 
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peritumorally, was shown to effectively eradicate various metastatic and subcutaneous tumors.92  
Further studies supported the anti-tumor activity of IL-12 in murine adenocarcinoma and 
sarcoma models.93  However, use of recombinant IL-12 was associated with profound toxicity.93 
 While investigations into the anti-cancer properties of recombinant IL-12 continued, 
therapies involving restriction of IL-12 expression to the tumor microenvironment were devised.  
This included either treatment with cells transduced to express IL-12 in vitro or the direct 
transduction of tumors in vivo with IL-12 cDNA.  Such strategies circumvent the toxicity 
associated with systemic delivery of recombinant IL-12 by restricting IL-12 expression 
predominantly to the tumor compartment.  Additionally, high, local concentrations of IL-12 
could possibly enhance induction of potent systemic anti-tumor immunity.  Treatment of tumors 
with cells stably expressing IL-12 was highly successful.  Expression of IL-12 in various murine 
tumor models, including renal cell,94 pancreatic95 and colon carcinoma96 inhibited tumor growth.  
Likewise, IL-12-expressing syngenic fibroblasts have been shown to successfully hinder tumor 
growth in various murine models of cancer, including melanoma,97-98 ovarian,99 sarcoma,100 
hepatocellular carcinoma,101 and pancreatic peritoneal carcinomatosis,102 as well as inhibit liver 
metastases in a breast cancer model.103  Additionally, treatment with syngenic DCs expressing 
IL-12 have shown therapeutic benefit in a variety of preclinical models including melanoma,15,104 
sarcoma,15 adenocarcinoma,105 as well as inhibit liver metastases in a colon carcinoma model.106 
Similarly, IL-12-based therapies involving direct transduction of tumor cells with genes 
encoding this cytokine have also proved highly successful.  Transfer of naked IL-12 DNA 
successfully inhibited tumor growth in various cancer models including melanoma,107 colon 
carcinoma,108 and renal carcinoma.108  Other nonviral delivery methods including 
electroporation,109-110 gene gun111-112 and liposome113-114-mediated transfer of IL-12 have 
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similarly yielded clinically relevant inhibition of tumor growth in a variety of cancer models.  IL-
12 cDNA has also been delivered to tumor cells using a variety of viruses, including 
retrovirus,115-117 vaccinia virus,118-119 alphaviruses,120-122 herpes simplex viruses,123-125 with 
therapeutic benefit demonstrated in a number of cancer models including melanoma, colon 
adenocarcinoma, neuroblastoma,123 colorectal,124 squamous cell carcinoma,116-117,125 and 
glioma.119   
The anti-tumor effects of adenovirally delivered IL-12 have been exhaustively 
investigated.  Direct injection of adenovirus expressing IL-12 into tumors results in enhanced 
survival and induction of protective immunity.18,126-128  Adenoviral-mediated expression of IL-12 
yielded therapeutic benefit in a variety of preclinical cancer models including sarcoma,18,126 
colorectal,127 hepatocellular carcinoma,128 adenocarcinoma,18 glioma,129 prostate,130 thyroid,131 
and breast.132  Additionally, in animals bearing two tumors, treatment of one tumor was 
associated with regression of the distal tumor.128  Thus, adenovirus has proven to be an effective 
tool for delivery of IL-12 into the tumor microenvironment to yield clinical anti-tumor benefit.  
1.2.6.1 Mechanism of IL-12-mediated anti-tumor effects 
The dual ability of IL-12 to stimulate both innate and adaptive arms of immunity  is evident in its 
mechanisms of tumor eradication.  IL-12 induction of IFN-γ production from NK and T-cells is 
important in tumor eradication, especially early on in the immune response.115,133-134  IFN-γ 
inhibits angiogenesis,135 at least in part by induction of chemokines IP-10 and Mig.136-137  IFN-γ 
also induces iNOS expression in tumor cells, leading to NO production and subsequent inhibition 
of tumor growth.138   During generation of adaptive immunity, IL-12 activates CD4+ and CD8+ 
T-cells for effective tumor eradication and generation of long-lasting protective 
immunity.93,111,115,134  NKT cells also appear to play an important role in the anti-tumor activity 
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of IL-12.139  Additionally, IL-12 may inhibit formation of metastases by inhibiting migration and 
invasion of tumor cells by upregulation of E-cadherin cell surface molecules.140   
1.2.7 IL-12 in Clinical Trials  
1.2.7.1 Recombinant IL-12 
Due to the initial success of IL-12 treatment in preclinical models of cancer, IL-12-based 
therapies quickly progressed to use in human clinical trials.  While IL-12 therapy in preclinical 
animal models was relatively well tolerated, recombinant IL-12 treatment of advanced 
malignancies in humans was associated with toxicity in the form of fever, chills, nausea, 
vomiting and headache.141  In fact, recombinant IL-12 treatment led to the death of two kidney 
cancer patients enrolled in a Phase II clinical trial, using a dose previously found to be safe 
during Phase I studies.  It was subsequently discovered that predosing of IL-12 is necessary to 
ameliorate toxicity associated with subsequent, higher doses.142-143  To date, there have been 
numerous human clinical trials investigating the usefulness of IL-12 as an anti-cancer agent.  
Recombinant IL-12 has been utilized in the treatment of numerous cancers, including melanoma, 
renal and bladder.  However, clinical efficacy was minimal, with only 0 to 7 percent response 
based on RECIST grading criteria initially established for  chemotherapy agents.144  IL-12 has 
also been investigated within the context of cancer vaccines, other cytokines such as IL-2 and 
IFN-α2b, or antitumor monoclonal antibodies (Trastuzumab), again with only modest clinical 
success and at most an 11 percent response rate.144   
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1.2.7.2 IL-12 gene therapy  
As was indicated before, use of recombinant IL-12 is limited due to severe toxicity in humans.  
Thus, to simultaneously increase the dose of IL-12 used and decrease associated toxicity, local 
production of IL-12 within the tumor using various gene therapy approaches has been 
investigated.  IL-12 has been delivered using autologous fibroblasts in advanced cancer patients, 
with transient anti-tumor effects reported in five of nine treated patients.145  Treatment of 
melanoma patients with autologous tumor cells expressing IL-12 resulted in a moderate clinical 
response in one patient.146  Intratumoral injection of dendritic cells transduced with adenovirus 
expressing IL-12 for treatment of gastrointestinal tumors yielded similar results, with a partial 
response reported in only one patient.147  In contrast, direct injection of plasmid DNA encoding 
IL-12 into melanoma lesions yielded more promising results, with two instances of stable disease 
and one complete remission reported in one study,148 and significantly decreased lesion size in 
more than 30 percent of patients in another.149  Canarypox virus has also been used to deliver IL-
12 cDNA intratumorally, in combination with B7.1 cDNA, in treatment of melanoma; however, 
no tumor regressions occurred.150  In all trials, little to no toxicity was observed.  However, 
overall clinical efficacy of IL-12 cancer gene therapy has been limited; thus new cytokines are 
continuously sought out for use in combination with IL-12, to enhance therapeutic efficacy and 
decrease the effective dose needed. 
1.2.8 Augmentation of IL-12 anti-tumor effects  
Numerous cytokines have been previously shown to synergistically enhance the anti-tumor 
activity of IL-12.  When administered either locally or systemically, recombinant IL-2 enhances 
the anti-tumor activity of IL-12 cDNA transduced fibroblasts151 and the vaccine effect of TS/A 
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tumor cells stably expressing IL-2 was synergistically enhanced upon co-treatment with systemic 
recombinant IL-12.152  Mice bearing B16 melanoma tumors expressing IL-12 family member IL-
27 exhibited synergistically decreased tumor volume when co-treated with an intraperitoneal 
injection of recombinant IL-12.153   
Anti-tumor synergism between IL-12 and IL-18 has also been extensively studied due to 
the ability of IL-18 to synergistically enhance IL-12-mediated IFN-γ production from T-77 and 
NK cells.78  Co-delivery of IL-12 and IL-18 using electro-gene therapy synergistically enhanced 
reduction of tumor volume and was associated with an increase in IFN-γ and CD8+ T-cells in 
tumors.154  Likewise, administration of recombinant IL-18 synergistically enhanced vaccine 
effects of Renca cells stably expressing IL-12 and was dependent upon involvement of CD4+ 
and CD8+ T-cells and NK cells.155  Finally, use of systemically delivered recombinant IL-18 and 
MBT2 mouse bladder cancer cells stably expressing IL-12 synergistically enhanced anti-tumor 
effects in an IFN-γ dependent fashion.156   
TNF-α has also been studied at length for its ability to synergize with IL-12, due to its 
shared ability to induce inflammation and inhibit tumorigenesis.  When co-delivered with TNF-α 
using poly-lactic acid microspheres, IL-12 synergistically enhanced anti-tumor effects in both 
primary and contralateral B16 and MCA205 tumors, an effect that was dependent upon CD8+ T- 
and NK cells.157  IL-12 pretreatment of HT144 melanoma cells followed by treatment with TNF-
α also synergistically enhanced survival over use of either cytokine alone.158  Co-treatment of 
CT26 colon and Renca renal carcinoma with IL-12 and TNF-α led to synergistically enhanced 
tumor rejection, due likely to involvement of CD8+ T and NK cells.159   
The combination of IL-12 and IL-15 has also yielded therapeutic anti-tumor benefit.  
Like IL-12, IL-15 activates NK cells160 and aids in maintenance of memory T-cells,161 as well as 
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activates tumor-specific CD8+ T-cells.162  Stable co-expression of IL-12 and IL-15 cDNA in 
TS/A breast adenocarcinoma cells also resulted in synergistically enhanced anti-tumor effects, 
which was independent of IFN-γ, but dependent upon CD8+ T-cells.163  Similarly, stable co-
expression of IL-12 and IL-15 cDNA in N592 small-cell lung cancer cells synergistically 
enhanced tumor rejection, possibly due to activation of macrophages.164  When injected 
intratumorally, recombinant IL-12 and IL-15 synergistically enhanced anti-tumor effects in a 
B16 melanoma model of cancer, most likely due to enhanced IFN-γ production.165   
Overall, IL-12 has been previously shown to synergize with other cytokines to 
synergistically enhance anti-tumor effects, commonly using mechanisms characteristic of a Th1 
response, including involvement of CD8+ T-cells and enhancement of IFN-γ production.  Thus, 
any potentially Th1 polarizing cytokine has the ability to synergize with IL-12 to enhance its 
anti-tumor effects. 
1.3 INTERLEUKIN 23 
1.3.1 Discovery 
IL-23 is a relatively newly described member of the IL-6/IL-12 family of heterodimeric 
cytokines.  It shares the IL-12 p40 subunit and is also composed of a unique p19 subunit.  IL-23 
was identified during a computational screen for IL-6 helical cytokine family members, in which 
p19 was first identified.166  Although its discovery came some 11 years after the first description 
of IL-12, its existence was somewhat anticipated.  Mice deficient in p40 were shown to be more 
susceptible to bacterial infection, died earlier and exhibited higher bacterial burdens than p35 
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deficient mice,167 suggesting that p40 may interact with another subunit to form a novel cytokine 
important in driving Th1 immunity.     
1.3.2 Expression 
IL-23 is composed of disulfide-bonded p40 and p19 subunits.166  The p40 subunit is similar to 
cytokine receptors and is shared with IL-12.52  The p19 subunit is comprised of four α-helices 
and is most closely related to IL-12p35.166  Like p35, p19 is only secreted from cells in the 
context of p40.166  Similar to IL-12, IL-23 is expressed by activated antigen presenting cells, 
including dendritic cells166 and macrophages,168 activated monocytes,169 endothelial cells and T- 
and B cells.166  IL-23 expression is induced by activation of Toll-like receptors by microbial 
products,166,170 as well as by Fas and CD40 ligand engagement by dendritic cells.171-172      
1.3.3 Receptor 
The IL-23 receptor likewise shares the IL-12Rβ1166 subunit and is also composed of a unique 
subunit designated IL-23R.173  Both subunits must be present to confer IL-23 responsiveness.173 
IL-12Rβ1 is a Type 1 transmembrane protein most closely related to the cytokine receptor 
gp130.59  IL-23R is also a Type 1 transmembrane protein and a member of the hemopoietin 
receptor superfamily related to IL-12Rβ2 and gp130.173  The extracellular region of IL-23R is 
comprised of an IgG-like and two cytokine receptor domains and possesses signaling 
capabilities.173  The p40 subunit binds to IL-12Rβ1, while p19 binds to the IL-23R.173  The IL-23 
receptor is found on T and NK cells, as well as macrophages173 and dendritic cells.174 
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IL-23 activates similar JAK/STAT signaling molecules as IL-12, including JAK2, TYK2, 
and STATS 1, 3, 4 and 5.166,173  IL-12Rβ1 binds Tyk2,175 while IL-23R associates with Jak2.173  
Binding of IL-23 to its receptor leads to JAK activation, which in turn leads to STAT 
recruitment.  Unlike IL-12, however, STAT4 is induced by IL-23 to a lesser extent and STAT3 
appears to be the most prominent STAT activated.173   
1.3.4 Biological activity 
Due to its structural similarities to IL-12, IL-23 was expected to share many of its 
immunostimulatory  and Th1-polarizing properties.  Like IL-12, IL-23 was found to stimulate 
proliferation and IFN-γ production from human activated T-cells; however, IL-23 treatment 
resulted in lower levels of IFN-γ production versus IL-12.166  Unlike IL-12, IL-23 appeared to 
preferentially activate both mouse and human memory, but not naïve, T-cells.166  Overall, it 
appears as though IL-12 acts early on in the development of a Th1 response, by activating and 
committing T-cells to this phenotype.  In contrast, IL-23, appears to promote maintenance of the 
Th1 response by enhancing proliferation and activation of the memory T-cell subset.  
Additionally, IL-23 has also been reported to inhibit Treg-induced immunosuppression in a 
UVR-induced DNA damage model.176   
IL-12 had been previously implicated in a variety of inflammatory and autoimmune 
conditions due to induction of a Th1 response and subsequent IFN-γ production.  Indeed, in the 
absence of p40, conditions such as collagen-induced arthritis (CIA),177 inflammatory bowel 
disease (IBD),178 and experimental autoimmune encephalomyelitis (EAE)179 exhibit reduced 
pathogenesis, affirming this assertion.  However, studies of CIA, EAE and IBD in mice lacking 
IFN-γ did not mirror these findings.  In fact, the absence of IFN-γ appeared to exacerbate CIA 
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and EAE disease.180-182  These findings suggested (1) a role of IFN-γ in attenuating inflammatory 
disease and (2) the role of an as of yet undiscovered cytokine involved in autoimmune 
inflammation.  Lack of EAE development in IL-23 (p19) deficient mice confirmed its role as a 
mediator of autoimmune inflammation.183  The discovery that IL-23 induces IL-17 production 
from a unique subset of CD4+ T-cells,184 followed by the implication of these cells in 
autoimmune pathogenesis,30 solidified the role of IL-23 in autoimmune inflammation.   
These studies ushered in new paradigms in both the physiologic role of IL-23 and the 
types of T-helper cells in existence.  The primary role of IL-23 appeared not to be in driving a 
Th1 response, but rather induction of  unique subset of T-cells characterized by expression of IL-
17A and F, IL-6 and TNF.30  These IL-17 producing T-cells, termed Th17, are distinct from 
traditional Th1 and Th2 helper cell lineages, being generated upon exposure to IL-23 and 
inhibited by exposure to IFN-γ.185  Further studies have shown that commitment to the Th17 
subset also requires TGF-β and IL-6,31-32 which induce expression of Th17-specific transcription 
factor RORγt.33  IL-6 also induces expression of IL-21, which enhances RORγt and IL-17 
expression.186  Upregulation of RORγt requires STAT3, while STAT4 is needed for maximal IL-
17 production in response to IL-23.187-188   RORγt in turn induces transcription of IL-17A and F 
in naïve T-cells and is responsible for differentiation into the Th17 effector cells.33  Overall, it 
appears as though TGF-β and IL-6 are necessary to drive cells towards a Th17 lineage, while IL-
23 is required for the maintenance of this subset.31  However, the precise role of TGF-β is 
unclear and as it is  a strong inhibitor of both Th1 and Th2 cells, TGF-β may indirectly favor 
polarization to the Th17 subset.189  Interestingly, Th1/Th17 cells have been discovered in 
Crohn’s disease patients, which are characterized by expression of both T-bet and RORγt 
transcription factors, as well as both IL-17 and IFN-γ.190  Th1/Th17 cells have been since 
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identified in mice and have also been associated with inflammatory conditions such as 
arthritis.191 
Since its discovery, the IL-23/Th17 axis has been implicated in a variety of autoimmune 
and inflammatory conditions.  The use of IL-23 p19-deficient mice has implicated IL-23 as the 
major mediator of inflammation in a variety of models, including EAE,183 Crohn's disease and 
ulcerative colitis.192  In humans, the IL23 receptor gene is associated with Crohn’s disease.193  
Additionally, IL-23 promotes expression of IL-22 in Th17 cells, a cytokine implicated in 
psoriasis, and indeed, increased IL-23 has been observed in psoriatic lesions of patients with 
psoriasis vulgaris.169,194  Increased systemic IL-23 levels are associated with disease activity in 
rheumatoid arthritis.195  IL-23 and Th17 cells have also been implicated in asthma.196    
Additionally, IL-23 appears to play a role in the control of infectious disease.  In studies 
investigating susceptibility to a variety of microorganisms, including Salmonella enteritidis, 
Cryptococcus neoformans, T. gondii and mouse cytomegalovirus, IL-12 p35-deficient mice are 
more resistant to a variety of microorganisms than their p40-deficient counterparts.167,197-199  
Furthermore, IL-23 p19 deficient mice are highly susceptible to Klebsiella pneumoniae infection, 
likely due to lack of induction of IL-17 production.200  Additionally, administration of IL-23 to 
p40 deficient mice enhanced resistance to T. gondii infection.199  Thus, IL-23 appears to play a 
role in limiting the severity of infectious disease. 
1.3.5 Regulation 
Due to their association with highly pathologic inflammatory conditions, it is not surprising that 
the development of Th17 cells is highly regulated.   IL-12, IFN-γ and IL-4185,190 all inhibit Th17 
development.  IL-12/IL-23 family member IL-27 also blocks differentiation of Th17 cells.201  
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However, regulatory T-cells appear to be somewhat ineffectual against Th17 cells.190,202  
Additionally, LPS induced IL-23 expression in macrophages can also be inhibited by IFN-γ.203  
IL-10 can also inhibit p40 transcription, presumably resulting in reduced IL-23 production.204  
Finally, like IL-12, IL-23-mediated IFN-γ production is inhibited by p40 homodimers.205  
1.3.6 IL-23 and cancer 
Due to its similarity to IL-12 and ability to induce IFN-γ expression, IL-23 was expected to act 
as a potent anti-cancer agent.  Indeed, initial studies in various establishment models of cancer 
exemplified its ability to inhibit tumor growth and induce anti-tumor immunity.  However, recent 
studies highlighting the pro-cancer effects of IL-23 call this paradigm into question.  Overall, it 
appears as though pro- or anti-tumor effects of IL-23 depends upon expression levels of this 
cytokine.  At physiologic levels, IL-23 may possess pro-tumor effects, but when expressed at 
artificially high levels, IL-23 can act as an anti-cancer agent.  
1.3.6.1 Anti-tumor activity 
Shortly after its discovery, the first study investigating the anti-tumor effects of IL-23 in an 
establishment model of colon carcinoma was published.  Colon carcinoma cells stably 
expressing a single-chain version of IL-23 experienced inhibited growth and were subsequently 
rejected, with concomitant induction of tumor specific immunity.  Tumor rejection was 
associated with CD8+ T-cell production of IFN-γ and was dependent upon T-, but not NK, 
cells.206  When stably expressed in B16F1 melanoma cells, single chain IL-23 also inhibited 
tumor growth and formation of metastases in a CD8+ T-cell dependent, but CD4+ T-cell and NK 
cell independent, manner.207  Studies investigating the anti-tumor effects of single-chain IL-23 in 
 26 
a variety of establishment models of cancer followed, including pancreatic,208 human 
esophageal,209  colon carcinoma,210-211 melanoma,153 hepatocellular carcinoma,212 and mouse 
mammary carcinoma.213  Mechanisms appeared to exclude the involvement of NK cells,208 and 
some discrepancies exist over the importance of T-cells.209  However, overall, IL-23-mediated 
anti-tumor immunity appears to involve generation of a Th1 response, with dependence upon 
CD8+ T-cells and IFN-γ,153  CD40 expression,212 and production of Th1 polarizing cytokines, 
such as IFN-γ, IL-12 and TNF-α.211,213   
IL-23 has also been shown to possess anti-cancer effects in therapeutic cancer models as 
well.  Bone marrow-derived neural stem-like cells stably transduced with adenovirus expressing 
single chain IL-23 significantly enhanced survival of mice bearing intracranial gliomas and 
established protective immunity against tumor challenge.214  Induction of anti-tumor immunity in 
this model was dependent on CD4+ and CD8+ T-cells, as well as NK cells, and was associated 
with production of IFN-γ, not IL-17.214  Similarly, treatment of intracranial gliomas with 
dendritic cells transduced by an adenoviral vector to express single chain IL-23 also resulted in 
tumor rejection and generation of protective immunity mediated primarily by CD8+ T-cells, but 
also by CD4+ and NK cells as well.215  Systemic expression of IL-23 by electroporation of 
muscle cells with IL-23 plasmid DNA decreased tumor burden and enhanced survival of mice 
using CD4+, CD8+ and NK cells.216  Interestingly, a study using adenoviral-mediated delivery of 
IL-23 into the tumor microenvironment showed prophylactic, but not therapeutic, anti-tumor 
activity in a variety of cancer models, including melanoma and colon carcinoma.217  However, 
this was in stark contrast to our studies, which indicate that adenoviral-mediated delivery of IL-
23 into established fibrosarcoma tumors results in potent anti-tumor effects and induction of 
systemic immunity using mechanisms including IFN-γ and CD4+ and CD8+ T-cells.218      
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IL-23 has also been investigated as a vaccine adjuvant.  When used in conjunction with a 
gp100 peptide-based vaccine, IL-23 suppressed B16 tumor growth and enhanced the cytotoxic 
activity of vaccine induced CD8+ T-cells.219  While IL-23 therapy was also associated with 
enhanced IFN-γ production, the anti-tumor effects appeared to be primarily mediated by TNF-
α.219  Additionally, B16 cells expressing single chain IL-23 generated protective immunity 
against parent tumors.153 
Investigation of IL-23 synergy with a variety of cytokines has also been conducted.  
Interestingly, stable co-expression of IL-12 and IL-23 in osteosarcoma cells could only 
moderately enhance induction of IFN-γ expression from mononuclear cells compared to IL-12 
alone.220  However, inoculation with mixed populations of colon carcinoma  cells expressing 
single chain IL-12 and IL-23 did not synergistically enhance anti-tumor effects on a distal parent 
tumor over use of either cytokine alone.210  Additionally, co-transduction of tumor cells with IL-
18 and IL-23 cDNA by gene gun synergistically enhanced anti-tumor effectiveness.221  Similarly, 
the combination of IL-23-expressing B16 cells and recombinant IL-18 treatment synergistically 
enhanced anti-tumor immunity.153  Unsurprisingly, co-expression of free p40 and IL-23 inhibited 
the anti-tumor effects of IL-23 in colon carcinoma cells.205 
In summary, IL-23 appears to be a potent anti-cancer agent.  Its therapeutic capabilities 
have been demonstrated in a variety of establishment and therapeutic models of cancer, using a 
number of methods to achieve local levels of expression within the tumor microenvironment.  
Moreover, the ability of IL-23 to act as a vaccine adjuvant and to synergize with other 
Th1polarizing cytokines has been established as well.  Mechanisms of IL-23 mediated tumor 
eradication and establishment of protective immunity appear to involve activation of innate 
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immune cells as well as generation of a Th1 immune response, characterized by involvement of  
CD4+ and CD8+ T-cells, as well as Th1 polarizing cytokines such as IFN-γ, IL-12, TNF-α  
1.3.6.2 Pro-tumor effects 
While numerous studies have hailed the anti-tumor activity of IL-23, a few recent studies have  
laid doubt on this claim by declaring that IL-23 is indeed a tumor-promoting cytokine.  In a 
seminal paper, Langowski, et al. showed that IL-23, but not IL-12, expression is enhanced in 
human tumors and is associated with a decrease in CD8+ T-cell infiltrate and enhanced 
angiogenesis.222  Additionally, they demonstrated that inhibition of IL-23 expression leads to 
increased  resistance to both chemically induced and transplanted tumors.222  The authors 
explained the discrepancies between their study and numerous others asserting the anti-tumor 
effects of IL-23 as result of biologically relevant versus artificially inflated levels of IL-23 
expression.223  In their model, at physiologic levels, IL-23 acts as a proinflammatory mediator, 
inducing expression of factors such as matrix metalloproteinases and IL-17, which act in wound 
healing and repair responses and create an environment dominated by innate and inflammatory 
cells.223  In contrast, when expressed at artificially high levels within the tumor 
microenvironment, IL-23 may result in enhanced DC, macrophage and granulocyte infiltration, 
which would lead to tumor destruction.223  Other studies have supported the pro-tumor assertion.  
Production of lactic acid by tumors promotes IL-23 production by macrophages, thus creating a 
proinflammatory, pro-tumor environment.224  In colorectal carcinoma patients, serum IL-23, as 
well as p19 mRNA in tumor tissue, was found to be upregulated.225  Additionally, a correlation 
was found between IL-23 receptor gene polymorphisms and ovarian cancer risk and 
prognosis.226  Thus, much evidence suggests that IL-23, at physiologic levels, may possess pro-
tumor activity by promoting inflammation.    
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Recently, a mechanism has been proposed to explain the role of IL-23 in carcinogensis.  
IL-23 signaling results in STAT3 activation.173  Interestingly, STAT3 is also constitutively 
expressed in a variety of cancers and results in cell cycle progression, inhibition of apoptosis, 
immune evasion and angiogenesis.227  STAT3 activation also inhibits production of pro-
inflammatory cytokines as well as increasing expression of immunosuppressive factors such as 
IL-10.228  In tumors, STAT3 activation prompts IL-23 production from tumor associated 
macrophages.  IL-23 then binds to the IL-23 receptor on tumor associated Tregs, activating 
STAT3 and leading to increased Foxp3 and IL-10 expression.229  Thus IL-23 may create a pro-
tumor environment, at least in part, by enhancing Treg induced immunosuppression. 
1.3.7 Th17 cells and cancer  
As IL-23 has been shown to be a potent anti-cancer agent, yet drives IL-17 expression and is 
imperative for commitment of CD4+ T-cells to a Th17 phenotype, it begs the question whether 
either IL-17 or Th17 T-cells also possess anti-cancer activity.  Indeed, several studies have 
implicated IL-17 in anti-cancer immunity.  IL-17 deficient mice are more susceptible to lung 
melanoma230 and colon carcinoma development.231  Additionally, expression of IL-17 in 
hematopoietic tumors was found to significantly inhibit tumor growth in a T-cell dependent 
fashion.232  However, IL-17 may also possess pro-cancer effects.  Cervical carcinoma cells stably 
expressing IL-17 exhibit enhanced growth compared to parental cells in nude mice.233  
Additionally, a recent study found that IL-17 receptor-deficient mice are refractory to the 
development of  lymphoma, melanoma, and prostate tumor development and that antibody-
mediated depletion of IL-17 inhibits, while systemic administration of recombinant IL-17 
enhances, tumor growth.234   
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Numerous studies highlighting the anti-cancer effects of Th17 cells have also been 
published.  CD4+ T-cells specifically recognizing a B16 melanoma antigen polarized to a Th17 
phenotype in vitro effectively inhibited melanoma development  in an IFN-γ, but not IL-17 or 
IL-23, dependent manner.235  Additionally, adoptive T-cell therapy utilizing Th17 cells inhibited 
tumorigenesis by activation of tumor specific CD8+ T-cells and recruitment of DCs into the 
tumor microenvironment.230  Interestingly, in this study, adoptively transferred Th17 cells 
exhibited more potent anti-tumor effects than their Th1 counterparts.230   
However, Th17 cells have also been strongly implicated in carcinogenesis. Colonic 
carcinogenesis associated with human colonic bacterium Bacteroides fragilis expressing B. 
fragilis toxin is linked with a Th17 response and inhibition of IL-17 or the IL-23 receptor inhibits 
tumorigenesis.236  Additionally, melanoma, breast and colon cancers exhibit higher numbers of 
Th17 tumor infiltrating lymphocytes.237  Likewise, gastric cancer patients possess greater levels 
of Th17 cells in peripheral blood and tumor-draining lymph nodes.238   
Largely, the role of IL-17 and Th17 cells in cancer remains controversial.  Numerous 
studies have correlated IL-17 and Th17 cells with cancer incidence and mice deficient in IL-17 
appear to be refractory to development various types of cancers.  However, additional studies 
have shown that IL-17 and Th17 cells exert therapeutic effects utilizing mechanisms such as 
activation of CD8+ T-cells and induction of IFN-γ.  It may be that IL-17 and Th17 cells, like IL-
23, possess both pro- and anti-tumor activities, depending upon tumor model, expression level 
and means of administration.  Due to the role of IL-23 in IL-17 production and the purported 
anti-cancer properties of IL-17, we propose to investigate both the role of IL-17 in IL-23-
mediated anti-tumor immunity, as well as investigate any possible anti-tumor synergism between 
IL-23 and IL-17.    
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1.4 ADENOVIRUS 
Adenovirus was first identified in the 1950s upon isolation of the virus from adenoid tissue and 
currently includes 51 different serotypes, which are divided into 6 subtypes based on 
haemagglutination properties, oncogenic potential and DNA homology.239-240  Adenoviruses 
infect a variety of hosts, including mammals, birds and reptiles.241  Adenoviral infection is 
common in humans, can occur via respiratory, fecal-oral or ocular conjunctival routes and has an 
incubation period of 2 to 14 days.240  Adenovirus types 1, 2 and 5 account for 5 to 10% of all 
childhood respiratory diseases and can cause other mild gastrointestinal, urogenital and ocular 
diseases as well.240 
1.4.1 Structure 
Adenovirus is a non-enveloped, icosahedral virus approximately 90nm in diameter.  A fiber rod 
protrudes from each of the vertices from a penton base, which is composed of 5 penton 
polypeptides.  The fibers are composed of an N-terminal tail which binds to the penton base, a 
slender shaft and a C-terminal globular domain that interacts with the cocksackie and adenovirus 
receptor (CAR) on host cells.  The remainder of the virus is comprised of at least 7 additional 
minor capsid proteins that are believed to play important structural roles. Protein II, also called 
hexon, is also part of the capsid shell.  Proteins IIIa, VI, XIII and IV are involved in capsid 
stabilization.  The core is comprised of the terminal protein, which is linked to the genome, and 
proteins V, VII and μ, which are involved in DNA packaging.  The genome is a linear, 
approximately 35 kb double stranded DNA molecule which contains 103 nucleotide long 
inverted terminal repeats in which the origin of replication is embedded.242-243 
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1.4.2 Replication 
The classical pathway of adenovirus entry into cells first involves binding of the fiber knob to the 
cocksackie and adenovirus receptor (CAR) on host cells.  Alternatively, binding of the fiber knob 
to heparin sulfate glycosaminoglycans is sufficient to initiate entry of adenovirus serotypes 2 and 
5.244   Internalization is mediated by interaction of the RGD motif on the adenovirus penton base 
with integrins αvβ3 and αvβ5.245  While still on the surface, adenovirus particles shed the fiber 
proteins and internalization then occurs via receptor-mediated endocytosis into clathrin-coated 
pits.246-247  Grouping of integrins triggers endocytosis and signaling pathways such as protein 
kinase A (PKA) and p38/MAP kinase, which direct microtubule-mediated trafficking of 
adenovirus to the nucleus248 and others, such as phosphatidylinositol-3-OH (PI3) kinase, which is 
responsible for cytoskeletal remodeling.242  Within the endosome, decreased pH is believed to 
cause a conformational change in the penton base, leading to release of the nucleocapsid into the 
cytosol.  The nucleocapsid then traffics along microtubules to the nucleus, where the remaining 
capsid is dissembled and DNA released into the nucleus via the nuclear pore complex.242,249  
Shortly after infection, transcription of the early region 1 (E1) takes place, which includes E1A 
and E1B genes that activate other early transcription units.  Altogether, there are six early 
transcription units, E1A, E1B, E2A, E2B, E3 and E4.  Transcription of E2A results in expression 
of DNA-binding protein (DBP), while E2B encodes the terminal protein (TP) and DNA 
polymerase (Pol).  TP and Pol dimers, together with DBP and a core origin of replication, 
maintain basal replication.  The E3 gene products inhibit transport of MHC class I molecules to 
the cell surface, but are nonessential for viral replication in culture.  E4 is involved in a variety of 
functions including shifting translation to viral mRNA.  Assembly of adenoviruses takes place 
within the nucleus of the infected cell and all structural proteins are transported to this site 
 33 
following synthesis in the cytoplasm via nuclear localization signals.  Newly synthesized 
particles are then released by lysis of the host cell, enabled, in part, by E1B and E3 encoded 
proteins, which disrupt the host cell filament networks and the nucleus.242-243      
1.4.3 Immune response 
Shortly after delivery, adenovirus elicits a rapid innate immune response that involves expression 
of various cytokines, chemokines and neutrophils resulting in necrosis and apoptosis of infected 
tissues.250-251  Adenoviral-mediated activation of innate immunity involves toll-like receptor 9 
(TLR9) and cytosolic sensing of adenoviral DNA, leading to production of type-1 interferons.252 
Moreover, this response is independent of transgene expression.250  The innate immune response 
subsequently initiates generation of adaptive immunity.  Antigen presenting cells such as DCs 
and macrophages present adenoviral and transgene products to direct a Th1 and, to a lesser 
extent, Th2-type immune responses against these antigens.253  Thus, eliciting of innate and 
adaptive immune responses against adenovirus can be seen as a barrier to gene therapy efforts 
focusing on replacement of missing or defective genes.  However, in the context of cancer gene 
therapy, where the ultimate goal is activation of the host immune response to tumors, use of a 
highly immunogenic vector could be an asset.    
1.4.4 Gene Therapy 
As a gene therapy vector, adenovirus in particular has received much attention, due to its large 
insert capacity, ability to infect a wide range of cells, both replicating and quiescent, relative ease 
of propagation and low toxicity associated with use.  Furthermore, DNA encoded by adenovirus 
 34 
is not germline transmitted; however, transgene expression is limited to a few weeks to months 
due to activation of both innate and adaptive immune responses. 
First generation adenoviral vectors, also referred to as E1-deleted, are the most widely 
used.  The deletion of E1A and E1B transcription units disrupts the replication cascade and frees 
up some  5kb of space for transgene inserts.  Some vectors combine E1 and E3 deletions to 
create even more space for foreign DNA insertions (up to 8kb), as E3 is expendable in viral 
production.242  First generation adenoviruses are constructed by co-transfection of E1 
complementing cell lines, such as 293, with (1) a shuttle plasmid encoding the left ITR, 
packaging domain and transgene of interest and (2) a plasmid encoding the viral backbone that 
contains homologous sequences to the shuttle plasmid.  Following homologous recombination, 
E1-deleted viral particles are rescued.  First generation adenoviruses are propagated by infection 
of E1 complimenting cell lines, including 293s, which provide viral proteins in trans.242  
However, passage on 293 cells is associated with emergence of E1 containing, replication 
competent viruses due to recombination of adenovirus DNA within 293 cells with vector 
DNA.254  Additionally, deletion of E1 does not completely abolish remaining viral gene 
expression, as some cellular proteins can mimic E1 activity in trans and activate viral gene 
expression. 
To reduce viral gene expression, reduce immunogenicity and increase carrying capacity, 
adenoviral vectors deficient in other early genes in addition to E1 and E3, such as E2A, E2B or 
E4 were generated, with moderate success.242  Also to this end, high capacity (HC) adenoviral 
vectors devoid of all viral genes and boasting a 37kb insert capacity were created.255  Production 
of HC adenoviruses require transfection of vector DNA into E1 complementing cell lines, 
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followed by infection with E1-deficient “helper” adenovirus to supply in trans all necessary viral 
amplification and packaging functions.242      
Adenoviruses have been used to replace genes in variety of disease models involving 
mutations of a particular gene, such as muscular dystrophy256-257 and cystic fibrosis.258  However, 
due to their high immunogenicity, first generation adenoviruses are uniquely suited to deliver 
immunostimulatory molecules in a variety of gene therapy of cancer protocols.  Indeed, 
adenoviruses have been used to deliver a variety of Th1 polarizing cytokines intratumorally, 
including IL-12,18 IL-18,259 and IL-2260 in the treatment of murine fibrosarcoma, melanoma and 
breast cancer models to name a few.  Likewise, adenoviruses have been used in a variety of 
human clinical trials of cancer and the first approved gene therapy product was an E1-deleted 
adenovirus aimed at restoring p53 expression in head and neck cancer.242  Thus, adenoviruses are 
attractive agents for the delivery of immunostimulatory genes in the treatment of cancer.     
1.5 SUMMARY 
Cancer often arises and progresses as a result of a dysregulated immune response to oncogenic 
cells.  I hypothesize that the problem lies specifically within the CD4+ T-cell response to tumors.  
Initially, the host immune system recognizes the growing tumor as foreign, due to expression of 
proteins not typically found on normal cells, and thus mounts a cell mediated immune response 
aided by Th1-polarized CD4+ T-cells.  However, as tumor growth progresses, the CD4+ T-cell 
response becomes skewed to a Th2 and ultimately a Treg phenotype, which actively inhibits 
activation of the host immune response.  I propose that expression of Th1-polarizing cytokines 
will reactivate the cell-mediated immune response, leading to tumor destruction and induction of 
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tumor-specific immunity.  Previous studies have shown that expression of IL-12 within the 
tumor microenvironment leads to tumor regression and generation of tumor-specific immunity 
utilizing Th1-type mechanisms, but its use is associated with severe toxicity and its efficacy in 
clinical trials has been unimpressive.  Thus, novel cytokines, to use either alone or in 
combination with IL-12, are continuously sought out.  IL-23, a newly described member of the 
IL-12 family of heterodimeric cytokines, has been reported to posses Th1-polarizing functions 
similar to IL-12, but also may specifically activate memory T-cells.  First generation 
adenoviruses are an attractive means to attain local expression of immunostimulatory cytokines, 
due to their large carrying capacity, ease of propagation and ability to activate both innate and 
adaptive immune responses.  Thus, I propose that adenoviral-mediated, intratumoral expression 
of IL-23 will mount an effective anti-tumor response using mechanisms similar to, yet divergent 
from, IL-12.  Additionally, due to the Th1-polarizing nature of these two cytokines, I propose 
that adenoviral-mediated co-expression of both IL-12 and IL-23 within the tumor 
microenvironment will result in synergistic enhancement of anti-tumor effects over use of either 
cytokine alone.   
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2.0  THERAPEUTIC, ANTITUMOR ACTIVITY OF ADENOVIRALLY DELIVERED 
IL-23 
2.1 INTRODUCTION 
IL-12 is a heterodimeric proinflammatory cytokine composed of p40 and p35 subunits.  Its 
receptor is also a heterodimer, composed of the IL-12Rβ1 and IL-12Rβ2 subunits.  IL-12 
stimulates IFN-γ production, promotes Th1 differentiation of naïve CD4+ T -cells and links the 
innate and adaptive immune responses.  IFN-γ is responsible for most of the inflammatory 
actions of IL-12, drives Th1 differentiation and induces IL-12 secretion from DCs, thereby 
forming a positive feedback loop for Th1 differentiation.58  IL-12 enhances proliferation of 261, 
cytolytic activity of 50,262, and IFN-γ production from activated NK and T-cells.50,57,76     
The proinflammatory and immunostimulatory activities of IL-12 are responsible for its 
potent anti-tumor effects in various preclinical animal models of cancer.  IL-12 inhibits tumor 
establishment, causes regression of established tumors and induces tumor-specific 
immunity.92,263-265  However, systemically delivered IL-12 is associated with severe toxicity.265  
Delivery of IL-12 directly into the tumor microenvironment using adenoviral vectors promotes 
tumor regression and generation of tumor-specific immunity, while alleviating the toxicity 
associated with systemic delivery.18  However, new cytokines are continuously sought out for 
use in cancer gene therapy either alone and or in combination with IL-12.   
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IL-23 is a member of the IL-6/IL-12 family of heterodimeric cytokines and is composed 
of two subunits:  p40, which is shared with IL-12, and p19, which is unique to IL-23.  p19 is 
related to the p35 subunit of IL-12 and is active only when co-expressed with IL-12 p40.166  The 
IL-23 receptor is composed of IL-12Rβ1 and the IL-23 receptor and is found on human Th0 and 
Th1 clones and several NK cell lines.173  IL-23 is expressed by activated dendritic cells and 
stimulates proliferation of and IFN-γ production from memory Th1 CD4+ T-cells, suggesting an 
important role for this cytokine in the maintenance of Th1 immunity.166  IL-23 also acts on 
dendritic cells to increase IL-12 production and the combination of IL-12 and IL-23 causes 
dendritic cells to secrete levels of IFN-γ greater than either cytokine alone.174  Furthermore, IL-
23-treated dendritic cells pulsed with an otherwise poorly immunogenic peptide induced a 
CD4+/CD8+ T-cell response in vivo.174  Thus, IL-23 is capable of promoting a protective 
immune response to tumors and, similar to IL-12, may act at the interface of innate and adaptive 
immunities.174  Additionally, IL-23 plays an important role in chronic inflammation, as IL-23 
exposure can induce IL-17 production from activated CD4+ T-cells.184  Multiple studies 
previously performed on various murine carcinoma establishment models have shown that stable 
expression of IL-23 in tumor lines results in decreased tumor growth, increased survival and 
ultimately tumor rejection with generation of anti-tumor immunity.207-209,211  When engineered to 
stably express single chain IL-23, murine colon adenocarcinoma, melanoma, and esophageal 
tumors exhibited regression and eventual rejection in mice.207,209  Tumor rejection due to 
expression of IL-23 coincided with the generation of a specific adaptive immune response and 
appears to be dependent on natural killer (NK) and T-cells.206,208,211  Additionally, treatment with 
dendritic cells expressing IL-23, as well as systemic expression of this cytokine, resulted in 
inhibition of growth of pre-established tumors utilizing mechanisms that appear to be T and NK 
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cell dependent.215-216  However, the effects of local, intra-tumoral expression of IL-23 in a 
therapeutic cancer model have yet to be investigated. 
Here we have analyzed the anti-tumor activity of adenovirally-delivered IL-23 (Ad.IL-
23) in comparison to adenovirally delivered IL-12 (Ad.IL-12) in a day 7 MCA205 murine 
fibrosarcoma tumor model.  Multiple intratumoral injections of Ad.IL-23 resulted in a significant 
increase in survival time and complete rejection in 40 percent of tumors with subsequent 
generation of protective immunity and MCA205-specific cytotoxic T-lymphocytes (CTLs).  
Ad.IL-12 treatment exhibited greater efficiency in tumor eradication compared to Ad.IL-23, but 
did not generate protective immunity as well as IL-23 treatment.   Additionally, we have 
demonstrated that the anti-tumor activities of IL-12 and IL-23 are similar in their need for IFN-γ 
and lack of requirement for IL-17, perforin and Fas ligand.  The anti-tumor mechanisms of the 
two cytokines diverge in IL-23’s requirement of CD4+ and CD8+ T-cells, which IL-12 is 
independent of.  Taken together, these results demonstrate that direct intratumoral injection of 
adenovirus expressing IL-23 results in enhanced survival, tumor eradication and generation of 
protective anti-tumor immunity by generating a Th1 immune response.  In contrast, our data 
suggests that much of the anti-tumor activity of Ad.IL-12 utilizes innate immune mechanisms.  
Thus, use of similar, yet divergent, mechanisms of action by IL-12 and IL-23 suggest that 
therapy utilizing both cytokines will result in synergistic anti-tumor effects.  
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2.2 METHODS 
2.2.1 Adenoviruses 
Adenoviruses expressing IL-12 (Ad.IL-12) and IL-23 (Ad.IL-23) have been described 
previously18,266.  Ad.IL-12, Ad.IL-23 and Ad.Psi5 (empty vector) were prepared as follows:   
Viruses were propagated on HEK-293 cells and purified by CsCl banding, followed by dialysis 
in 3% sucrose solution.  Particle titer of purified viruses was determined by spectroscopy using 
the following equation: (OD260)(50)/9.09x10-13.  Infectious titers were determined using  
quantitative real-time PCR as previously described267 and were approximately 100-fold less than 
particle titers. Viruses were aliquoted and stored at -80° C until use.  Relative cytokine 
expression of each adenoviral preparation was analyzed by infecting 4x104 MCA205 cells with 
increasing MOIs of Ad.IL-12 or Ad.IL-23 for 1 hour at 37°C/5% CO2 in serum free media.  
Complete media was added and cells were then incubated for 72 hours, after which the 
supernatants were harvested.  IL-12 and IL-23 content was analyzed using the mouse IL-12 p70 
and mouse IL-23 p19/p40 Ready-Set-Go IL-23 ELISA kits (eBioscience, San Diego, CA), 
respectively, following manufacturer’s instructions. 
2.2.2 Animals 
Female C57BL/6 and perforin, Fas ligand, IFN-γ, CD4+ and CD8+ T-cell deficient mice on a 
C57BL/6 background were obtained from The Jackson Laboratory (Bar Harbor, ME). The IL-17 
receptor knockout mice are also on a C57BL/6 background, have been described previously and 
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were a kind gift of Dr. Jay Kolls.268 Mice were used at 6 to 10 weeks of age.  Animals were 
maintained under pathogen free conditions at the Biotechnology Center Animal facility at the 
University of Pittsburgh.  All procedures performed were approved by the University of 
Pittsburgh Institutional Animal Care and Use Committee. 
2.2.3 Cell Lines 
MCA205 fibrosarcoma, YAC-1 (American Type Culture Collection, Manassas, VA) and B16 
melanoma cells were maintained in RPMI supplemented with 10% fetal bovine serum 
(Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin (Gibco, Carlsbad, CA) and L-
glutamine (Gibco, Carlsbad, CA).  Cells were kept in a humidified chamber at 37°C/5% CO2 and 
passaged every 2-3 days.   
2.2.4 Cytotoxic T-Lymphocyte Assay 
Two to three weeks after tumor resolution, cured mice were sacrificed and spleens harvested.  
Spleens were mechanically dissociated and treated with Red Cell Lysis buffer (Invitrogen, 
Carlsbad, CA) to remove all red blood cells.  Remaining lymphocytes were cultured with 
recombinant human IL-2 (R&D Systems, Minneapolis, MN) for 7 days prior to use in CTL 
assay.  CTL assays were performed using the CytoTox 96® Non-Radioactive Cytotoxicity Assay 
kit (Promega, Madison, WI) following manufacturer’s instructions.   
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2.2.5 In Vivo Tumor Studies 
For use in in vivo tumor experiments, confluent layers of MCA205 or B16 cells were dissociated 
by trypsin, washed 3 times with Hanks Balanced Salt Solution (HBSS) (Gibco, Carlsbad, CA) 
and counted using trypan blue exclusion.  Mice were inoculated with 1x105 MCA205 cells in 
100uL HBSS subcutaneously in the abdomen.  On days 7, 9 and 11 after tumor inoculation, mice 
were injected intratumorally with 5x1010 particles (approximately 5x108 PFUs) of either Ad.IL-
12, Ad.IL-23 or Ad.Psi5.  Tumor volume was monitored using a metric caliper until mice were 
sacrificed due to excessive tumor size or tumor ulceration.  Tumor-free or “cured” mice were 
subject to tumor challenge 1-2 months after initial tumor resolution with 1x105 MCA205 cells 
subcutaneously in the abdomen. 
2.2.6 Statistics 
Kaplan-Meier survival curves were plotted using SPSS version 16.0.  Mice were monitored until 
excessive tumor volume or tumor ulceration, at which time they were sacrificed and recorded as 
occurrence of an event (death).  Cured mice or those with tumors that did not warrant sacrifice 
by the end of the experiment were censored.  Log-rank tests of the survival curves provided p-
values.  Statistical analyses were 2-tailed, with a p value less than 0.05 considered statistically 
significant. 
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2.3 RESULTS 
2.3.1 Confirmation of IL-12 and IL-23 expression from adenovirally transduced MCA205 
tumor cells 
To confirm cytokine expression following Ad.IL-12 or Ad.IL-23-mediated transduction of 
MCA205 fibrosarcoma tumor cells, 4x104 MCA205 cells were infected with increasing MOIs of 
adenovirus. Supernatants were harvested 72 hours post-adenoviral infection and analyzed for 
cytokine expression by ELISA.  As shown in Figure 3, transduction of MCA205 cells with either 
Ad.IL-12 or Ad.IL-23 resulted in release of respective cytokine from the infected cells, but not 
from Ad.Psi5 or mock infected cells.  While both Ad.IL-12 and Ad.IL-23 produce detectible 
amounts of cytokine, Ad.IL-12 expresses almost 100-fold more cytokine than Ad.IL-23.  The 
biological activity of both Ad.IL-12 and Ad.IL-23 has been previously investigated and 
published.18,269 
 
 
    Figure 3:  Ad.IL-12 and Ad.IL-23 express detectable levels of cytokine 
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2.3.2 Adenoviral delivery of IL-12 or IL-23 into the tumor microenvironment result in 
eradication of subcutaneous MCA205 tumors 
2.3.2.1 Three injections of Ad.IL-12 or Ad.IL-23 result in enhanced survival and tumor 
rejection 
To examine the anti-tumor activity of Ad.IL-23 in comparison to Ad.IL-12, 6 to 8-week old 
C57BL/6 mice were inoculated with 1 x 105 MCA205 cells subcutaneously.  On days 7, 9 and 11 
post-tumor inoculation, mice were injected intratumorally with 5 x 1010 particles of Ad.IL-12, 
Ad.IL-23 or Ad.Psi5 in 100 uL of saline.  Mice treated with Ad.IL-23 exhibited a statistically 
significant increase in survival (p=0.000) versus empty vector controls (Figure 4a).  In six 
experiments involving 40 mice treated with three injections of Ad.IL-23, treated mice showed 
decreased tumor volumes compared to empty vector controls and exhibited an overall tumor 
rejection rate of 40 percent (Figure 4b), with no evidence of cytokine-mediated toxicity.  
As has been reported previously18, Ad.IL-12 exhibited potent anti-tumor activity, 
significantly increasing survival (p = 0.00) compared to empty vector treated controls and 
leading to tumor eradication in 70 percent of treated animals (Figures 4a and b).  However, there 
was evidence of IFN-γ mediated toxicity, as some Ad.IL-12 treated animals lost weight, 
exhibited a hunched appearance and were lethargic; however, none died as a result of Ad.IL-12 
treatment. 
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    Figure 4: Three treatments with Ad.IL-12 or Ad.IL-23 result in potent anti-tumor effects 
2.3.2.2 Ad.IL-12 and Ad.IL-23 mediated generation of protective immunity and tumor-
specific cytotoxic T-lymphocytes 
To determine if Ad.IL-12 and Ad.IL-23 mediated tumor rejection led to generation of protective 
immunity, cured mice were challenged with 1x105 MCA205s in the contralateral flank.  Overall, 
Ad.IL-23 treated, cured mice remained tumor-free for up to three months and all animals 
challenged with a second dose of MCA205 cells were resistant to tumor development.  In 
contrast, two Ad.IL-12 treated mice that initially experienced tumor rejection later had the 
tumors recur.  In addition, only approximately 50 percent of tumor-free Ad.IL-12 treated mice 
were resistant to subsequent tumor challenge.     
To determine if treatment of MCA205 tumors with Ad.IL-12 or Ad.IL-23 resulted in the 
generation of tumor-specific CTLs, spleens were harvested from treated, tumor free mice within 
2-3 weeks of tumor resolution.  Purified lymphocytes were cultured with rhIL-2 for 7 days and 
re-stimulated with MCA205 cells.  CTL activity was measured by LDH release from target cells.  
Cytotoxic activity was detected against MCA205 tumor cells in splenocytes harvested from both 
Ad.IL-12 and Ad.IL-23 treated animals (Figures 5a and b).  Splenocytes from Ad.IL-23 treated 
animals exhibited no activity against YAC-1 (NK cell sensitive) cells (Figure 5b), suggesting 
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that treatment of subcutaneous MCA205 tumors with Ad.IL-23 resulted in generation of anti-
tumor immunity by production of MCA205-specific CTLs. This result is consistent with the 
ability of Ad.IL-23 treated, cured mice to resist MCA205 tumor challenge.  In contrast, 
splenocytes from Ad.IL-12 treated animals showed strong cytotoxicity against YAC-1 cells, 
suggesting involvement of an innate immune response in the anti-tumor properties of IL-12. 
  
 
    Figure 5: Ad.IL-23, but not Ad.IL-12, treatment results in generation of tumor-specific CTLs 
2.3.2.3 Determining the minimal effective dose of Ad.IL-12 and Ad.IL-23 
Given that three injections of Ad.IL-23 were highly effective in inducing anti-tumor immunity, 
we subsequently examined whether two or even one injection of Ad.IL-12 or Ad.IL-23 would be 
sufficient to mount an anti-tumor response. Established MCA205 tumors were injected intra-
tumorally twice on days 7 and 11.  Treatment with two injections of Ad.IL-23 resulted in a 40 
percent tumor eradication rate (2 of 5 mice), but did not significantly increase survival compared 
to empty vector controls (Figures 6a and b). Treatment with two injections of Ad.IL-12 resulted 
in significant increase in survival compared to Ad.Psi5 and Ad.IL-23 treated animals and 
resulted in a 100 percent (5 mice total) tumor rejection rate (Figures 6a and b).  As before, there 
was some evidence of IL-12-mediated toxicity, but no animals died as a result of Ad.IL-12 
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therapy.  Interestingly, Ad.IL-23 treated animals that experienced tumor rejection were 
completely refractory to MCA205 tumor challenge.  In contrast, all cured, Ad.IL-12 treated mice 
developed tumors upon challenge, two of which were not ultimately rejected (data not shown).  
 
 
     Figure 6: Two treatments with Ad.IL-12 or Ad.IL-23 mount an anti-tumor response 
 
In animals treated once on day 7 with 5 x 1010 particles of Ad.IL-12 or Ad.IL-23, Ad.IL-
12 treatment significantly increased survival compared to Ad.Psi5 treated controls and led to 
tumor rejection in 60 percent of animals (3 of 5) (Figures 7a and b).  Although one treatment 
with Ad.IL-23 did not lead to tumor rejection in any animals, survival was significantly 
enhanced compared to empty vector controls (Figures 7a and b). Again, Ad.IL-12 treatment 
significantly increased survival of tumor bearing mice compared to those treated with Ad.IL-23 
(Figure 7a).  Similar to previous results, cured, Ad.IL-12 treated animals developed tumors upon 
MCA205 challenge.  Overall, these results suggest that Ad.IL-12 is the more potent anti-tumor 
agent, exhibiting strong anti-tumor activity even at low does, but generates only moderate, if any, 
protective immunity.  Furthermore, although Ad.IL-23 treatment is beneficial to survival even at 
low does, multiple injections are necessary for maximal anti-tumor effect.  
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     Figure 7: 1 treatment with Ad.IL-12 or Ad.IL-23 mounts an anti-tumor response 
2.3.2.4 Systemic Anti-tumor effects of Ad.IL-12 and Ad.IL-23 
To determine if Ad.IL-12 or Ad.IL-23 treatment resulted in induction of systemic immunity, 
mice bearing two MCA205 tumors were treated on days 7, 9 and 11 in only one tumor with 
5x1010 particles of either Ad.IL-12, Ad.IL-23 or Ad.Psi5.   While Ad.IL-23 treatment only led to 
modest tumor rejection in this model, overall inhibition of tumor growth was observed in both 
injected and contralateral tumors (Figures 8a-d).  In contrast, Ad.IL-12 demonstrated potency 
both in reducing tumor volume and enhancing tumor rejection compared to empty vector treated 
controls (Figure 8a-d).  These results demonstrate that direct intratumoral injection of adenovirus 
expressing either IL-12 or IL-23 results in induction of a systemic anti-tumor response, with IL-
12 treatment yielding maximal anti-tumor benefits. 
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      Figure 8: Ad.IL-12 or Ad.IL-23 treatment induces systemic anti-tumor immunity 
2.3.3 Ad.IL-23 anti-tumor activity is not model-specific 
While the anti-tumor activity of adenovirus expressing IL-12 has been established in other 
preclinical animal models of cancer,18,127,130,270-278 we sought to show that the anti-tumor activity 
of Ad.IL-23 was not model specific.  To this end, C57BL/6 mice were inoculated with 1x105 
B16 melanoma cells in the flank and treated on days 7, 9 and 11 with 5x1010 particles of Ad.IL-
23.  While overall tumor rejection was modest at 20 percent (1 of 5), Ad.IL-23 treated animals 
survived significantly longer than their untreated counterparts (Figures 9a and b).  These data 
show that the anti-tumor activity of adenovirally delivered IL-23 is not limited to the MCA205 
fibrosarcoma model and may potentially have broad applicability. 
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    Figure 9: Ad.IL-23 exhibits anti-tumor activity against B16 melanoma 
2.3.4 IL-12 and IL-23 anti-tumor activity is independent of endogenous IL-17 production 
The results above clearly demonstrate that adenoviral mediated intra-tumoral delivery of IL-23 
results in a significant anti-tumor response.  To examine the nature of this immune response in 
comparison to adenovirally delivered IL-12, the abilities of both Ad.IL-12 and Ad.IL-23 to 
induce regression of MCA205 tumors was examined in mice deficient for various 
immunoregulatory molecules or cell types.  In vivo, IL-23 strongly induces production of IL-
17,30 which has been previously shown to possess anti-tumor activity.232  In contrast, IL-12 
induces IFN-γ production, which has been shown to limit IL-17 producing T-cells.279 To 
determine if IL-23-mediated, endogenous IL-17 production may be responsible for the observed 
anti-tumor effects or if lack of IL-17 signaling may affect the anti-tumor activity of Ad.IL-12, 
IL-17 receptor-deficient mice were inoculated with subcutaneous MCA205 tumors and treated 
with either Ad.IL-12 or Ad.IL-23 on days 7, 9 and 11 post-tumor inoculation.  IL-23 treatment 
significantly increased animal survival (p=0.047) compared to empty vector treated mice (Figure 
10a).  Additionally, 60 percent (3 of 5) of tumor-bearing mice experienced tumor resolution with 
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kinetics similar to wild-type mice (Figure 10b) and were resistant to tumor challenge (data not 
shown).   
In marked contrast to IL-23 treatment, Ad.IL-12 therapy resulted in severe, most likely 
IFN-γ, or possibly TNF-α, mediated toxicity in IL-17 receptor deficient mice.  By day 15 post-
tumor inoculation, all Ad.IL-12 treated mice had minimal size tumors, but appeared lethargic, 
hunched over and exhibited matted coats and wasting.  All but one mouse, which had 
experienced tumor rejection, had perished as a result of treatment by day 28.  Although statistics 
on survival could not be generated due to the toxicity of treatment (Figure 10a), it was apparent 
that Ad.IL-12 therapy did inhibit tumor growth and most likely all treated animals would have 
rejected the tumors if death due to toxicity would not have occurred prior. 
 Taken together, these data suggest that adenovirally-delivered IL-23 anti-tumor activity 
is not mediated by endogenous IL-17 production.  Furthermore, while lack of IL-17 signaling 
does not appear to affect the anti-tumor activity of adenovirally delivered IL-12, it does appear to 
affect toxicity associated with IL-12 treatment. 
 
 
    Figure 10: Ad.IL-12 and Ad.IL-23 anti-tumor activity in IL-17R-deficient mice 
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2.3.5 IL-12 and IL-23 anti-tumor activity is independent of perforin 
Perforin is produced by CD8+ T-cells and NK cells and is released upon contact with the target 
cell to induce cell death.  To determine if the anti-tumor activity of adenovirally delivered IL-12 
or IL-23 is dependent on perforin-mediated lysis of tumor cells, perforin-deficient mice with 
established MCA205 tumors were treated with Ad.IL-12 or Ad.IL-23 as described above.  
Treatment with Ad.IL-23 resulted in a significant increase in survival (p=0.013) (Figure 11a), 
and led to tumor rejection in 30 percent of mice (3 of 10) (Figure 11b).  Cured, perforin-deficient 
mice experienced tumor rejection in a similar time frame as cured, Ad.IL-23 treated wild-type 
mice and were resistant to tumor challenge (data not shown).   
 Similar to Ad.IL-23, Ad.IL-12 treatment in perforin deficient animals led to a significant 
increase in survival compared to empty vector treated controls (p = 0.005).  Likewise, 100 
percent (5 mice total) of IL-12 treated animals experienced tumor rejection in a timeframe 
comparable to wild type mice (Figure 11b).  Similar to what was seen in IL-17 receptor deficient 
mice, there was some evidence of toxicity due to treatment, but none of the perforin deficient 
animals perished as a result of Ad.IL-12 therapy.  Upon challenge, 2 of 3 IL-12 treated, cured, 
perforin deficient mice developed tumors that did not regress, mirroring the lack of establishment 
of strong protective immunity seen in wild-type mice.  
Overall, these data suggest that adenovirally delivered IL-12 and IL-23 do not utilize 
perform-mediated killing as an anti-tumor effector mechanism.  Furthermore, lack of perforin 
does not affect establishment of protective immunity in animals treated with either Ad.IL-12 or 
Ad.IL-23. 
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     Figure 11: Ad.IL-12 and Ad.IL-23 anti-tumor activity in perforin-deficient mice 
2.3.6 IL-12 and IL-23 anti-tumor activity is independent of Fas ligand 
Interactions between Fas and Fas ligand (FasL) are used by activated CD8+ T-cells and some 
CD4+ effector cells to kill target cells via apoptosis.  To determine if the anti-tumor activity of 
adenovirally delivered IL-12 or IL-23 requires Fas-Fas ligand interactions to eradicate tumor 
cells and generate anti-tumor immunity, FasL-deficient mice were inoculated with tumors and 
treated as described above.  Interestingly, while Ad.IL-23 treatment did not lead to tumor 
rejection in any treated animals (10 mice total) (Figure 12b), it did significantly increase survival 
compared to empty vector controls (p=0.000) (Figure 12a).   
 Similar to Ad.IL-23, treatment with Ad.IL-12 led to enhanced survival compared to 
empty vector controls (p=0.002) (Figure 12a).  Furthermore, treatment led to complete tumor 
rejection in 60 percent of animals (3 of 5).  Ad.IL-12 therapy was again associated with some 
toxicity (in the form of weight loss and lethargy), but did not lead to death in any treated animals.   
Interestingly, one IL-12 treated, cured animal had a recurrence of the tumor, similar to what was 
seen in wild-type mice. 
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The above data leads us to conclude that both adenovirally delivered IL-12 and IL-23 are 
able to function through a Fas-FasL-independent mechanism to exert their anti-tumor effects. 
However, in the case of IL-23, given that treatment did not result in eradication of tumors in any 
of the mice, it is also possible that at least part of the anti-tumor effect of IL-23 involves a Fas-
FasL-dependent pathway.   
 
 
     Figure 12: Ad.IL-12 and Ad.IL-23 anti-tumor activity in Fas ligand-deficient mice 
2.3.7 Interferon gamma is necessary for IL-12 and IL-23 anti-tumor activity 
Cytotoxic T-lymphocytes and a subset of Th1 T-cells secrete IFN-γ upon engagement of the T 
cell receptor in order to exert their cytotoxic effects on target cells.  To determine if IFN-γ is 
necessary for the anti-tumor activity of adenovirally delivered IL-12 and IL-23, IFN-γ deficient 
mice with established tumors were treated as described above.  Tumor-bearing mice treated with 
either Ad.IL-12 or Ad.IL-23 showed no significant increase in survival when compared to empty 
adenoviral vector controls (Figure 13a).  Additionally, neither Ad.IL-12 nor Ad.IL-23 treatment 
led to tumor rejection (6 mice total treated with Ad.IL-12 and 11 mice total treated with Ad.IL-
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23) (Figure 13b), suggesting that adenovirally delivered IL-12 and IL-23 both utilize IFN-γ as an 
effector mechanism to exert their anti-tumor effect.   
 
 
    Figure 13: Ad.IL-12 and Ad.IL-23 anti-tumor activity in IFN-γ-deficient mice 
2.3.8 Anti-tumor activity of IL-23, but not IL-12, is dependent on CD4+ T-cells 
CD4+ T-cells have a variety of functions, including “helping” the activation of CTLs and 
directly killing target cells, utilizing mechanisms including Fas-FasL interactions and release of 
IFN-γ.   To  determin e if th e an ti-tumor activity of adenovirally delivered IL-12 or IL-23 is 
dependent on the presence of CD4+ T-cells, CD4 deficient mice were inoculated with MCA205 
tumors and treated with either vector as described above.  Ad.IL-23 treated mice showed no 
significant increase in survival when compared to empty adenoviral vector controls (Figure 14a) 
and none rejected their tumor (10 animals total) (Figure 14b).   
 In contrast, Ad.IL-12 treated, CD4-deficient mice survived significantly longer than their 
Ad.Psi5 treated counterparts (p = 0.003) and exhibited an 80 percent (4 of 5) tumor rejection rate 
(Figures 14a and b).  Again, IL-12 treatment resulted in some toxicity, presenting as lethargy and 
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weight loss in mice, but no animals died as a result of treatment.  Additionally, upon MCA205 
challenge, all cured, CD4-deficient mice were resistant to tumor challenge. 
These data suggest that IL-12 mediated establishment of protective immunity is 
independent of the presence of CD4+ T-cells, whereas IL-23 requires the activity of CD4+ T-
cells to exert optimal anti-tumor effects. 
 
 
     Figure 14: Ad.IL-12 and Ad.IL-23 anti-tumor activity in CD4-deficient mice 
2.3.9 IL-23, but not IL-12, utilizes CD8+ T-cells to exert its anti-tumor effects 
Since IL-23 anti-tumor activity is dependent on IFN-γ, a mechanism utilized by CD8+ T-cells to 
exert cytotoxic effects, it is possible that CD8+ T-cells are responsible for the anti-tumor effects 
of IL-23. Thus CD8+ T-cell deficient mice were inoculated with MCA205 tumors and treated as 
described above with either Ad.IL-12 or Ad.IL-23.  Interestingly, while treatment with Ad.IL-23 
did lead to tumor rejection in 20 percent of animals (2 of 10) (Figure 15b), IL-23 therapy did not 
significantly increase animal survival (Figure 15a).   
In contrast, treatment with Ad.IL-12 did significantly enhance survival (p = 0.021) and 
likewise led to tumor rejection in 40 percent of animals (2 of 5) (Figure 15b).  Again, however, 
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IL-12 treatment was associated with lethal toxicity, with three animals perishing as a result of 
therapy by day 17 post-tumor inoculation.  It must be noted that tumors in these mice were quite 
small and would likely have regressed entirely had the animals survived. 
These results suggest that at least part of the anti-tumor effect of adenovirally delivered 
IL-23 is mediated through CD8+ T-cell activity, in addition to other effector mechanisms that 
may be important in tumor elimination.  In contrast, CD8+ T-cells are not necessary for IL-12 to 
exert its anti-tumor effects, as adenovirally delivered IL-12 maintains anti-tumor activity in their 
absence.   
 
 
     Figure 15: Ad.IL-12 and Ad.IL-23 anti-tumor activity in CD8-deficient mice 
2.4 DISCUSSION 
2.4.1 The case for IL-23-mediated gene therapy of cancer 
The use of gene therapy for the treatment of cancer has been proven effective in many mouse 
cancer models and comprises the vast majority of human gene therapy clinical trials performed 
to date.280  Here we have investigated the potential anti-tumor activity of the IL-12 family 
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member IL-23.  IL-23 is a relatively new member of the IL-12 family of heterodimeric cytokines 
and shares many immunostimulatory166,173-174 and anti-tumor activities with IL-12.92,263-265 IL-23 
has been shown to possess anti-tumor activity in the context of various establishment models of 
cancer.206-209,211 and to inhibit established tumor growth when overexpressed systemically or 
locally via dendritic cells.215-216  We chose to investigate the ability of adenovirally delivered IL-
23 (Ad.IL-23) to inhibit tumor growth in a therapeutic mouse model of cancer for a number of 
reasons.  First, systemic overexpression of immunostimulatory cytokines may be associated with 
toxicity, as is the case with systemically delivered IL-12.265  Additionally, as IL-23 is associated 
with a variety of autoimmune inflammatory diseases which are believed to be mediated at least 
in part by the generation of a specific subset of T-cells that produce IL-17,281  we hypothesized 
that local, rather than systemic, expression would reduce the risk of the unintentional 
development of any autoimmune pathology.  Finally, expression of immunostimulatory 
cytokines within tumor cells greatly increases the chances of generating an effective immune 
response against the tumor itself and is technically much simpler than transduction of any 
intermediate cell type.   
2.4.2 In vitro expression of IL-12 and IL-23 
To ensure adenoviruses expressing IL-12 and IL-23 secrete active cytokine from tumor cells, 
MCA205 cells were infected with either Ad.IL-12 or Ad.IL-23.  Both viruses indeed secreted 
cytokine, which has been previously shown possess biological activity.18,269  Interestingly, 
Ad.IL-12 secreted approximately 100-fold greater amounts of cytokine compared to Ad.IL-23.  
This is most likely due to design of the adenoviral vectors.  Both viruses express the individual 
subunits separately using an internal ribosomal entry site (IRES).  However, Ad.IL-12 expresses 
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p40 before the IRES, while Ad.IL-23 expresses the subunit after, which most likely leads to 
decreased p40 expression from Ad.IL-23.  As p19 can only be released from cells in the context 
of p40,166 it is possible that less IL-23 is secreted from cells due to lack of sufficient p40.  
However, though less IL-23 is produced, Ad.IL-23 exhibited potent anti-tumor activity and 
generated better protective immunity than Ad.IL-12 treatment; thus, production of a vector that 
expresses greater amounts of IL-23 may result in a more effective anti-tumor agent. 
2.4.3 Anti-tumor activity of IL-23 
Our results clearly demonstrate that treatment of day 7 MCA205 tumors with repeated intra-
tumoral injections of Ad.IL-23 results in a significant increase in animal survival when compared 
to empty vector treated controls.  In a total of 6 experiments involving 40 mice, Ad.IL-23 treated 
mice overall exhibited decreased tumor volume, with 40 percent of mice rejecting their tumors in 
about 25 days (Figures 4a and b).   
To determine the minimal effective dose of Ad.IL-23, mice with established tumors were 
treated with two or one injections of Ad.IL-23.  Tumor bearing mice treated with two doses of 
Ad.IL-23 on days 7 and 11 exhibited a 40 percent tumor rejection rate, but treatment did not 
significantly increase survival compared to empty vector controls (Figures 4a and b).  In contrast, 
mice treated with one dose of Ad.IL-23 on day 7 showed a significant increase in survival 
compared to controls, but did not exhibit any tumor rejection (Figures 5a and b).  We chose three 
separate injections of Ad.IL-23 as our treatment plan as it yielded both enhanced survival 
compared to controls and maximum tumor rejection rates. However, increased survival even at 
the lowest dose has therapeutic implications, as this suggests that use of low dose Ad.IL-23 in 
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combination with other Th1-polarizing cytokines, such as IL-12, will provide even greater 
therapeutic response with minimal adenoviral or cytokine mediated toxicity.  
Additionally, we have shown that treatment with Ad.IL-23 results in induction of 
systemic immunity, as treatment of one tumor leads to inhibition distal tumor growth (Figure 8a 
and b).  Complete tumor rejection due to IL-23 treatment was not attained in this model, most 
likely due to the large tumor burden (Figure 8c and d).  Furthermore, we have shown that the 
anti-tumor activity of Ad.IL-23 is not model-specific, as IL-23 treated mice bearing B16 tumors 
survived significantly longer than controls (Figure 9a and b).  The potency of IL-23 treatment 
was somewhat less than in the MCA205 model, but this is probably due to differences in 
immunogenicity of the tumor cell lines.  
The anti-tumor activity of IL-23 is consistent with previously published reports showing 
that stable expression of IL-23 in tumor cell lines leads to tumor rejection in tumor establishment 
models.206-209,211  Although the overall cure rate in our experiments was slightly lower than was 
obtained in previous studies using establishment models (70 percent versus our 40), this disparity 
is likely due to differences in the model.  An established tumor is more difficult to eradicate than 
a tumor expressing IL-23 from the onset.  Additionally, differences in IL-23 expression levels in 
therapeutic versus establishment models may also ultimately affect the outcome, as it has been 
suggested that IL-23 expression levels may dictate whether IL-23 exhibits pro- or anti-tumor 
effects.223  It is also necessary to note that while this work was undergoing, a paper 
demonstrating a prophylactic, but not therapeutic, effect of adenovirally delivered IL-23 in 
variety of murine tumors was published.217  This disparity in results may be due to the use of 
different murine tumor models, use of a mutant form of p40 or initiating treatment at a different 
stage of the tumor model.  In our studies, tumor bearing mice were treated on days 7, 9 and 11 
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starting with an average tumor size of 4mm compared to the studies performed in the previously 
mentioned paper, in which treatment was initiated when the average tumor volume reached 7mm 
in diameter.   
2.4.4 Anti-tumor activity of IL-12 
As has been previously demonstrated,18,127,130,270-278 adenovirus expressing IL-12 possesses 
potent anti-tumor activity in our hands.  Treatment with three injections of 5x1010 particles of 
Ad.IL-12 led to enhanced survival compared to empty vector controls and an overall 70 percent 
tumor rejection rate (Figures 4a and b).  IL-12 therapy was, however, associated with some 
degree of toxicity, presenting as lethargy, weight loss and disheveled coat appearance in treated 
animals, suggesting a high level of intratumoral IL-12 production.  Such toxicity has been 
reported previously mice treated with recombinant murine IL-12.282  Ad.IL-12-mediated toxicity 
observed in treated animals is in accordance with in vitro MCA205 Ad.IL-12 transduction data 
(Figure 3a), which shows 100-fold greater expression of cytokine compared to Ad.IL-23 (Figure 
1b).  While toxicity was seen, it must be noted that it was not severe enough be lethal in any 
wild-type treated animals. 
In contrast to Ad.IL-23, Ad.IL-12 maintained its potency as an anti-tumor agent even at 
low doses and distal sites.  Treatment of tumor bearing mice with two doses of Ad.IL-12 led to a 
significant increase in survival and rejection of 100 percent of tumors (Figures 6a and b).  Even 
at one dose of Ad.IL-12, treated animals survived significantly longer than their Ad.Psi5 treated 
counterparts and rejected 60 percent of tumors (Figures 7a and b).  This is not surprising, as 
Ad.IL-12 expresses high amounts of cytokine (Figure 3b), which most likely correlates with its 
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anti-tumor activity.  Likewise, mice treated with Ad.IL-12 in one tumor exhibited tumor 
eradication at both injected and distal sites, exhibiting induction of potent systemic immunity. 
2.4.5 Comparison of Ad.IL-12 and Ad.IL-23 anti-tumor activities 
Interestingly, at all treatment doses of Ad.IL-12, treated mice survived significantly longer than 
their IL-23 treated counterparts.  This fact, combined with enhanced survival and high tumor 
rejection rates even at low doses of Ad.IL-12, strongly suggests that Ad.IL-12 is a much stronger 
anti-tumor agent than Ad.IL-23.    However, all (8 mice total) cured, Ad.IL-23 treated mice 
(regardless of dose) exhibited protective immunity upon tumor challenge up to three months 
after rejection of the initial tumor.  In contrast, only 56 percent (5 of 9) of mice treated with 
adenovirus-expressing IL-12 were resistant to tumor challenge.  IL-12 is a potent activator of 
innate immunity50,262 and it is possible that tumor eradication was due largely to activation of the 
innate immune response and inhibition of angiogenesis.  Thus, upon tumor challenge, cured 
animals would have no immunologic memory, as the adaptive response was not needed to 
eradicate the primary tumor.  Indeed, CTL assay data from cured, IL-12 and IL-23 treated mice 
support this assertion.  Splenocytes from cured, Ad.IL-23 treated animals show strong MCA205-
specific cytotoxicity, with little to no non-specific, YAC-1 (NK cell-mediated) lysis (Figure 5b).  
In contrast, splenocytes from cured, Ad.IL-12 treated animals exhibited lysis of MCA205 cells, 
but at levels comparable to those observed in YAC-1 cells (Figure 5a), suggesting involvement 
of NK cells rather than CTLs.   
Overall, these data suggest that, while IL-12 is highly efficient in tumor eradication, IL-
23 may activate a robust memory T cell response and generate superior long-term protective 
immunity.   Such results are promising in the context of using IL-23 in conjunction with IL-12. 
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Presumably using IL-23 in combination with IL-12 will result in efficient tumor eradication 
using a lower dose of IL-12, thereby reducing toxicity, and enhancement of the duration of 
protective anti-tumor immunity.  
2.4.6 Evaluation of the mechanisms of IL-12 and IL-23-mediated anti-tumor activities  
2.4.6.1 Role of CD4+ T cells 
CD4+ T-cells perform a variety of functions in the context of anti-tumor immunity, including 
aiding the generation of specific adaptive immune responses or acting directly on target cells to 
induce apoptosis.  IL-23 utilizes CD4+ T-cells to exert its anti-tumor effects, as IL-23 treatment 
in tumor-bearing mice deficient in CD4+ T-cells does not result in enhanced survival or lead to 
tumor rejection (Figures 14a and b).  This is in agreement with other published studies detailing 
the role of CD4+ T-cells in IL-23 anti-tumor effects.212,216 
In contrast to IL-23, IL-12 anti-tumor activity does not require CD4+ T-cells in our 
model.  CD4+ T-cell deficient mice treated with adenovirus expressing IL-12 boasted 
significantly enhanced survival and rejection of 80 of tumors (Figures 14a and b).  This is in 
accordance with earlier reports, as lack of requirement for CD4+ T-cells in the anti-tumor 
activity of IL-12 has been previously established.92  However, other reports have also implicated 
a role for CD4+ T-cells in IL-12-mediated tumor eradication.93  Such discrepancies are likely 
due to IL-12 expression levels; at high doses, IL-12 eradicates tumors using solely innate 
immune mechanisms, while lower doses require involvement of adaptive immune responses.    
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2.4.6.2 Role of CD8+ T cells 
CD8+ T-cells comprise cytotoxic T-lymphocytes, which are responsible for destruction of tumor 
cells and somatic cells that are infected with intracellular pathogens.   CD8+ T-cell-mediated 
apoptosis of target cells is induced by release of IFN-γ, perforin or granzymes or via surface 
expression of Fas ligand.  To determine if activation of CD8+ T-cells is responsible for IL-23-
mediated tumor eradication, tumor bearing mice deficient in CD8+ T-cells were treated with 
adenovirus expressing IL-23.  While tumor rejection was observed, survival of IL-23 treated 
animals was not significantly enhanced compared to empty vector controls (Figures 15a and b), 
leading us to conclude that the anti-tumor activity of IL-23 is dependent on CD8+ T-cells.  This 
is in accordance with previously published reports that confirm the dependence of IL-23 
mediated inhibition of tumor growth on CD8+ T-cells.153,212,214-216 
 In contrast, the anti-tumor activity of adenovirally delivered IL-12 does not require CD8+ 
T-cells in our model, as tumor bearing, CD8+ deficient mice survived significantly longer than 
Ad.Psi5 treated controls and experienced tumor regression and rejection (Figure 15a and b).  
This is in contrast to previous studies indicating a role of CD8+ T-cells.92  Again, this 
discrepancy is likely due to expression levels of IL-12 and activation of an innate versus an 
adaptive immune response.   
Interestingly, CD8+ T-cell deficient mice were subject to severe toxicity, with 60 percent 
of mice perishing as a result of IL-12 treatment.  These results suggest that CD8+ T-cells may 
play a role in inhibiting IFN-γ production or attenuating a Th1 response.  CD8+ regulatory T-
cells with immunosuppressive effects have been described283 and have been shown to produce 
IL-10,284 which inhibits IL-12 activity285 and thereby may explain observed toxicity in mice 
deficient in all CD8+ T-cells. 
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2.4.6.3 Role of IL-17  
IL-23 has been shown to induce IL-17 production by aiding the development of Th17 T-cells.30  
Since IL-17 itself may possess anti-tumor activity232 we investigated whether the anti-tumor 
activity of IL-23 is mediated by endogenous IL-17 production.  Using IL-17 receptor deficient 
mice, we demonstrated that the anti-tumor activity of IL-23 appears to be independent of 
endogenous IL-17 expression.  IL-17 receptor-deficient mice treated with Ad.IL-23 exhibited 
increased survival and enhanced tumor rejection compared to animals treated with empty 
adenoviral vector (Figures 10a and b).  Thus, although IL-23 has been shown to be a potent 
activator of IL-17 producing cells,184 in the context of adenovirally transduced tumor cells, either 
Th17 cells do not play a role in the anti-tumor activity or the development of Th1 T-cells is 
favored. 
Anti-tumor activity of adenovirally delivered IL-12 also appeared to be independent of 
endogenous IL-17 signaling, as MCA205 tumors in IL-17 receptor deficient mice regressed 
rapidly upon treatment.  However, exact statistics were not generated, as IL-12 treated animals 
all succumbed to presumed IFN-γ mediated toxicity as a result of treatment.  While some toxicity 
was observed in tumor-bearing, Ad.IL-12 treated wild-type mice, the severe toxicity observed in 
the absence of IL-17 signaling suggests a role of IL-17 in inhibiting either IL-12 or IFN-γ 
production or attenuating development of Th1 response.  Indeed, in vitro studies have shown that 
IL-17 inhibits IL-12 mediated IFN-γ production in PBMCs and Th1 cells by downregulating IL-
12 receptor expression.286  Thus, toxicity was likely a result of high levels of IL-12 induced IFN-
γ production that was unable to be downregulated by IL-17 signaling. 
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2.4.6.4 Role of perforin   
Perforin is released by NK and CD8+ T-cells upon engagement of target cells and forms holes 
through which granzymes can enter, thereby inducing apoptosis in the target cell.  As we have 
shown that the anti-tumor activity of IL-23 is dependent on CD8+ T-cells, we sought to 
determine if CD8+ T-cells in IL-23 treated mice utilize perforin as to eradicate tumor cells.  The 
anti-tumor activity of IL-23 does not appear to be dependent on perforin, as treatment of tumor 
bearing, perforin deficient mice led to significantly enhanced survival and tumor rejection in 30 
percent of mice (Figures 11a and b).   
Likewise, IL-12 anti-tumor effects are independent of perforin, as IL-12 treated, perforin 
deficient mice survived significantly longer and rejected 100 percent of tumors (Figures 11a and 
b).  This is in agreement with previous studies investigating the mechanism of adenovirally 
delivered IL-12 anti-tumor activity.287  Additionally, cured mice showed similar resistance to 
MCA205 challenge compared to wild-type mice, suggesting that lack of perforin does not affect 
adaptive anti-tumor immunity generated by IL-12 treatment.  
2.4.6.5 Role of Fas ligand 
Fas ligand is used by activated CD8+ T-cells and some CD4+ effector cells to kill target cells via 
apoptosis.  As we have previously shown that the anti-tumor activity of IL-23 is dependent on 
involvement of CD4+ and CD8+ T-cells, we sought to determine if Fas/Fas ligand interactions 
were an effector mechanism utilized by T-cells to induce tumor cell death.  Upon treatment of 
tumor bearing, Fas ligand deficient mice with adenovirally delivered IL-23, it was apparent that 
IL-23 mediated eradication of tumors does not utilize Fas-FasL interactions.  Tumor bearing 
mice deficient in Fas ligand survived significantly longer than their empty vector treated 
counterparts (Figure 12a).  Interestingly, however, IL-23 treatment did not lead to tumor 
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rejection in any FasL deficient mice (Figure 12b), indicating possibly some role of FasL in 
complete tumor eradication.   
 Likewise, the anti-tumor effects of adenovirally delivered IL-12 are independent of FasL, 
as IL-12 treated, FasL deficient mice survived significantly longer than empty vector treated 
controls and rejected 60 percent of tumors (Figures 12a and b).  This is consistent with the 
independence of IL-12 anti-tumor activity from CD4+ and CD8+ T-cells.  While previous 
studies have shown a role of Fas/Fas ligand interactions in the anti-tumor effects of adenovirally 
delivered IL-12, anti-tumor effects are not completely abrogated as a result of inhibition of this 
pathway,288 and thus our results do not entirely contradict previous studies. 
2.4.6.6 Role of IFN-γ 
Interferon gamma is produced by a variety of innate and adaptive immune cells, including NK 
cells and T-cells and induces apoptosis in target cells, including tumors.  IL-23 has been shown 
to induce IFN-γ production from CD4+ T-cells.166  We thus sought to determine if release of 
IFN-γ was responsible for the anti-tumor effects of IL-23.  Indeed, IFN-γ is indispensable for IL-
23 anti-tumor effects, as treated mice deficient in this cytokine experience neither enhanced 
survival nor tumor rejection (Figure 13a and b).   
 IL-12 is also a potent activator of IFN-γ production from both T and NK cells289 and has 
been shown to play a role in its anti-tumor activity.158,290-291  Likewise, in our model, the anti-
tumor effects of IL-12 were dependent upon endogenous IFN-γ expression.  Mice deficient in 
this cytokine were completely refractory to Ad.IL-12 treatment, exhibiting no enhancement of 
survival or tumor rejection (Figures 13a and b).   
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2.4.7 Mechanism of anti-tumor activities of IL-12 and IL-23 
As IL-12 and IL-23 share the p40  subunit and possess similar immunostimulatory properties,166  
it was expected that these cytokines would use similar, yet divergent, cytokines and cell types to 
enact their anti-tumor effects.  Indeed, IL-12 and IL-23 anti-tumor effects are similar in their 
independence of endogenous IL-17, perforin and Fas ligand and their requirement for IFN-γ.  
The only divergence in effector mechanisms lies in the requirement of CD4+ and CD8+ T-cells, 
which IL-23 requires, but IL-12 does not.   
With regards to the mechanism of anti-tumor activity of adenovirally delivered IL-23, the 
requirement for CD4+ and CD8+ T-cells along with IFN-γ suggests induction of a Th1 type 
immune response.  Supporting this assertion, cytotoxicity of splenocytes harvested from cured, 
wild-type animals demonstrate that tumor eradication was mediated, at least in part, by 
MCA205-specific CTLs (Figure 5b) and is consistent with previous reports.215-216  Collectively, 
these data suggest that the primary mechanism of IL-23 anti-tumor activity is CD4+ T-cell-
mediated activation of CD8+ T-cells to produce IFN-γ, which then induces apoptosis in tumor 
cells.  Our proposed model IL-23 anti-tumor activity is consistent with other reports detailing the 
mechanism of IL-23 anti-tumor activity .216   
The anti-tumor activity of IL-12, in contrast, is dependent strictly on the involvement of 
IFN-γ.  This fact combined with the lack of involvement of CD4+ and CD8+ T-cells, implies 
that in our model, IL-12 anti-tumor activity may require not an adaptive immune response for 
efficient tumor eradication.  Indeed, our studies show that IL-12 treatment generates protective 
anti-tumor immunity in only 50 percent of cases and that tumor-specific CTLs are not generated 
(Figure 5a).  Therefore, as adenovirally delivered IL-12 has been previously shown to eradicate 
tumors by activation of NK cells and inhibition of angiogenesis,128,287  and that IL-12-mediated 
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inhibition of angiogenesis is dependent upon induction of IFN-γ,292 it is likely that the anti-tumor 
effects of Ad.IL-12 are moderated primarily by utilization of the innate immune response. 
2.4.8 Summary 
Overall, our results demonstrate that adenoviral delivery of IL-23 into the tumor 
microenvironment of early stage tumors is therapeutic and able to generate strong protective 
immunity.  Furthermore, our results show that the anti-tumor activity of IL-23 is independent of 
endogenous IL-17, perforin and, in part, FasL, but dependent on CD4 and CD8 positive T-cells 
and IFN-γ.  Together, these data imply that tumor cell expression of IL-23 drives a Th1-type 
immune response, which is responsible for its anti-tumor activity.   
Adenovirally delivered IL-12 appears to be the more potent anti-tumor agent, causing 
greater and faster tumor rejection; however, IL-12 treatment generates only limited protective 
immunity.  IL-12 treatment requires only endogenous IFN-γ to exert optimal anti-tumor benefits, 
suggesting, in our model, generation of a strong innate immune response, with only limited 
adaptive immune involvement.  
In conclusion, the combination of the strong protective immune response generated by 
IL-23 treatment combined with the rapid and potent eradication of tumors by IL-12 and the 
utilization of similar, yet divergent effector mechanisms by these two cytokines, suggest that co-
treatment of tumors with Ad.IL-12 and Ad.IL-23 together may result in synergistic enhancement 
of tumor eradication and induction of anti-tumor immunity.  
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3.0  INVESTIGATION INTO ANTI-TUMOR SYNERGY BETWEEN 
ADENOVIRALLY DELIVERED IL-12, IL-23 AND IL-17 
3.1 INTRODUCTION 
IL-12 is a heterodimeric, proinflammatory cytokine comprised of p40 and p35 subunits. IL-12 
enhances proliferation of 261, cytolytic activity of 50,262, and IFN-γ production from activated NK 
and T-cells.50,57,76  Furthermore, in response to microbial infection, IL-12 is produced by 
macrophages, which in turn generates a Th1-type adaptive immune response; therefore, IL-12 
acts as a bridge between both innate and adaptive arms of the immune system.80  IFN-γ is 
responsible for the majority of the inflammatory activities of IL-12, drives Th1 differentiation, 
and induces IL-12 secretion from DCs, thereby forming a positive feedback loop for Th1 
differentiation.58  IL-12 activates the JAK/STAT pathway, with STAT4 being preferentially 
activated.289  In accordance with the proinflammatory and immunostimulatory activities of this 
cytokine, IL-12 possesses potent anti-tumor effects.  IL-12 has been shown to inhibit tumor 
establishment, cause regression of established tumors and induce tumor-specific immunity.92,263-
265  However, systemically delivered IL-12 is associated with severe toxicity.265  Delivery of IL-
12 directly into the tumor microenvironment using adenoviral vectors promotes tumor regression 
and generation of tumor-specific immunity, while alleviating the toxicity associated with 
systemic delivery.18  Yet new cytokines are continuously sought out for use in cancer gene 
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therapy, either alone and or in combination with IL-12, to decrease the effective dose needed and 
enhance long-term protective immunity.   
IL-23 is a relatively newly described member of the IL-6/IL-12 family of heterodimeric 
cytokines and is composed of two subunits: p40, which is shared with IL-12, and p19, which is 
unique to IL-23.166  Like IL-12, IL-23 can act on both innate and adaptive arms of immunity.  IL-
23 stimulates production of IFN-γ from NK cells.293  Furthermore, IL-23 stimulates proliferation 
of and IFN-γ production from CD4+ memory T-cells, suggesting an important role in 
maintenance of Th1 immunity.166  IL-23 activates the same panel of signaling molecules as IL-
12, differing only in that STAT3, as opposed to STAT4, appears to be the most prominent STAT 
activated.173  Due to the structural and functional similarities between IL-12 and IL-23, it is not 
surprising that IL-23 also acts as a potent anti-cancer agent in various establishment207-209,211 and 
therapeutic215-216,218 models of cancer.  We have previously shown that treatment of established 
MCA205 fibrosarcoma tumors with adenovirus expressing IL-23 leads to significant 
enhancement of survival, tumor rejection and establishment of protective immunity using 
mechanisms similar to IL-12.218 
IL-12 and IL-23 both activate the JAK/STAT pathway,173,289 induce IFN-γ production 
from NK and T-cells,50,57,76,166,293 and utilize common mechanisms of tumor eradication.218  
Furthermore, IL-23 acts on DCs to induce IL-12 production and the combination of IL-12 and 
IL-23 causes DCs to secrete greater levels of IFN-γ than either cytokine alone.174  We thus 
proposed that co-delivery of adenoviruses expressing IL-12 and IL-23 in the tumor 
microenvironment would result in synergistic enhancement of anti-tumor effects due to enhanced 
IL-12 and IFN-γ production. 
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In addition to inducing IFN-γ production, IL-23 also strongly drives production of IL-17 
from a newly described subset of T–helper cells designated as Th17.30,184  In fact, the primary 
role of IL-23 appears to be expanding and committing T-cells to the Th17 phenotype.  Th17 cells 
are characterized by expression of IL-17A , but can also produce IL-17F.  Th17 cells appear to 
play an important role in activating innate immunity to extracellular pathogens.294  In addition, 
IL-23 and Th17 cell-driven inflammation have been implicated in a variety of autoimmune 
conditions including psoriasis, rheumatoid arthritis, multiple sclerosis and inflammatory bowel 
disease.295   Due to their pro-angiogenic and pro-inflammatory activities, Th17 cells and IL-17 
have been implicated in tumor promotion.296-298  However, IL-17 may also possess therapeutic 
anti-tumor effects.  Th17 T-cells have been shown to exact potent anti-tumor benefit, primarily 
via activation of tumor-specific CD8+ T-cells.230  Likewise, treatment with IL-17 leads to tumor 
rejection in a variety of cancer models.232,299    
IL-23 strongly promotes expression of IL-17 from Th17 T-helper cells and stabilizes the 
Th17 cell population.30,184  As IL-17 and Th17 cells have been shown to possess anti-tumor 
activities,230,232,299 we hypothesized that adenoviral-mediated co-delivery of IL-17 and IL-23 
would result in synergistic enhancement of anti-tumor benefits as a result of increased Th17 T-
cell production. 
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3.2 METHODS 
3.2.1 Adenoviruses 
Adenoviruses expressing IL-12 (Ad.IL-12) and IL-23 (Ad.IL-23) have been described 
previously18,266.  Ad.IL-12, Ad.IL-23 and Ad.Psi5 (empty vector) were prepared as follows:   
Viruses were propagated on HEK-293 cells and purified by CsCl banding, followed by dialysis 
in 3% sucrose solution.  Particle titer of purified viruses was determined by spectroscopy using 
the following equation: (OD260)(50)/9.09x10-13.  Infectious titers were determined using  
quantitative real-time PCR as previously described267 and were approximately 100-fold less than 
particle titers. Viruses were aliquoted and stored at -80° C until use.   
Adenoviruses expressing single-chain (sc) versions of IL-12 and IL-23 were designed as 
follows:  To construct Ad.scIL-12, the IL-12p40 precursor (Met1 to Ser335) was linked to the 
mature p35 subunit (Arg23 to Ala215) using the previously described 15 amino acid linker 
(Gly4Ser)3.153  To construct Ad.scIL-23, the IL-12 p40 precursor (Met1 to Ser335) was linked to 
the mature p19 subunit (Leu20 – Ala196) using (Gly4Ser)3.  The viruses were constructed and 
propagated at the University of Pittsburgh’s Vector Core Facility. 
3.2.1.1 Cytokine production and biological activity of adenoviruses 
Relative cytokine expression of each adenoviral preparation was analyzed by infecting 4x104 
MCA205 cells with increasing MOIs of Ad.IL-12 or Ad.IL-23 for 1 hour at 37°C/5% CO2 in 
serum free media.  Complete media was added and cells were incubated for 72 hours, after which 
supernatants were harvested.  IL-12 and IL-23 content was analyzed using the mouse IL-12 p70, 
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mouse IL-23 p19/p40 and mouse IL-12/IL-23 p40 Ready-Set-Go IL-23 ELISA kits (eBioscience, 
San Diego, CA), respectively, following manufacturers’ instructions. 
 Biological activity of Ad.scIL-23 was assayed as follows:  4x104 MCA205 cells were 
infected with a MOI 1000 of Ad.scIL-23 or Ad.Psi5 and supernatants harvested 72 hours post-
infection.  Splenocytes were then harvested from C57BL/6 mice, mechanically dissociated and 
treated with Red Cell Lysis buffer (Invitrogen, Carlsbad, CA) to remove all red blood cells.  
Splenocytes were plated at a concentration of 2x106 cells per well in a 24 well plate and 24 hours 
later treated with supernatants from adenovirus infected MCA205s.  Forty-eight hours after 
treatment, splenocyte supernatants were collected and analyzed for induction of IL-17 expression 
using the Mouse IL-17 Immunoassay (R&D Systems, Minneapolis, MN). 
3.2.2 Animals 
Female C57BL/6 and p40-deficient mice on a C57BL/6 background were obtained from The 
Jackson Laboratory (Bar Harbor, ME).  IL-23 (p19) deficient mice have been previously 
described and were a kind gift of Dr. Jay Kolls.300  Mice were used at 6 to 7 weeks of age.  
Animals were maintained under pathogen free conditions at the Biotechnology Center Animal 
facility at the University of Pittsburgh.  All procedures preformed were approved by the 
University of Pittsburgh Institutional Animal Care and Use Committee. 
3.2.3 Cell Lines 
MCA205 fibrosarcoma cells were maintained in RPMI supplemented with 10% fetal bovine 
serum (Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin (Gibco, Carlsbad, CA) and L-
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glutamine (Gibco, Carlsbad, CA).  Cells were kept in a humidified chamber at 37°C/5% CO2 and 
passaged every 2-3 days.   
3.2.4 In Vivo Tumor Studies 
For use in in vivo tumor experiments, confluent layers of MCA205 were dissociated by trypsin, 
washed 3 times with Hanks Balanced Salt Solution (HBSS) (Gibco, Carlsbad, CA) and counted 
using trypan blue exclusion.  Mice were inoculated with 1x105 MCA205 cells in 100uL HBSS 
subcutaneously in the abdomen.  For studies investigating induction of systemic immunity, mice 
were inoculated with 1x105 MCA205 cells subcutaneously at two distal sites on the abdomen.  
To analyze Ad.IL-12 and Ad.IL-23 anti-tumor activity in the context of p40 and p19 deficiency, 
tumor bearing mice were injected on days 7, 9 and 11 post-tumor inoculation with 5x1010 
particles (approximately 5x108 PFUs) of either Ad.IL-12, Ad.IL-23 or Ad.Psi5.   
To investigate synergy by delivering Ad.IL-12 and Ad.IL-23 at separate time points, 
mice were treated with 5x108 particles of Ad.IL-12 or 2.5x1010 particles of Ad.IL-23 as follows: 
Ad.IL-12 on day 7, followed by Ad.IL-23 on day 11; Ad.IL-23 on day 7, followed by Ad.IL-12 
on day 11; Ad.IL-12 on days 7 and 11; Ad.IL-23 on days 7 and 11; or Ad.Psi5 on days 7 and 11.  
In studies utilizing mice with two tumors, only one tumor was treated.   
To assess synergy by co-delivery of Ad.IL-12 and Ad.IL-23, day 7 tumor-bearing mice 
were treated once with either Ad.IL-12 and Ad.IL-23 simultaneously or either virus alone.  The 
quantity of virus particles injected were as follows:  1x109 Ad.IL-12 and 5x1010 Ad.IL-23; 5x108 
Ad.IL-12 and 2.5x1010 Ad.IL-23; and 1x108 Ad.IL-12 and 1x1010 Ad.IL-23.  The total amount of 
viral particles injected was kept constant between groups by co-delivery of Ad.Psi5.  In mice 
bearing two tumors, only one tumor was treated.  
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To characterize the anti-tumor activities of Ad.scIL-12 and Ad.scIL-23, tumor-bearing 
mice were injected intratumorally on days 7, 9 and 11 post-tumor inoculation with 5x1010 
particles of Ad.scIL-12, Ad.scIL-23 or Ad.Psi5.  To investigate possible synergy between 
Ad.scIL-12 and Ad.scIL-23, mice bearing day 7 MCA205 tumors were treated once 
intratumorally with 1x108 particles of Ad.IL-12 and 1x109 particles of Ad.scIL-23, either virus 
alone or Ad.Psi5.  Total quantity of virus injected was kept constant by use of Ad.Psi5. 
In all experiments, tumor volume was monitored using a metric caliper until mice were 
sacrificed due to excessive tumor size or tumor ulceration.  Tumor-free or “cured” mice were 
subject to tumor challenge 1-2 months after initial tumor resolution with 1x105 MCA205 cells 
subcutaneously in the abdomen. 
3.2.5 Immunohistochemistry 
Tumors of treated mice were harvested on day 15 post-tumor inoculation (day 8 post-treatment), 
snap frozen in 2-methylbutane and stored at -80˚C.  Tumors were then cut by cryostat, ten 
micron sections placed onto charged slides and stained for CD4, CD8, Foxp3, CD11c and CD31 
as follows. 
3.2.5.1 CD4 and CD8 
For analysis of tumors from mice treated with Ad.IL-12 and Ad.IL-23, sections were fixed in -
20˚C acetone and slides blocked in Exogenous Peroxidase Block (DAKO, Carpinteria, CA), 
followed by block in 10% goat serum.  CD4 or CD8 antibody (1:250 and 1:150 dilution, 
respectively)(BD Biosciences, San Jose, CA) was then added, followed by incubation with 
biotinylated goat anti-rat secondary antibody (1:250)(BD Biosciences, San Jose, CA) in DAKO 
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Antibody Diluent (DAKO, Carpinteria, CA).  Slides were treated with ABC Vectastain kit 
(Vector Laboratories, Burlingame, CA)  and developed using DAB Peroxidase Substrate Kit 
(Vector Laboratories, Burlingame, CA) following manufacturers’ instructions.  Slides were then 
counterstained with eosin, dehydrated in increasing concentrations of ethanol, followed by 
xylene, and coverslipped using Permount Media (Fisher, Pittsburgh PA).  
 For analysis of tumors from mice treated with Ad.scIL-12 and Ad.scIL-23, sections were 
permeabilized using 10% Triton-X (Sigma, St. Louis, MO), blocked in 2% BSA (Sigma, St. 
Louis, MO) and incubated with rat anti-mouse CD4 or CD8 antibody (1:50 and 1:100 dilution, 
respectively)(BD Biosciences, San Jose, CA) overnight at room temperature.  Slides were then 
incubated with Alexa-Flour goat anti-rat secondary (1:500 dilution)(Invitrogen, Eugene, OR) and 
coverslipped using Flourmount media (SouthernBiotech, Birmingham, AL).  
3.2.5.2 Dendritic cells 
Sections were stained for DCs using an anti-CD11c primary antibody (1:50 dilution) (BD 
Biosciences, San Jose, CA) and the Anti-Hamster Ig HRP Detection Kit (BD Pharmingen, San 
Jose, CA) following manufacturers’ instructions. 
3.2.5.3 Foxp3 
Sections were permeabilized with 10% Triton-X (Sigma, St. Louis, MO) followed by block in 
2% BSA (Sigma, St. Louis, MO).  Sections were then incubated with Alexa-Flour 488 
congugated rat anti-mouse Foxp3 (1:100 dilution)(eBioscience, San Diego, CA) for two hours 
followed by Alexa-Flour goat anti-rat secondary (1:500 dilution)(Invitrogen, Eugene, OR). 
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3.2.5.4 Angiogenesis 
Sections were permeabilized with 10% Triton-X (Sigma, St. Louis, MO) followed by block in 
2% BSA (Sigma, St. Louis, MO).  Sections were then incubated in rat anti-mouse CD31 primary 
antibody (1:100) (BD Biosciences, San Jose, CA), followed by Alexa-Flour goat anti-rat 
secondary (1:500 dilution)(Invitrogen, Eugene, OR).   
3.2.6 Statistics 
Kaplan-Meier survival curves were plotted using SPSS version 16.0.  Mice were monitored until 
excessive tumor volume or tumor ulceration, at which time they were sacrificed and recorded as 
occurrence of an event (death).  Cured mice or those with tumors that did not warrant sacrifice 
by the end of the experiment were censored.  Log-rank tests of the survival curves provided p-
values.   
An unpaired T-test was used to analyze immunohistochemistry results if variances 
between data were equal; if variances were unequal, the Mann-Whitney U test was performed.  
Statistical analyses were 2-tailed, with a p value less than 0.05 considered statistically 
significant. 
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3.3 RESULTS 
3.3.1 Anti-tumor activity of Ad.IL-23 requires endogenous IL-12, while Ad.IL-12 does not 
Previously, we have shown that adenoviral delivery of IL-23 into the tumor microenvironment 
results in efficient and long lasting tumor eradication by generating a Th1 immune response that 
is dependent upon the presence of CD4+ and CD8+ T-cells and endogenous IFN-γ.218  Our 
studies have also indicated a role major role for IFN-γ in the anti-tumor activity of adenovirally 
delivered IL-12.  To further elucidate the potential for IL-12 and IL-23 to synergize in tumor 
eradication, we sought to determine the role of endogenous IL-12 and IL-23 in Ad.IL-12 and 
Ad.IL-23 anti-tumor activity.  To this end, IL-12/23 p40 deficient mice bearing MCA205 tumors 
were treated on days 7, 9 and 11 post-tumor inoculation with 5x1010 particles of Ad.IL-12, 
Ad.IL-23 or saline.  Lack of endogenous p40 abolished the anti-tumor activity of Ad.IL-23, with 
no enhancement of survival or rejection of tumors in treated mice (8 total) (Figures 16a and b).  
Thus, IL-23 requires either endogenous IL-12 or IL-23, or both, to exert maximal anti-tumor 
effects. 
 In contrast, Ad.IL-12 retained its anti-tumor activity in the absence of endogenous IL-12 
and IL-23.  When treated with Ad.IL-12, tumor bearing, p40 deficient mice survived 
significantly longer than saline treated controls (p = 0.007) and exhibited tumor rejection in 60 
percent of mice (5 total) (Figures 16a and b).  Interestingly, there was little evidence of Ad.IL-12 
mediated toxicity seen in p40-deficient mice. 
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      Figure 16: Ad.IL-12 and Ad.IL-23 anti-tumor activity in p40-deficient mice 
3.3.2 Anti-tumor activities of neither Ad.IL-12 nor Ad.IL-23 require endogenous IL-23 
expression 
To determine the requirement for endogenous IL-23 expression in the anti-tumor effects of 
Ad.IL-12 and Ad.IL-23, mice deficient in IL-23 p19 were inoculated with MCA205 tumors and 
treated as described above.  Ad.IL-23 retained anti-tumor effectiveness in the absence of 
endogenous IL-23, with treated mice surviving significantly longer than controls (p = 0.027) and 
attaining a 60 percent (3 of 5) rejection rate (Figures 17a and b).  Furthermore, the lack of 
requirement for IL-23 indicates that Ad.IL-23 anti-tumor activity is dependent upon endogenous 
IL-12, as p40 knockout studies suggested a role of either IL-12 or IL-23. 
Likewise, treatment of tumor bearing, p19 deficient mice with Ad.IL-12 significantly 
enhanced survival compared to saline treated controls (p = 0.007) and initially led to tumor 
rejection in 100 percent of mice (5 total) (Figures 17a and b).  Interestingly, two tumors recurred 
at day 35 post-tumor inoculation, similar to what was seen previously in wild type mice and 
again suggesting lack of induction of strong protective immunity. 
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     Figure 17: Ad.IL-12 and Ad.IL-23 anti-tumor activity in p19-deficient mice 
3.3.3 Ad.IL-12 and Ad.IL-23 co-infection of MCA205 cells in vitro results in enhanced IL-
12 and IL-23 expression 
We next sought to determine if co-infection of MCA205 cells in vitro with Ad.IL-12 and Ad.IL-
23 results in altered cytokine production due to sharing of the common p40 subunit.  To this end, 
4x104 MCA205 cells were transduced with Ad.IL-12 and Ad.IL-23 or either vector alone and 
supernatants analyzed for IL-12/23 p40, IL-12 and IL-23 expression 72 hours post-infection.  
Co-infection of MCA205s with Ad.IL-12 and Ad.IL-23 resulted in enhanced IL-12/23 p40 
production compared to infection with either virus alone (Figure 18a).  Similarly, co-infection 
with both viruses led to enhanced IL-12 expression when compared to MCA205s treated with 
Ad.IL-12 alone (Figure 18b).  Finally, co-transduction with both Ad.IL-12 and Ad.IL-23 resulted 
in enhanced IL-23 expression compared to Ad.IL-23 infection alone. (Figure 18c).  The above 
results indicate that co-transduction of MCA205 cells in vitro leads to enhanced IL-12 and IL-23 
expression.  As we have previously shown that both Ad.IL-12 and Ad.IL-23 possess potent anti-
tumor activity, these results suggest that use of both viruses together may result in additive or  
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    Figure 18: Ad.IL-12 and Ad.IL-23 co-infection results in enhanced cytokine expression 
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even synergistic enhancement of anti-tumor effects due to increased production of both IL-12 
and IL-23. 
3.3.4 Investigation of synergism between Ad.IL-12 and Ad.IL-23    
The preceding studies in IL-12/23 p40 and IL-23 p19 deficient mice suggest that Ad.IL-23 
exacts at least part of its anti-tumor effects via induction of endogenous IL-12.  Furthermore, we 
have shown that co-infection of MCA205 cells with both Ad.IL-12 and Ad.IL-23 enhances 
production of both IL-12 and IL-23.  Additionally, our previous studies have suggested that IL-
12 rapidly eradicates tumors, while IL-23 generates better long-lasting protective immunity.  
Therefore, we hypothesized that co-treatment of tumors with both Ad.IL-12 and Ad.IL-23 would 
result in enhanced anti-tumor benefit due to greater cytokine production, which would lead to 
rapid tumor rejection and subsequent generation of long-lasting protective immunity.  To 
investigate possible synergism between the two viruses, tumor bearing, C57BL/6 mice were  
treated with Ad.IL-12 and Ad.IL-23 at various doses and time points and animal survival and 
tumor rejection monitored for enhancement of anti-tumor activity. 
3.3.4.1 Treatment with Ad.IL-12 and Ad.IL-23 at separate time points does not lead to 
enhanced anti-tumor benefit    
Our previous results have shown that Ad.IL-12 treatment induces rapid tumor rejection, while 
Ad.IL-23 generates superior protective immunity.  We first sought to determine if treatment with 
Ad.IL-12 followed by Ad.IL-23 would result in rapid tumor rejection followed by induction of 
 84 
strong protective immunity. To this end, tumor bearing, C57BL/6 mice were treated with two 
injections of Ad.IL-12 and Ad.IL-23 at suboptimal doses (5x108 and 2.5x1010 particles, 
respectively) as follows:  Ad.IL-12 on day 7, followed by Ad.IL-23 on day 11 (Ad.IL-12,23);  
Ad.IL-23 on day 7, followed by Ad.IL-12 on day 11(Ad.IL-23,12); Ad.IL-12 on both days 7 and 
11 (Ad.IL-12), Ad.IL-23 on both days 7 and 11 (Ad.IL-23) or Ad.Psi5 on days 7 and 11 
(Ad.Psi5).  Treatment with Ad.IL-12 on day 7 followed by Ad.IL-23 on day 11 did not result in 
significant enhancement of survival versus treatment with either Ad.IL-12 or Ad.IL-23 alone 
(Figure 19a).  Treatment with Ad.IL-12 followed by Ad.IL-23 resulted in 40 percent tumor 
rejection (15 mice total) and was not significantly greater than rejection rates in animals treated 
with either Ad.IL-12 or Ad.IL-23 alone (Figure 19b).  A regimen consisting of Ad.IL-23 
treatment on day 7 followed by Ad.IL-12 on day 11 yielded similar results, with no significant 
enhancement of survival or tumor rejection compared to use of Ad.IL-12 or Ad.IL-23 alone 
(Figures 19a and b). 
  
 
    Figure 19: Ad.IL-12 and Ad.IL-23 do not synergize when delivered at separate time points  
 
 To determine if induction of systemic anti-tumor immunity is enhanced by co-treatment 
with Ad.IL-12 and Ad.IL-23 at separate time points, mice bearing two tumors were treated in 
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one as described above.  In injected tumors, treatment with Ad.IL-12 on day 7 followed by 
Ad.IL-23 on day 11 resulted in a 29 percent tumor rejection rate, similar to the 43 percent 
rejection rate achieved with Ad.IL-12 treatment alone (7 mice total per group) (Figure 20a).  
Likewise, Ad.IL-23 treatment on day 7 followed by Ad.IL-12 on day 11 resulted in rejection of 
only 11 percent of tumors (9 mice total).  
A similar trend was observed in contralateral tumors.  Only 14 percent of contralateral 
tumors in mice treated with Ad.IL-12 on day 7 followed by Ad.IL-23 on day 11 were rejected, 
less than the 42 percent rejection rate in mice treated with Ad.IL-12 alone (7 mice total per 
group) (Figure 20b).  Taken together, our results suggest that intratumoral delivery of Ad.IL-12 
and Ad.IL-23 at separate time points does not enhance local or systemic induction of anti-tumor 
immunity over use of either virus alone. 
 
 
Figure 20: Ad.IL-12 and Ad.IL-23 do not synergistically enhance systemic anti-tumor activity 
3.3.4.2  Co-treatment with Ad.IL-12 and Ad.IL-23 does not enhance anti-tumor benefit 
As delivery of Ad.IL-12 and Ad.IL-23 at separate time points did not yield additive or 
synergistic anti-tumor benefits, we next sought to determine if co-delivery of the viruses would 
result in enhanced anti-tumor activity.  To this end, MCA205 tumor bearing C57BL/6 mice were 
 86 
treated once on day 7 with suboptimal doses of Ad.IL-12 and Ad.IL-23 (5x1010 and 1x109 
particles, respectively) or either virus alone.  Our previous studies indicated that Ad.IL-23 had 
only minimal anti-tumor activity at one dose of 5x1010 particles, while Ad.IL-12 retained much 
of its anti-tumor activity at this dose.  Thus we chose to use 1x109 particles of Ad.IL-12 in 
conjunction with 5x1010 particles of Ad.IL-23 in our initial investigation into possible synergism 
between Ad.IL-12 and Ad.IL-23.  While co-treatment with Ad.IL-12 and Ad.IL-23 doubled 
tumor rejection (4 of 5) versus use of either virus alone (2 of 5), survival was not significantly 
enhanced (Figures 21 a and b).  Thus, no additive or synergistic benefit was seen using Ad.IL-12 
and Ad.IL-23 at this dose.  Three cured, Ad.IL-12 and Ad.IL-23 co-treated mice were resistant to 
tumor challenge, as was the cured mouse treated with Ad.IL-23 alone.  The cured, Ad.IL-12 
treated mouse did, however, develop a tumor that did not regress, similar to our previous 
challenge data in wild-type mice.   
 
 
Figure 21: Co-treatment with Ad.IL-12 (1x109 particles) and Ad.IL-23 (5x1010 particles) does not 
synergistically enhance tumor eradication  
 
 Since some anti-tumor activity was retained at 1x109 and 5x1010 particles of Ad.IL-12 
and Ad.IL-23, respectively, we decided to use a lower viral titer to possibly unmask any additive 
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or synergistic anti-tumor benefit between the two viruses.  To this end tumor bearing mice were 
treated once on day 7 with 2.5x1010 particles of Ad.IL-23 and 5x108 particles of Ad.IL-12 or 
either virus alone.  Mice treated with Ad.IL-12 and Ad.IL-23 survived significantly longer than 
mice treated with Ad.IL-23 alone (p = 0.006), but not longer than Ad.IL-12 alone (Figure 22a).  
This suggests the enhancement of anti-tumor benefit was due to the contribution of Ad.IL-12 
alone and was not synergistic in nature.  Treatment with Ad.IL-12 and Ad.IL-23 yielded 
identical tumor rejection rates at 80 percent, while treatment with Ad.IL-23 alone resulted in a 40 
percent overall tumor rejection rate (15 mice total per group) (Figure 22b).  Again, tumor 
rejection data supports the assertion that the anti-tumor benefits of Ad.IL-12 and Ad.IL-23 
treatment was due solely to contribution of Ad.IL-12 and was not synergistic.  Additionally, all 
cured mice challenged were resistant to tumor development, suggesting that treatment with the 
combination of Ad.IL-12 and Ad.IL-23 does not enhance protective anti-tumor immunity. 
 
 
Figure 22: Co-treatment with Ad.IL-12 (5x108 particles) and Ad.IL-23 (2.5x1010 particles) does not 
synergistically enhance anti-tumor effects 
 
 Again, significant anti-tumor benefit was still observed at a dose of 5x108 particles of 
Ad.IL-12 and 2.5x1010 particles of Ad.IL-23.   We thus attempted to further titrate down the 
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doses of Ad.IL-12 and Ad.IL-23 to possibly reveal any additive or synergistic benefits associated 
with co-treatment.  Tumor bearing, C57BL/6 mice were treated once on day 7 with 1x108 
particles of Ad.IL-12 and 1x1010 particles of Ad.IL-23, or either virus alone.  Mice treated with 
both Ad.IL-12 and Ad.IL-23 did not survive significantly longer than animals treated with either 
Ad.IL-12 or Ad.IL-23 alone (Figure 23a).  Obviously a minimum effective dose was reached, as 
all treatment groups experienced an overall 20 percent tumor rejection rate (5 mice total per 
group) (Figure 23b); however, no synergistic or even additive benefit was observed in mice 
treated with both Ad.IL-12 and Ad.IL-23. 
 
 
Figure 23: Co-treatment with Ad.IL-12 (1x108 particles) and Ad.IL-23 (1x1010 particles) does not 
synergistically enhance anti-tumor activity 
       
 Finally, we wished to determine if Ad.IL-12 and Ad.IL-23 co-treatment leads to 
enhancement of systemic anti-tumor immunity compared to use of either virus alone.  To this 
end, C57BL/6 mice were inoculated with two tumors on the flank and treated once on day 7 with 
1x109 particles of Ad.IL-12 and 5x1010 particles of Ad.IL-23.  This treatment regimen yielded 
maximum tumor eradication as a result of Ad.IL-12 and Ad.IL-23 co-treatment in our previous 
experiments compared to use of either virus alone (Figure 21b) and thus was the most likely 
treatment plan to result in additive or synergistic tumor eradication in the systemic model.  
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Animals co-treated with Ad.IL-12 and Ad.IL-23 rejected 67 percent of injected and 45 percent of 
contralateral tumors (18 mice total).  Similarly, mice treated with Ad.IL-12 rejected 78 percent 
of injected and 36 percent of contralateral tumors (14 mice total).  Ad.IL-23 treatment yielded no 
tumor rejection in any treated animals (15 total)(Figures 24a and b).  Thus, it is evident that co-
treatment with Ad.IL-12 and Ad.IL-23 does not result in enhanced generation of local or 
systemic anti-tumor immunity compared to treatment with Ad.IL-12 alone. 
 
 
Figure 24: Ad.IL-12 and Ad.IL-23 co-treatment does not result in synergistic systemic anti-tumor effects 
 
Additionally, all Ad.IL-12 and Ad.IL-23 co-treated, cured mice, regardless of dose, were 
resistant to MCA205 tumor challenge (7 animals total).  All cured Ad.IL-23 treated mice (2 
total), but only 75 percent of Ad.IL-12 treated animals (4 total) were resistant to tumor challenge.  
Thus, co-treatment with Ad.IL-12 and Ad.IL-23 does not appear to generate enhanced MCA205-
protective immunity. 
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3.3.5 Determining the mechanism of lack of synergism between Ad.IL-12 and Ad.IL-23 
We hypothesized that differences in tumoral immune cell infiltrate or angiogenesis may be 
behind the lack of additive or synergistic anti-tumor effects between Ad.IL-12 and Ad.IL-23.  To 
investigate, mice inoculated with two tumors in the flank were treated in one on day 7 with 1x109 
particles of Ad.IL-12 and 5x1010 particles of Ad.IL-23 or either virus alone.  Tumors were 
removed at day 15 post-tumor inoculation, snap frozen, cryosectioned and stained for various 
immune cell infiltrates. 
3.3.5.1 Ad.IL-12 and Ad.IL-23 co-treatment does not alter CD4+ T-cell infiltrate 
Analysis of CD4+ T-cell infiltrate showed no significant difference between tumors of mice 
treated with Ad.IL-12 and Ad.IL-23 and those treated with either Ad.IL-12 or Ad.IL-23 alone 
(Figures 25a and b).  In injected tumors, there was no significant difference in CD4+ T-cell 
infiltrate between Ad.IL-12 and Ad.IL-23, Ad.IL-23 or Ad.IL-12 and control groups (Figure 
25a).  However, in contralateral tumors, co-treatment with Ad.IL-12 and Ad.IL-23 significantly 
increased CD4+ T-cell infiltrate compared to control treated mice (p = 0.00, Mann-Whitney U 
test), but was not greater than Ad.IL-12 treatment alone.   With the exception of those treated 
with Ad.IL-12, similar amounts of CD4+ T-cells were present in both injected and contralateral 
tumors. 
3.3.5.2 Ad.IL-12 and Ad.IL-23 co-treatment significantly reduces tumor-infiltrating CD8+ 
T-cells 
Analysis of tumor-infiltrating CD8+ T-cells yielded interesting results.  In injected tumors, co-
treatment with Ad.IL-12 and Ad.IL-23 resulted in a significant inhibition of infiltrating CD8+ T-  
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Figure 25:  Effects of Ad.IL-12 and Ad.IL-23 co-treatment on CD4+ and CD8+ T-cell infiltrate 
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cells compared to control treated animals (p = 0.00, Mann-Whitney U test) (Figure 25c).  
Additionally, co-treatment significantly reduced CD8+ T-cell infiltrate compared o use of Ad.IL-
12 alone (p = 0.00, T-test) (Figure 25c).  Between groups, tumors of Ad.IL-12 treated animals 
contained significantly more tumor infiltrating CD8+ T-cells than those treated with either 
Ad.IL-23 (p = 0.011, T-test) or controls (p = 0.024, T-test) (Figure 25c). 
Similar to injected tumors, contralateral tumors co-treated with Ad.IL-12 and Ad.IL-23 
contained significantly less CD8+ T-cells than tumors treated with either Ad.IL-12 alone (p = 
0.004, T-test) or controls (p = 0.035, T-test) (Figure 25d).  Overall, with the exception of animals 
treated with Ad.IL-12, similar amounts of CD8+ T-cells were present in both injected and 
contralateral tumors.   
3.3.5.3 Ad.IL-12 and Ad.IL-23 treatment does not affect dendritic cell infiltrate in tumors  
In both injected and contralateral tumors, co-treatment with Ad.IL-12 and Ad.IL-23 did not 
affect dendritic cell (DC) infiltrate in tumors versus Ad.IL-12, Ad.IL-23 or control treated groups 
(Figures 26a and b).  Likewise, there was no difference in DC infiltrate between tumors treated 
with Ad.IL-12 alone or Ad.IL-23 alone (Figures 26a and b).  Additionally, DC cell infiltrate was 
roughly equivalent in both injected and contralateral tumors in all treatment groups. 
3.3.5.4 Co-treatment with Ad.IL-12 and Ad.IL-23 does not alter Foxp3 infiltrate   
Co-treatment with Ad.IL-12 and Ad.IL-23 did not significantly alter Foxp3-positive cells in 
injected or contralateral tumors compared to controls (Figure 26c and d).  Likewise, numbers of 
tumor-infiltrating Foxp3 positive cells did not significantly differ between animals treated with 
Ad.IL-12 or Ad.IL-23 alone (Figures 26c and d).  Co-treatment with Ad.IL-12 and Ad.IL-23 did  
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Figure 26:  Effects of Ad.IL-12 and Ad.IL-23 co-treatment on dendritic cell and regulatory T-cell infiltrate 
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result in a trend towards decreased Foxp3 positive cells compared to therapy with Ad.IL-23 
alone (p = 0.074, T-test). 
In contralateral tumors, Ad.IL-12 and Ad.IL-23 co-treatment did result in significantly 
less Foxp3 positive cells than treatment with Ad.IL-23 alone (p = 0.013, T-test) (Figure 26d).   
Likewise, co-treatment resulted in a trend towards decreased Foxp3 positive cells compared to 
Ad.IL-12 treatment alone (p = 0.064, T-test). 
3.3.5.5 Ad.IL-12 and Ad.IL-23 co-treatment significantly enhances angiogenesis 
To elucidate the effects of Ad.IL-12 and Ad.IL-23 co-treatment on tumor angiogenesis, sections 
were analyzed for CD31.  Interestingly, in injected tumors, co-treatment with Ad.IL-12 and 
Ad.IL-23 resulted in significantly enhanced CD31 expression versus controls (p = 0.044, T-test) 
(Figure 27a).  Additionally, co-treatment resulted in enhanced angiogenesis compared to 
treatment with Ad.IL-23 alone (p = 0.001, T-test), but not Ad.IL-12 alone (Figure 27a).  Finally, 
treatment with Ad.IL-12 alone resulted in enhanced angiogenesis compared to Ad.IL-23 alone (p 
= 0.006, T-test).   
 In contralateral tumors, Ad.IL-12 and Ad.IL-23 co-treatment did not alter tumor 
angiogenesis versus controls (Figure 27b).  Furthermore, no significant difference in CD31 
expression was observed between Ad.IL-12 alone and Ad.IL-23 alone treatment groups (Figure 
27b). 
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Figure 27:  Effects of Ad.IL-12 and Ad.IL-23 co-treatment on angiogenesis 
3.3.6 Generation and characterization of adenoviruses expressing single chain IL-12 and 
IL-23 
Co-treatment with Ad.IL-12 and Ad.IL-23 did not result in any additive or synergistic anti-tumor 
effects over use of either cytokine alone and resulted in curious patterns of tumor angiogenesis 
and CD8+ T-cell infiltrate.  Since IL-12 and IL-23 share the common p40 subunit, it is possible 
that in vivo co-infection of tumors with Ad.IL-12 and Ad.IL-23 leads to preferential expression 
of one cytokine over another.  Therefore, the lack of therapeutic benefit of co-treatment with 
Ad.IL-12 and Ad.IL-23 may be a result of suboptimal expression of one cytokine combined with 
over expression of the other.  Use of adenoviruses expressing single chain (sc) IL-12 and IL-23 
would circumvent this possibility, as subunits could not be shared and the amount of cytokine 
produced in tumors should correlate linearly with treatment dose.  We therefore hypothesized 
that co-treatment with Ad.scIL-12 and Ad.scIL-23 would result in enhanced therapeutic benefit 
over use of either virus alone. 
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3.3.6.1 Adenovirus expressing single-chain IL-12 possesses potent anti-tumor effects, but is 
characterized by severe toxicity 
Adenovirus expressing single chain IL-12 (Ad.scIL-12) was designed to express the complete 
p40 precursor linked to the mature p35 subunit using a 15 amino acid (Gly4Ser)3 spacer153 
(Figure 28a).  To ensure cytokine expression, MCA205 cells were infected in vitro with Ad.scIL-
12.  Cells were also infected with Ad.IL-12 for comparison.  Ad.scIL-12 infection led to high 
levels of scIL-12 expression, which was detectible by ELISA in spite of the fact that the p35 and 
p40 subunits were linked.  Expression of IL-12 from Ad.scIL-12 was greater than its double 
chain counterpart (Figure 28b). 
Having shown that Ad.scIL-12 expresses detectable amounts of cytokine from infected 
MCA205 cells, we next sought to examine the anti-tumor effects of this virus.  To this end, 
tumor bearing, C57BL/6 mice were treated with Ad.scIL-12 or Ad.Psi5 on days 7, 9 and 11 post-
tumor inoculation.  While Ad.scIL-12 treatment did result in rapid and efficient tumor 
eradication in all animals (10 total) (Figure 28c), treatment was associated with severe toxicity.  
Treated mice exhibited classic signs of IFN-γ mediated toxicity, including weight loss, lethargy 
and ragged appearance.  In fact, toxicity associated with Ad.scIL-12 treatment was so severe that 
all animals perished as a result of treatment by day 35 (Figure 28d).  Thus, while Ad.scIL-12 
effectively eradicated tumors, survival was not enhanced compared to Ad.Psi5 treated controls 
due to treatment-associated toxicity.  We thus decided against pursuing further investigations 
into the anti-tumor activity of Ad.scIL-12 due to its association with severe toxicity. 
3.3.6.2 Adenovirus expressing single-chain IL-23 possesses potent anti-tumor activity  
An adenovirus expressing single chain IL-23 (Ad.scIL-23) was designed to express the complete 
p40 subunit linked to the mature p19 subunit using a 15-amino acid (Gly4Ser)3 spacer.153  To 
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ensure expression of scIL-23 from Ad.scIL-23 transduced cells, MCA205s were infected with 
Ad.scIL-23 and supernatants analyzed by ELISA.  Cells were also infected with Ad.IL-23 for 
comparison.  Ad.scIL-23 expressed very high levels of cytokine, which was detectable by ELISA 
regardless of its single chain form (Figure 29b).  While Ad.IL-23 did express detectible levels of 
cytokine (approximately 270 pg/mL), its expression was eclipsed by that of Ad.scIL-23.   
To ensure that scIL-23 expressed by Ad.scIL-23 was biologically active, splenocytes 
were treated with supernatants from Ad.scIL-23 infected cells for 48 hours and splenocyte 
supernatants analyzed for induction of IL-17 expression.  Treatment of splenocytes with 
supernatants from Ad.scIL-23 infected cells resulted in induction of IL-17 expression, while 
splenocytes treated with supernatants from cells infected with Ad.Psi5 or mock treated did not 
(Figure 29c).  Additionally, splenocytes did not spontaneously release IL-17 (Figure 29c). 
We next sought to determine what, if any, anti-tumor activity Ad.scIL-23 possessed.  To 
this end, MCA205-tumor bearing, C57BL/6 mice were treated on days 7, 9 and 11 post-tumor 
inoculation with 5x1010 particles of Ad.scIL-23 or Ad.Psi5.  Treatment with Ad.scIL-23 
significantly increased survival compared to Ad.Psi5 treated controls (p = 0.00), decreased tumor 
volume and led to an overall 90 percent tumor rejection rate (10 mice total) (Figures 29d and e).  
Very moderate signs of toxicity were observed in a few Ad.scIL-23 treated animals, mostly in 
the form of weight loss, but did not result in death.  Upon MCA205 tumor challenge, all mice (8 
total) remained tumor free up to 45 days after challenge.  This indicates induction of strong 
MCA205 protective immunity, similar to anti-tumor immunity generated by treated with Ad.IL-
23. 
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Figure 28: Characterization of adenovirus expressing single-chain IL-12 
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3.3.7 Co-treatment with Ad.scIL-23 and Ad.IL-12 does not result in enhanced anti-tumor 
activity     
We next sought to determine if co-treatment with adenovirally delivered IL-12 and IL-23 
enhanced local or systemic anti-tumor effects when there is no possibility of subunit switching.  
To this end, mice bearing two tumors were co-treated in one with 1x109 particles of Ad.scIL-23 
and 1x108 particles of Ad.IL-12 or either cytokine alone.  We chose against using Ad.scIL-12 in 
this study due to the toxicity associated with its use.  Co-treatment with Ad.IL-12 and Ad.scIL-
23 did not enhance tumor rejection in injected or contralateral tumors compared to use of 
Ad.scIL-23 alone (Figures 30a and b).  In both injected and contralateral tumors, 40 percent of 
co-treated animals experienced tumor rejection, identical to mice treated with Ad.scIL-23 alone 
(5 mice total per group) (Figures 30a and b).  Ad.IL-12-treated mice experienced only a 20 
percent rejection rate in injected tumors and did not reject any contralateral tumors (Figures 30a 
and b).  Overall, it is obvious that co-treatment with Ad.IL-12 and Ad.scIL-23 does not result in 
any additive or synergistic benefits.   
Taken together, the absence of any additive or synergistic anti-tumor effects in all of the 
aforementioned studies strongly suggests that IL-12 and IL-23 do not synergize to enhance anti-
tumor immunity.   
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Figure 29: Characterization of adenovirus expressing single-chain IL-23 
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   Figure 30: Co-treatment with Ad.scIL-23 and Ad.IL-12 do not synergistically enhance anti-tumor effects 
3.3.8 Determining the mechanism behind the lack of synergy between Ad.IL-12 and 
Ad.scIL-23 
Overall, these data show no indication of additive or synergistic anti-tumor benefits to use of 
Ad.IL-12 and Ad.scIL-23 together.  To elucidate the precise mechanism underlying the lack of 
therapeutic benefit, tumor bearing C57BL/6 mice were treated with suboptimal doses of Ad.IL-
12 and Ad.scIL-23 once on day 7 as described above.  On day 15 post-tumor inoculation, tumors 
were harvested and snap frozen.  Cryosections of tumors were then analyzed for various immune 
cell infiltrates and angiogenesis. 
3.3.8.1 Ad.IL-12 and Ad.scIL-23 co-treatment does not alter CD4+ T-cell infiltrate 
Co-treatment with Ad.IL-12 and Ad.scIL-23 did not significantly alter CD4+ T-cell infiltrate 
compared to treatment with either virus alone or control treated animals (Figure 31a).  Likewise, 
no significant difference was observed in CD4+ T-cell infiltrate between Ad.IL-12 and Ad.scIL-
23 treated animals and controls (Figure 31a).    
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3.3.8.2 Co-treatment with Ad.IL-12 and Ad.scIL-23 does not alter CD8+ T-cell infiltrate 
versus controls 
Ad.IL-12 and Ad.scIL-23 co-treatment significantly enhanced CD8+ T-cell infiltrate of tumors 
compared to animals treated with Ad.scIL-23 alone (Figure 31b).  However, co-treatment did not 
significantly alter CD8+ T-cell infiltrate compared to use of Ad.IL-12 alone or empty vector 
(Figure 31b).   
3.3.8.3 Co-treatment with Ad.IL-12 and Ad.scIL-23 does not alter Foxp3 positive cell 
infiltrate 
To determine if co-treatment with Ad.IL-12 and Ad.scIL-23 altered regulatory T-cell infiltrate, 
tumor sections were analyzed for presence of Foxp3 positive cells.  No difference in Foxp3 
positive cell infiltrate was observed between Ad.IL-12 and Ad.scIL-23 co-treated tumors versus 
use of either virus alone or Ad.Psi5 (Figure 31c)  Additionally, there was no difference in Foxp3 
positive cells in tumors treated with Ad.IL-12 or Ad.scIL-23 alone and controls (Figure 31c).   
3.3.8.4 DC infiltrate 
To determine if co-treatment with Ad.IL-12 and Ad.scIL-23 altered dendritic cell infiltrate, 
tumor sections were stained for CD11c.  Ad.IL-12 and Ad.scIL-23 co-treatment did not enhance 
tumor infiltrating DCs compared to use of Ad.IL-12 or Ad.scIL-23 alone.  Furthermore, neither 
treatment with both Ad.IL-12 and Ad.scIL-23 nor either virus alone significantly enhanced 
tumor-infiltrating DCs versus empty vector treated controls (Figure 31d). 
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3.3.8.5 Angiogenesis 
To determine if tumor angiogenesis is altered as a result of co-treatment with Ad.IL-12 and 
Ad.scIL-23, tumor sections were analyzed for CD31 expression.  Co-treatment did not 
significantly alter CD31 expression compared to use of either Ad.IL-12 or Ad.scIL-23 alone or 
empty vector controls (Figure 31e).  Likewise, no significant difference was observed between 
Ad.IL-12 alone and Ad.scIL-23 alone treatment groups versus controls (Figure 31e)  
3.3.9 Investigation into synergism between Ad.IL-17 and Ad.IL-23   
3.3.9.1 Ad.IL-17 co-treatment inhibits Ad.IL-23 anti-tumor effects 
In vivo, IL-23 strongly induces production of IL-17,30 which has been previously shown to 
possess anti-tumor activity.232  We next sought to determine whether intratumoral co-expression 
of IL-17 and IL-23 enhances anti-tumor effects.  To this end, tumor bearing C57BL/6 mice were 
co-treated with 2.5x1010 particles of Ad.IL-23 and adenovirus expressing IL-17 (Ad.IL-17) once 
on day 7 or with either virus alone.  Treatment with Ad.IL-17 alone had no anti-tumor effect, as 
treated mice did not survive significantly longer than Ad.Psi5 treated controls and did not 
experience tumor rejection (Figures 32a and b).  Similar to previous results, Ad.IL-23 treated  
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    Figure 31:  Effects of Ad.scIL-23 and Ad.IL-12 co-treatment on immune cell infiltrate and angiogenesis 
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mice survived significantly longer than controls (p = 0.010) and rejected 60 percent of tumors 
(10 mice total) (Figures 32a and b).  Interestingly, co-treatment with Ad.IL-23 and Ad.IL-17 
significantly decreased survival compared to use of Ad.IL-23 alone (p = 0.045) (Figure 32a).  
Furthermore, use of Ad.IL-17 in conjunction with Ad.IL-23 decreased the tumor rejection rate of 
Ad.IL-23 by half (30 versus 60 percent, 10 mice total) (Figure 32b).  This is suggestive of a pro-
tumor effect of IL-17 in our model.   
 
 
    Figure 32: Effects of co-treatment with Ad.IL-17 and Ad.IL-23 
3.3.9.2 Inhibition of IL-17 signaling does not enhance IL-23 anti-tumor activity 
As IL-23 is a strong inducer of IL-17 expression,30 we next sought to determine if inhibition of 
IL-17 signaling in the tumor microenvironment enhances Ad.IL-23 anti-tumor activity.  To block 
IL-17 signaling, we utilized an adenovirus expressing IL-17 receptor Fc (Ad.IL-17RFc), a fusion 
of the IL-17 receptor and IgG.301  To this end, C57BL/6, tumor bearing mice were co-treated 
with 2.5x1010 particles of Ad.IL-23 and 5x1010 particles of Ad.IL-17RFc or either virus alone.  
Ad.IL-23 treatment resulted in an overall 60 percent rejection rate (5 mice total), similar to 
previous results.  Inhibition of IL-17 signaling did not appear to have any discernable anti-tumor 
effect, as treatment with Ad.IL-17RFc alone did not lead to tumor rejection in any animals 
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(Figure 33b).  Furthermore, inhibition of IL-17 signaling did not enhance IL-23 anti-tumor 
activity, as co-treatment with Ad.IL-23 and Ad.IL-17RFc did not significantly enhance survival 
or increase tumor rejection compared to animals treated with Ad.IL-23 alone (Figures 33a and 
b).  This is in agreement with our previous results which suggest that Ad.IL-23 treatment most 
likely results in IFN-γ production and a Th1, not IL-17 and Th17, response to eradicate tumors; 
therefore inhibition of IL-17 should have no effect anti-tumor activity.    
 
 
   Figure 33: Effects of co-treatment with Ad.IL-23 and Ad.IL-17RFc 
3.4 DISCUSSION 
3.4.1 Rationale for IL-12 and IL-23 anti-tumor synergism 
IL-12 is a heterodimeric, proinflammatory cytokine comprised of p40 and p35 subunits.  IL-12 
induces IFN-γ production from both NK and T-cells, is imperative in driving a Th1 immune 
response50,57-58,76 and strongly activates the JAK/STAT pathway, particularly STAT4.289  In 
accordance with its pro-inflammatory properties, IL-12 possesses potent anti-tumor activities in 
multiple cancer models, but is associated with severe toxicity.92,263-265  Additionally we have 
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shown that the anti-tumor activity is rapid, but transient.  Thus, cytokines are continuously 
sought out for use in conjunction with IL-12 to decrease the effective dose needed and enhance 
long-term protective immunity.  Indeed, many cytokines have been previously shown to 
synergistically enhance the anti-tumor activity of IL-12.  IL-12 has been shown to synergize with 
IL-2,152 IL-18,154-156 IL-27,153 TNF-α157-159 and IL-15,163-165 commonly using mechanisms 
involving CD8+ T-cells and enhancement of IFN-γ production.   
IL-23 is a relatively newly described member of the IL-6/IL-12 family of heterodimeric 
cytokines and is comprised of the IL-12 p40 subunit and a unique p19 subunit.166 IL-23 likewise 
induces IFN-γ production from NK and T-cells and activates STAT3 of the JAK/STAT 
pathway.166,173,293  Due to common structural and functional similarities, it is not surprising that 
IL-23, like IL-12, possesses potent anti-tumor activity in various establishment207-209,211 and 
therapeutic215-216,218 models of cancer.  Additionally, we have previously shown that IL-12 and 
IL-23 have similar, yet divergent, mechanisms of tumor eradication.218  Specifically, the anti-
tumor activities of adenovirally delivered IL-12 and IL-23 are dependent on induction of IFN-γ.   
IL-12 and IL-23 both activate JAK/STAT signaling,173,289 induce IFN-γ production from 
NK and T-cells, 50,57,76,166,293 and utilize IFN-γ for tumor eradication.  Furthermore, co-treatment 
of DCs with IL-12 and IL-23 results in greater levels of IFN-γ production than use of either 
cytokine alone. 174  We thus proposed that co-treatment with adenoviruses expressing IL-12 and 
IL-23 would result in additive or synergistic anti-tumor effects as a result of enhanced 
intratumoral IFN-γ expression.   
To further analyze the potential of adenovirally delivered IL-12 and IL-23 to 
synergistically enhance anti-tumor function, the roles of endogenous IL-12 and IL-23 in the anti-
tumor activities of Ad.IL-12 and Ad.IL-23 were investigated.  Tumor-bearing mice deficient in 
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IL-12/IL-23 p40 were completely refractory to treatment with Ad.IL-23 (Figures 16a and b), 
indicating that Ad.IL-23 induces production of IL-12, IL-23 or both to exert its anti-tumor 
effects.  To determine whether endogenous IL-12 or IL-23 was induced by Ad.IL-23 treatment, 
the anti-tumor activity of Ad.IL-23 was evaluated in the context of IL-23 p19-deficient mice.  
Ad.IL-23 retained its anti-tumor activity in p19-deficeint mice, with treatment significantly 
enhancing survival and resulting in a 60 percent tumor rejection rate (Figures 17a and b).  This 
indicates that Ad.IL-23 treatment induces IL-12 production to exert its anti-tumor effects.  
Furthermore, Ad.IL-23 treatment either does not induce endogenous production of additional IL-
23 or that endogenous IL-23 does not play a role in its anti-tumor activity.  As IL-12 eradicates 
tumors using mechanisms including perforin and Fas ligand, it is certainly intriguing that the 
anti-tumor activity of Ad.IL-23 is independent of these means.  However, the anti-tumor activity 
of Ad.IL-12, at least in our model, was independent of both perforin and Fas ligand, but 
completely dependent upon IFN-γ.  Thus, it is not surprising that in our model, IL-12-mediated 
induction of IFN-γ is the primary mechanism utilized by Ad.IL-23 to eradicate tumors.  Overall, 
these results are in accordance with our previous data that suggest the anti-tumor effect of Ad.IL-
23 is due to induction of a Th1 immune response, characterized by dependence on CD4+ and 
CD8+ T-cells and IFN-γ.   
Conversely, Ad.IL-12 retained its anti-tumor activity in tumor-bearing mice deficient in 
IL-12/IL-23 p40, significantly enhancing survival and leading to an overall 60 percent tumor 
rejection rate (Figures 16a and b).  This indicates that Ad.IL-12 either does not induce 
endogenous IL-12 expression or that Ad.IL-12 can eradicate tumors independently of 
endogenous IL-12.  Interestingly, p40-deficient mice showed no signs of Ad.IL-12-mediated 
toxicity, as was commonly seen in both wild-type and various knockout mice.  This suggests that 
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Ad.IL-12 induction of endogenous IL-12 expression is at least in part responsible for the toxicity 
observed.  Indeed, IL-12 induces IFN-γ expression, which in turn induces further IL-12 
expression, thereby forming a positive feedback loop.58      
 Like Ad.IL-23, Ad.IL-12 retained potent anti-tumor effectiveness in tumor-bearing IL-23 
p19 deficient mice.  Treated mice survived significantly longer and initially rejected 100 percent 
of tumors (Figures 17a and b).  This indicates that Ad.IL-12 treatment does not result in IL-23 
induction.  Similar to previous results in Ad.IL-12 treated animals, two mice had tumors recur, 
again suggesting lack of induction of strong protective immunity.     
Overall, the above data indicates that Ad.IL-23 induces endogenous IL-12 production to 
eradicate tumors; therefore, use of Ad.IL-12 and Ad.IL-23 together would likely result in 
synergistic enhancement of anti-tumor benefit due to increased production of IL-12.  Likewise, 
data from co-infection of tumor cells suggest an overall enhancement of cytokine expression 
(Figure 18a-c).  Furthermore, our previous data have indicated that while Ad.IL-12 treatment 
results in rapid tumor eradication, treatment with Ad.IL-23 results in induction of superior 
protective immunity.   Thus, we decided that Ad.IL-12 and Ad.IL-23 would likely synergize to 
eradicate tumors as a result of overall enhancement of cytokine expression, leading to enhanced 
IFN-γ production, rapid tumor regression and IL-23-mediated induction of strong protective 
immunity. 
3.4.2 Ad.IL-12 and Ad.scIL-23 co-treatment does not synergistically enhance anti-tumor 
effects  
We first sought to determine if treatment with Ad.IL-12, followed by Ad.IL-23, would result in 
synergistically enhanced therapeutic benefit over use of either cytokine alone.  As synergism is 
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defined as “the interaction of two or more agents or forces so that their combined effect is greater 
than the sum of their individual parts,” we expected that synergy between Ad.IL-12 and Ad.IL-
23 would result in tumor eradication rates greater than the sum of treatment with either cytokine 
alone.  For example, if treatment with Ad.IL-12 or Ad.IL-23 alone both resulted in 20 percent 
tumor rejection rates, then tumor rejection rates of greater than 40 percent in animals treated with 
both Ad.IL-12 and Ad.IL-23 would be suggestive of synergism.  To statistically confirm 
synergistic activity, tumor rejection rates of animals treated with both Ad.IL-12 and Ad.IL-23, or 
either virus alone, would then be subjected to least squares regression analysis, which has been 
used previously to define synergy in cancer therapies.302   
Tumor-bearing mice treated on day 7 with Ad.IL-12 followed by Ad.IL-23 on day 11 did 
not survive significantly longer or experience greater overall tumor rejection than animals treated 
with Ad.IL-12 or Ad.IL-23 alone (Figures 19a and b).  Treatment with Ad.IL-23 on day 7 
followed by Ad.IL-12 on day 11 likewise did not enhance anti-tumor benefits over use of either 
virus alone (Figures 19a and b).  Similarly, no enhancement in systemic anti-tumor immunity 
was observed in mice bearing two tumors treated with Ad.IL-12 and Ad.IL-23, regardless of 
timing of delivery (Figures 20a and b).  These results suggest that delivery of Ad.IL-12 and 
Ad.IL-23 at separate time points does not result in synergistic or even additive enhancement of 
anti-tumor effects.  
 We next sought to determine if co-delivery of Ad.IL-12 and Ad.IL-23 resulted in 
enhanced anti-tumor benefit over use of either virus alone.  We attempted to determine the 
minimal effective doses of Ad.IL-12 and Ad.IL-23 that would generate maximal synergistic 
benefit.  To this end, various suboptimal doses of Ad.IL-12 and Ad.IL-23 were used to treat 
tumor bearing mice once on day 7.  Doses of 1x109 and 5x1010; 5x108 and 2.5x1010; and 1x108 
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and 1x1010 particles of Ad.IL-12 and Ad.IL-23, respectively, did not result in synergistic or even 
additive enhancement of anti-tumor benefits versus use of either virus alone (Figures 21-23).  
While co-treatment at 1x109 and 5x1010 particles of Ad.IL-12 and Ad.IL-23, respectively, did 
double the overall tumor rejection rate over use of either virus alone (40 versus 20 percent), 
survival was not significantly enhanced (Figures 21a and b).  Additionally, cured, co-treated 
mice at any dose were no more resistant to tumor challenge than their Ad.IL-23 counterparts.  
Ad.IL-12 treated, cured mice were again susceptible to tumor challenge, suggesting lack of 
induction of strong protective immunity by Ad.IL-12.   
 Likewise, co-treatment with Ad.IL-12 and Ad.IL-23 did not synergistically enhance 
induction of systemic immunity.  Mice bearing two tumors treated in one on day 7 with 1x109 
particles of Ad.IL-12 and 5x1010 particles of Ad.IL-23 did not survive significantly longer than 
and experienced similar tumor rejection rates to animals treated with Ad.IL-12 alone (Figures 
24a and b).  Mice treated with Ad.IL-23 at this dose did not reject any tumors, in contrast to the 
40 percent tumor rejection rate obtained using this dose in mice bearing only one tumor (Figure 
21b).  This is most likely due to the enhanced tumor burden.            
3.4.3 Determining the mechanism behind the lack of synergism between Ad.IL-12 and 
Ad.IL-23 
We hypothesized that differences in immune cell infiltrate or angiogenesis may be responsible 
for the lack of additive or synergistic benefit to use of Ad.IL-12 and Ad.IL-23 together.  To 
investigate this possibility, day 15 tumors from mice co-treated once on day 7 with 1x109 
particles of Ad.IL-12 and 5x1010 particles of Ad.IL-23, or either virus alone, were analyzed for 
various immune cell infiltrates and angiogenesis. 
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3.4.3.1 CD4 T-cell infiltrate 
Similar amounts of CD4+ T-cells were present in tumors of mice co-treated with Ad.IL-12 and 
Ad.IL-23, or either virus alone.  Co-treatment did not enhance CD4+ T-cell infiltrate of tumors 
over use of either virus alone in either injected or contralateral tumors (Figures 25a and b).  In 
contralateral, but not injected, tumors, co-treatment with Ad.IL-12 and Ad.IL-23 significantly 
enhanced CD4+ T-cell infiltrate over controls (Figure 25b).  This was the only treatment group 
to significantly enhance CD4+ T-cell infiltrate versus controls; however, this did not translate to 
therapeutic benefit, as co-treated animals did not exhibit significantly enhanced survival or tumor 
rejection compared to those treated with Ad.IL-12 or Ad.IL-23 alone (Figures 21a and b).  It is 
rather intriguing that no other treatment enhanced CD4+ T-cell infiltrate versus controls, as there 
was prolongation of survival and tumor rejection in all groups (Figures 21a and b).  This implies 
that CD4+ T-cell infiltrate at day 15 does not correlate with therapeutic outcome.  It is tempting 
to suggest that CD4+ T-cells are not important in direct MCA205 tumor eradication, as MCA205 
cells do not express MHC class II molecules. However, we have previously shown that Ad.IL-
23-mediated rejection of MCA205 tumors is dependent upon the presence of CD4+ T-cells.218  
Furthermore, it has been established that T-cell-mediated eradication of MCA205 tumors is 
dependent upon intratumoral CD4+ T-cell infiltration.303  Thus we would expect, at the very 
least, to see an enhancement of CD4+ T-cells in the Ad.IL-23 treatment groups versus controls.  
However, as the synergism studies utilized suboptimal doses of Ad.IL-23, it is possible that any 
therapeutic benefit obtained may have been due to utilization of other mechanisms of action.  It 
is also likely that the activation state and type of CD4+ T-cell present, rather than quantity, is the 
most important determinant in therapeutic outcome in our model.  CD4+ T-cells include Th1, 
Th2, Th17 and T regulatory-type T-cells, as well as natural killer T-cells.304  Thus, further 
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characterization of the types of CD4+ T-cells present may be necessary to correlate tumor 
infiltrate with therapeutic outcome.  Additionally, it is possible that day 15 post-tumor 
inoculation (8 days after treatment) may be too late to distinguish differences in CD4+ T-cell 
infiltrate.  Shortly after day 15, animals responding to treatment begin experiencing tumor 
rejection; therefore, we chose to analyze tumors at this time point.  However, it is possible that 
involvement of CD4+ T-cells occurred shortly after treatment and thus would have been 
overlooked in day 15 tumors.  Finally, as all tumors are equally analyzed at day 15 and it is 
impossible to discern whether any given tumor will ultimately respond to treatment, the variable 
results are likely a result of analysis of both responding and non-responding tumors.  
3.4.3.2 CD8+ T-cell infiltrate 
CD8+ T-cell infiltrate of tumors likewise yielded unexpected results.  Most notably, in both 
injected and contralateral tumors, Ad.IL-12 and Ad.IL-23 co-treatment resulted in a significant 
decrease in infiltrating CD8+ T-cells versus controls (Figures 25c and d).  However, this did not 
correlate with observed therapeutic benefit, as co-treated mice experienced tumor rejection and 
survived significantly longer than controls (Figures 21a and b).   Furthermore, co-treatment with 
Ad.IL-12 and Ad.IL-23 significantly inhibited CD8+ T-cell infiltration of tumors versus 
treatment with Ad.IL-12 alone (Figures 25c and d).  Finally, only treatment with Ad.IL-12 in the 
injected tumor led to a significant increase in CD8+ T-cells over controls (Figures 25c and d).   
CD8+ T-cells recognize and engage antigens in the context of MHC class I molecules on 
target cells to induce apoptosis.  Being “self” in origin, most tumor antigens are displayed in the 
context of MHC class I molecules, thereby making tumors susceptible to destruction by CD8+ T-
cells.  In the context of cancer, tumor-specific CD8+ T-cells may be deleted, become 
unresponsive or are not present in large enough quantities to elicit a therapeutic response.305  
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Thus, conventional wisdom suggests that enhancement of CD8+ T-cells within the tumor 
microenvironment would correlate with a positive therapeutic outcome.  Likewise, others have 
shown that various successful treatment strategies correlate with CD8+ T-cell infiltration of 
MCA205 tumors.18,303  Thus the lack of correlation between CD8+ T-cell infiltrate and 
therapeutic anti-tumor benefit was somewhat surprising.  Overall, these data suggest that 
quantity of tumor infiltrating CD8+ T-cells at day 15 is not reflective of therapeutic benefit.  This 
is not to say that CD8+ T-cells do not play a role in tumor eradication, as we, and others, have 
indicated a role of CD8+ T-cells in IL-12 and IL-23 anti-tumor activity.18,218  As was discussed 
above, these results may be due to timing of tumor analysis, treatment dose, and analyzing both 
responders and non-responders blindly.  Again, the activation state, specificity and cytotoxicity 
of tumor infiltrating CD8+ T-cells likely plays a greater role in therapeutic outcome than sheer 
quantities.  It is possible that the remaining CD8+ T-cells in co-treated tumors were highly 
efficacious in eradication and thus a relatively small amount could efficiently eliminate tumors. 
The fact that co-treatment with Ad.IL-12 and Ad.IL-23 resulted in significantly less 
tumor-infiltrating CD8+ T-cells than treatment with Ad.IL-12 alone suggests that either IL-23 is 
blocking IL-12 mediated recruitment of CD8+ T-cells or that co-infection of tumor cells with 
Ad.IL-12 and Ad.IL-23 results in expression of a particular cytokine profile that inhibits CD8+ 
T-cell infiltration of tumors.  IL-23 itself may exhibit both pro- or anti-tumor effects, depending 
upon expression levels.223  Furthermore, IL-23 expression in tumors has been shown to decrease 
CD8+ T-cell infiltration and inhibit CTL activity.222  We have shown that co-infection of 
MCA205 cells in vitro enhances IL-23 expression over 30-fold versus infection with Ad.IL-23 
alone (Figure 18c).  Thus it is possible that enhanced expression of IL-23 in tumors of mice co-
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treated with Ad.IL-12 and Ad.IL-23 results in inhibition of CD8+ T-cell recruitment, which may 
ultimately inhibit any synergistic anti-tumor benefit.   
3.4.3.3 Dendritic cell infiltrate 
Dendritic cells (DCs) play a pivotal role in anti-tumor immunity by enhancing cross presentation 
of tumor antigens and link innate and adaptive immune responses.306  Thus enhancement in 
tumor-infiltrating DCs would likely yield therapeutic benefit due to increased presentation of 
tumor antigens and concurrent generation of an anti-tumor immune response.  Co-treatment with 
Ad.IL-12 and Ad.IL-23 did not significantly alter DC infiltrate versus use of either virus alone in 
either injected or contralateral tumors.  Additionally, no difference was observed in DC infiltrate 
between tumor-bearing mice co-treated with Ad.IL-12 and Ad.IL-23, either virus alone and 
controls in either injected or contralateral tumors (Figures 26a and b).  Again the lack of 
correlation between therapeutic benefit and DC infiltrate suggests that, at day 15, tumor 
infiltrating DCs are not indicative of therapeutic outcome.  Indeed, this does not suggest that 
DCs do not play a role in induction of Ad.IL-12 and Ad.IL-23-mediated anti-tumor immunity.  
This simply suggests that other factors, such as timing of tumor analysis, treatment dose and 
analysis of both responders and non-responders, may affect immunohistochemical results in our 
model.  Again, it is likely that activation state, not quantity, of DCs most affects therapeutic 
outcome.  In control treated tumors, the population of cells staining positive for CD11c may 
include immature or anergic DCs, as well as possibly T-cells, and thus not all positive cells 
would prove useful in mounting an anti-tumor immune response. 
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3.4.3.4 Regulatory T-cell infiltrate           
Regulatory T-cells actively inhibit immune responses and are believed to play a key role in 
tumor immune evasion.  Previous studies have shown that CD4+CD25+ regulatory cells play a 
role in MCA205 immune evasion.307  Thus, we expected that uninhibited MCA205 tumor growth 
would be associated with greater number of tumor-infiltrating regulatory T-cells and that 
treatment with Ad.IL-12 and Ad.IL-23 would decrease these numbers.  However, in both 
injected and contralateral tumors, treatment with Ad.IL-12, Ad.IL-23 or both did not alter 
Foxp3-positive cell infiltrate versus controls (Figures 26c and d).  Interestingly, in contralateral 
tumors, co-treatment with Ad.IL-12 and Ad.IL-23 significantly decreased Foxp3+ cell infiltrate 
in tumors versus use of Ad.IL-23 alone (Figure 26d).  There was also a trend towards decreased 
Foxp3-positive cells in co-treated tumors versus use of Ad.IL-12 alone, but it was not significant.   
Overall these data suggest that the decrease of Tregs in co-treated tumors was due solely to the 
contribution of Ad.IL-12 alone and that co-treatment with Ad.IL-12 and Ad.IL-23 did not 
synergistically decrease Foxp3 positive cell infiltration.  Additionally, similar to results seen in 
contralateral tumors, co-treatment with Ad.IL-12 and Ad.IL-23 decreased Treg infiltrate versus 
Ad.IL-23 treatment alone in injected tumors, but the decrease was not statistically significant.   
Our results suggest that day 15 decrease in regulatory T- cell infiltration of tumors is not 
indicative of a positive prognosis.  However, as was discussed above, the lack of correlation 
between therapeutic benefit and Foxp3 positive cell infiltrate can likely be attributed to timing in 
tumor analysis, dose of treatment and blind analysis of both responders and non-responders.  
Furthermore, it is possible that treatment with Th1 polarizing cytokines directly enhances the 
activity of CD4+ and CD8+ T-cells, thereby overcoming Treg induced suppression without 
directly affecting Tregs themselves.  Finally, it must be noted that, while Foxp3 is widely 
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accepted as a marker for regulatory T-cells, it is also found on a significant, albeit small, 
population of CD8+ effector T-cells.308  However, as these cells also have a suppressive 
function, including them in our analysis would probably not skew results. 
3.4.3.5 Angiogenesis     
Inhibition of tumor angiogenesis is a primary goal in a variety of cancer therapies.  The anti-
tumor activity of IL-12 is mediated, at least in part, by IFN-γ mediated inhibition of 
angiogenesis.292  In contrast, it has been reported that IL-23 may possess pro-angiogenic 
properties.222  Thus, we sought to determine the effects of Ad.IL-12 and Ad.IL-23 co-treatment 
on angiogenesis, as analyzed by CD31 expression.  In contralateral tumors, no difference in 
angiogenesis was observed between animals treated with Ad.IL-12 and Ad.IL-23, Ad.IL-12 
alone or Ad.IL-23 alone and controls (Figure 27b).  In injected tumors, however, Ad.IL-12 and 
Ad.IL-23 co-treatment significantly enhanced CD31 expression versus control treated animals 
(Figure 27a).  Furthermore, co-treatment significantly increased angiogenesis compared to 
treatment with Ad.IL-23 alone in injected tumors (Figure 27a).  In contrast to previously 
published results, Ad.IL-23 alone treatment did not result in enhanced angiogenesis compared to 
controls (Figure 27a).  This may be due to expression levels of IL-23, as the enhanced 
angiogenesis observed in Ad.IL-12 and Ad.IL-23 co-treated animals may be due to increased IL-
23 expression.     
3.4.4 Summary of investigation into anti-tumor synergy between Ad.IL-12 and Ad.IL-23 
In Chapter 2, we demonstrated that adenoviral-mediated delivery of IL-23 into the tumor 
microenvironment, like IL-12, results in enhancement of survival and tumor eradication.  
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However, while IL-23 treatment resulted in strong protective immunity, IL-12 treatment was 
associated with tumor recurrence.  Furthermore, we have shown that Ad.IL-12 and Ad.IL-23 
uses similar, yet divergent, mechanisms of action to generate anti-tumor immunity.  We have 
subsequently shown that Ad.IL-23 utilizes endogenous IL-12 to exert its anti-tumor effects and 
that co-infection of MCA205 tumor cells with Ad.IL-12 and Ad.IL-23 results in enhanced 
production of both cytokines.  Thus, we proposed that co-treatment with Ad.IL-12 and Ad.IL-23 
would result in enhanced anti-tumor activity, due to use of similar, yet divergent, effector 
mechanisms and enhanced cytokine expression.  However, neither sequential nor concurrent 
delivery of Ad.IL-12 and Ad.IL-23 resulted in enhanced anti-tumor effects over use of either 
cytokine alone.  To explain the lack of synergy, day 15 tumors of treated and control mice were 
analyzed for various immune cell infiltrates.  Co-treatment inhibited tumor infiltration of CD8+ 
T-cells and enhanced angiogenesis.  IL-23 expression has been previously associated with 
inhibition of CD8+ T-cell infiltration and enhancement of angiogenesis.222  Thus, we 
hypothesized that Ad.IL-12 and Ad.IL-23 co-infection of MCA205 tumors in vivo leads to 
enhanced IL-23 production, thereby inhibiting any synergism with IL-12.  
3.4.5 Investigation of synergism between Ad.IL-12 and Ad.scIL-23 
To eliminate the possibility of subunit switching, and subsequent enhancement of IL-23 
production within the tumor microenvironment in vivo, adenoviruses expressing single chain IL-
12 and IL-23 were produced and assayed for expression and anti-tumor activity.  Ad.scIL-12 
expressed greater quantities of cytokine than Ad.IL-12 and efficiently eradicated MCA205 
tumors in vivo (Figure 28c).  However, Ad.scIL-12 treatment was associated with severe, likely 
IFN-γ, or possibly TNF-α, mediated toxicity and all animals perished as a result of treatment by 
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day 35 (Figure 28d).  This toxicity was possibly due to the lack of p40 homodimers, which 
cannot be formed due to linkage of p40 to p35 and normally attenuate IL-12 activity by binding 
to the IL-12 receptor.  Regardless, due to the severe toxicity associated with use of this virus, 
further investigation into its therapeutic potential was discontinued.   
Ad.scIL-23 expressed almost 1000-fold greater amounts of cytokine that its double-chain 
counterpart and was biologically active, as indicated by induction of IL-17 expression from 
splenocytes in vitro (Figures 29b and c).  Ad.IL-23 also possessed potent anti-tumor activity, 
with treatment resulting in significant enhancement of survival, complete tumor rejection in 90 
percent of animals and establishment of strong protective immunity (Figures 29d and e).  
Furthermore, in spite of high expression levels, Ad.scIL-23 treatment showed little to no 
evidence of toxicity. 
We next sought to determine if co-treatment with Ad.IL-12 and Ad.IL-23 would 
synergistically enhance therapeutic anti-tumor immunity.  We chose to use Ad.IL-12, as the 
toxicity associated with its use was less severe than that associated with Ad.scIL-12.  
Furthermore, as the IL-23 utilized is in a single chain form, it was unlikely that subunit switching 
and enhancement of IL-23 production would occur.  Mice bearing two tumors were treated in 
one with suboptimal doses of either both Ad.IL-12 and Ad.scIL-23, either virus alone or 
Ad.Psi5.  Co-treatment resulted in identical tumor eradication rates to treatment with Ad.scIL-23 
alone in both injected and contralateral tumors (Figures 30a and b).  Thus, co-treatment with 
Ad.IL-12 and Ad.scIL-23 does not synergistically enhance anti-tumor effects over use of 
Ad.scIL-23 alone either locally or systemically.  Therefore, subunit switching and 
overproduction of IL-23 is not solely responsible for the lack of synergism between IL-12 and 
IL-23. 
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3.4.5.1   Investigating the lack of synergy between Ad.IL-12 and Ad.scIL-23 
To determine if co-treatment with Ad.IL-12 and Ad.scIL-23 resulted in altered immune cell 
infiltrate compared to use of either virus alone and to further elucidate the mechanism underlying 
the lack of synergy between these two cytokines, day 15 tumors were analyzed for CD4, CD8, 
CD11c and Foxp3 positive cell infiltrate, as well as angiogenesis. 
Overall, co-treatment with Ad.IL-12 and Ad.IL-23 did not augment CD4, CD8, or CD11c 
positive cell infiltrate compared to control treatment (Figures 31a-d).  Similarly, treatment with 
Ad.IL-12 or Ad.scIL-23 alone did not enhance overall immune cell infiltrate versus controls 
(Figures 31a-d).  Thus, no correlation was observed between enhanced immune cell infiltrate and 
positive therapeutic outcome.  This was similar to our previous immunohistochemical results 
and, as discussed above, may be due to timing of analysis, treatment dose and activation state of 
the analyzed cells. 
Co-treatment with Ad.IL-12 and Ad.scIL-23 did, however, significantly enhance CD8+ 
T-cell infiltrate compared to use of Ad.scIL-23 alone (Figure 31b).  This is in stark contrast to 
previous results, in which co-treatment with Ad.IL-12 and Ad.scIL-23 resulted in a significant 
decrease in tumor-infiltrating CD8+ T-cells compared to treatment with either Ad.IL-12 or 
Ad.IL-23 alone (Figures 25c and d).  This suggests that use of a single chain IL-23 in 
combination with a double chain IL-12 does indeed alter the cytokine profile expressed from in 
vivo MCA205 tumors.  Specifically, less IL-23 may be being produced and therefore CD8+ T-
cell infiltration of tumors is not inhibited.  However, increase in CD8+ T-cell infiltrate in co-
treated tumors compared to use of Ad.IL-23 alone did not translate to enhanced therapeutic 
benefit (Figures 30a and b).  
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Similar to immunohistochemical results from treatment with double chain IL-12 and IL-
23, treatment with both Ad.IL-12 and Ad.scIL-23, or either cytokine alone, did not result in 
decreased Foxp3 expression versus controls (Figure 31c).  Likewise, co-treatment did not 
decrease Foxp3 positive cell infiltrate compared to use of either virus alone (Figure 31c). 
Finally, angiogenesis was not altered in tumors treated with both Ad.IL-12 and Ad.scIL-
23, or either virus alone, compared to controls (Figure 31e).  This is in contrast to previous 
immunohistochemical results utilizing double-chain cytokines, in which co-treatment resulted in 
significantly enhanced angiogenesis compared to controls.  Again, this suggests that use of 
single-chain IL-23 in combination with IL-12 prevents enhanced expression of IL-23 due to 
subunit switching, which, in turn, does not lead to enhanced angiogenesis.  
3.4.6 Explaining the lack of anti-tumor synergism between IL-12 and IL-23 
Overall, co-treatment with Ad.IL-12 and Ad.scIL-23 enhanced tumor infiltrating CD8+ T-cells 
and did not enhance angiogenesis, yet no anti-tumor synergy was observed.  These results 
support our assertion that increased intratumoral production of IL-23 likely led to decreased 
CD8+ T-cell infiltrate and enhanced angiogenesis in Ad.IL-12 and Ad.scIL-23 co-treated 
animals.  However, as co-treatment with Ad.IL-12 and Ad.scIL-23 did not result in enhanced 
anti-tumor activity, it is obvious that IL-23-mediated enhancement of angiogenesis and decrease 
in CD8+ T-cell infiltration are not solely responsible for the absence of synergy between these 
two cytokines.   
 122 
3.4.7 Neither IL-17, nor inhibition of IL-17 signaling, enhances Ad.IL-23 anti-tumor 
activity 
IL-23 is responsible for commitment to a Th17 lineage and induces IL-17 production.30  IL-17 
has been shown to possess anti-tumor activity232 and Th17 cells have been shown to enhance 
activity of tumor-specific CTLs.230  We therefore sought to determine if IL-23 would synergize 
with IL-17 to enhance anti-tumor effects.  Treatment with Ad.IL-23 led to tumor rejection and 
enhancement of survival, while treatment with Ad.IL-17 did not (Figures 32a and b).  
Interestingly, use of Ad.IL-17 in conjunction with Ad.IL-23 decreased the tumor rejection rate of 
Ad.IL-23 by half (Figure 32b).  Furthermore, inclusion of Ad.IL-17 with Ad.IL-23 significantly 
decreased animal survival compared to treatment with Ad.IL-23 alone (Figure 32a).  Thus, in our 
model, Ad.IL-17 at the very least does not possess anti-tumor activity.  Furthermore, these 
results indicate that co-expression of IL-17 with IL-23 decreases the anti-tumor effects of IL-23, 
possibly by IL-17-mediated inhibition of tumor-specific CTLs or inhibition of an IL-23 driven 
Th1 response. 
 IL-23 is a strong inducer of IL-17 expression and IL-17 appears to inhibit the anti-tumor 
effects of IL-23 (Figures 32a and b).  Thus, we decided to investigate whether inhibition of IL-17 
signaling in the tumor microenvironment would enhance the anti-tumor effects of IL-23.  To 
block IL-17 signaling, an adenovirus expressing the IL-17 receptor fused to IgG was utilized.  
Treatment with Ad.IL-17RFc did not result in tumor rejection and survival was comparable to 
treatment with empty vector.  Furthermore, mice co-treated with Ad.IL-23 and Ad.IL-17RFc did 
not experience enhanced tumor rejection or survival compared to treatment with Ad.IL-23 alone 
(Figures 33a and b).  This is consistent with our previous results, which show that the anti-tumor 
activity of Ad.IL-23 in IL-17R-deficient mice is retained, not enhanced or diminished, compared 
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to wild-type mice (Figure 10).   These data indicate that inhibition of IL-17 signaling does not 
affect the anti-tumor activity of IL-23.  This suggests two things: (1) Ad.IL-23 treatment either 
does not result in IL-17 expression in the tumor microenvironment or (2) IL-23 treatment does 
result in some degree of IL-17 expression, but it is eclipsed by IL-23-mediated IFN-γ production.  
Overall, these data indicate that IL-23 does not utilize IL-17 and a Th17, but rather IFN-γ and a 
Th1, immune response to exert its anti-tumor effects.   
3.4.8 A step closer to explaining the lack of synergy between IL-12 and IL-23 
We expected that co-treatment with adenoviruses expressing IL-12 and IL-23 would 
synergistically enhance anti-tumor immunity, due to their shared ability to eliminate tumors by 
activating a Th1 immune response.  However, we found no evidence of synergy between these 
two cytokines.  Indeed, previous studies support our assertion: C57BL/6 mice bearing scIL-23-
secreting B16 cells do not show enhanced anti-tumor benefit when co-treated with recombinant 
IL-12 intraperitoneally.153  Thus, while it was widely accepted and anticipated that IL-12 and IL-
23 would synergize in the context of tumor eradication, our studies firmly contradict this notion.  
Furthermore, the lack of synergy is not entirely due to enhanced IL-23 production, which could 
result in decreased CD8+ T-cell infiltrate and enhanced angiogenesis.  Additionally, we have 
shown that IL-17 can actively inhibit an IL-23-mediated, Th1-driven anti-tumor response.  It is 
therefore likely that these two cytokines simply do not synergize due to their contrasting and 
mutually exclusive functions: IL-12 strongly drives IFN-γ expression and a Th1 response, while 
IL-23 is capable of driving IL-17 expression and a Th17 response.  While in our model it did not 
appear that IL-23-mediated eradication of tumors was mediated by a Th17 response, it is 
possible that some Th17 T-cells were produced.  Furthermore, it has been shown that Th17 cells 
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inhibit CD8+ T-cell cytotoxicity.222,309  Therefore, co-expression of IL-23 with IL-12 may skew 
the resulting immune response away from a Th1 phenotype and result in lack of enhancement of 
anti-tumor effects. 
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4.0  DISCUSSION 
We have conclusively shown that adenovirally delivered IL-23 possesses therapeutic antitumor 
activity in day 7 MCA205 fibrosarcoma and B16 melanoma models.  Ad.IL-23 treatment 
resulted in an overall 40 percent tumor rejection rate and significantly enhanced survival of 
tumor bearing mice compared to empty vector treated controls.  Additionally, IL-23 therapy 
results in generation of tumor specific CTLs and generation of potent, long-term protective 
immunity.  The anti-tumor activity of IL-23 is independent of endogenous IL-23, IL-17, perforin 
and Fas ligand, but dependent upon IL-12, IFN-γ and CD4+ and CD8+ T-cells, suggesting 
generation and utilization of a Th1-type immune response in tumor eradication. 
 In general, adenovirally delivered IL-12 proved to be the more effective anti-tumor agent 
with regards to both animal survival and tumor rejection.  Ad.IL-12 treatment resulted in a 90 
percent rejection rate and significantly enhanced survival compared to both empty vector treated 
controls and Ad.IL-23 treated animals.  Like Ad.IL-23, Ad.IL-12 treatment resulted in 
generation of tumor-specific CTLs; however, there was indication of involvement of innate 
immunity, as evidenced by lysis of YAC-1 cells in CTL assays.  In our model, IL-12 anti-tumor 
activity is dependent only on IFN-γ and independent of endogenous IL-12, IL-23, IL-17, 
perforin, FasL and CD4+ and CD8+ T-cells.  Ad.IL-12 treatment generated protective immunity 
only 50 percent of the time and some tumors that were rejected initially later recurred.  Overall, 
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this suggests that Ad.IL-12 treatment, at least part of the time, activates only an innate response 
to eradicate tumors. 
Due to the similar, yet divergent, mechanisms utilized by Ad.IL-12 and Ad.IL-23 to 
eradicate tumors, we proposed that use of both cytokines together would synergistically enhance 
tumor eradication and survival compared to use of either virus alone.  However, we have 
exhaustively shown that neither delivery at separate time points nor co-delivery of Ad.IL-12 and 
Ad.IL-23 led to synergistic or even additive anti-tumor effects compared to use of either 
cytokine alone.  In elucidating the underlying mechanism, we found that co-treatment with 
Ad.IL-12 and Ad.IL-23 resulted in significantly decreased tumor infiltrating CD8+ T-cells and 
significantly enhanced angiogenesis.  Our in vitro studies suggested that co-infection with Ad.IL-
12 and Ad.IL-23 results in enhanced IL-23 expression.  Additionally, previous studies have 
indicated that IL-23 can inhibit CD8+ T-cell infiltration and enhance angiogenesis.  Thus we 
proposed that IL-23 expression was increased as a result of p19 sequestration of p40, which 
inhibited synergism with IL-12 due to decreased CD8+ T-cell infiltration of tumors, increased 
angiogenesis and reduction of IL-12 expression. 
To prevent subunit switching between IL-12 and IL-23, adenoviruses expressing single 
chain IL-12 and IL-23 were constructed.  Ad.scIL-23 expressed much greater levels of cytokine 
and possessed greater anti-tumor activity than Ad.IL-23 (90 versus 40 percent rejection rates).  
Ad.scIL-12 also expressed greater levels of cytokine and treatment resulted in rapid tumor 
rejection, but was associated with severe, lethal mortality in mice and therefore use was 
discontinued.  Co-delivery of Ad.scIL-23 and Ad.IL-12 did not result in synergistic enhancement 
of anti-tumor effects compared to use of either virus alone.  Analysis of tumors revealed no 
inhibition of CD8+ T-cell infiltration and no enhancement of angiogenesis in Ad.scIL-23 and 
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Ad.IL-12 treated animals.  This suggests that subunit switching and enhancement of 
angiogenesis may have contributed to the these observations, but that other factors are definitely 
involved in the lack of synergism between IL-12 and IL-23  
We also investigated anti-tumor synergism between adenovirally delivered IL-23 and IL-
17 due to their shared roles in Th17 development.  We found that delivery of IL-17 with IL-23 
significantly inhibited the anti-tumor effects of IL-23.  However, blocking IL-17 signaling did 
not enhance the anti-tumor activity of IL-23.  Thus we propose that co-expression of IL-17 and 
IL-23 led to generation of a Th17, rather than a Th1, response.  Thus it is possible that under 
some circumstances IL-23 can drive a Th17 response and therefore the lack of synergism 
between IL-12 and IL-23 can be explained by IL-23-mediated generation of some Th17 cells 
which inhibit, not enhance, anti-tumor activity. 
Future studies could include characterization of tumor infiltrating CD4+ T-cells in 
animals co-treated with IL-12 and IL-23 to further elucidate the types of immunity generated.  
This could be accomplished by analyzing tumor infiltration lymphocytes for cytokine, as well as 
transcription factor, expression by flow cytometry.  To determine if generation of Th17 
immunity is indeed responsible for lack of synergism between IL-12 and IL-23, the anti-tumor 
effects of co-treatment in tumor-bearing mice deficient in either IL-17 or Th17 transcription 
factor rorγt could be investigated.     
Overall, we have advanced the knowledge in the cancer gene therapy field in a number of 
ways.  We were the first to show that adenovirally delivered IL-23 exhibited therapeutic anti-
tumor benefit by generation of a Th1-type immune response.  In doing so, we have reaffirmed  
the utility of adenovirus as a means to deliver therapeutic immunostimulatory cytokines, as well 
as add an additional cytokine with potential clinical use in the treatment of cancer.  We have also 
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added yet another line of evidence to suggest that IL-23 possesses anti-, not pro-,tumor effects 
and can drive Th1 immunity.      
Additionally, we have exhaustively shown that IL-12 and IL-23 do not synergize in 
tumor eradication, possibly by due to IL-23-driven Th17 immunity.  This is in stark contrast to 
the expectation that IL-23 and IL-12 would synergize to enhance anti-tumor effects due to shared 
IFN-γ inducing and Th1 polarizing abilities.  Due to these revelations, further investigations into 
use of IL-23 as an IL-12 adjuvant should be weighed wisely, especially in the clinic. 
Finally, we have shown that adenovirally-delivered single-chain IL-23 exhibits more 
potent anti-tumor activity than its double-chain counterpart.  Thus we have shown that 
augmentation of IL-23 expression enhances its anti-tumor activity and therefore, if use of IL-23 
were to proceed to clinical trials, use of a single chain version may be preferred. 
Whether IL-23 proceeds to clinical trials for the treatment of cancer remains to be seen.  
We have shown that it does possess potent anti-tumor effects with low associated toxicity.  
However, its association with a variety of inflammatory diseases and its implication in some 
cancers may inhibit its use therapeutically.  The role of IL-23 in cancer certainly needs to be 
further clarified prior to proceeding to clinical trials.   
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